MAGNESIUM A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Magnesium: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84026-1 1. Magnesium-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on magnesium. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON MAGNESIUM ............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Magnesium ................................................................................... 6 E-Journals: PubMed Central ....................................................................................................... 60 The National Library of Medicine: PubMed ................................................................................ 66 CHAPTER 2. NUTRITION AND MAGNESIUM ................................................................................. 111 Overview.................................................................................................................................... 111 Finding Nutrition Studies on Magnesium ................................................................................ 111 Federal Resources on Nutrition ................................................................................................. 117 Additional Web Resources ......................................................................................................... 117 CHAPTER 3. ALTERNATIVE MEDICINE AND MAGNESIUM ........................................................... 127 Overview.................................................................................................................................... 127 National Center for Complementary and Alternative Medicine................................................ 127 Additional Web Resources ......................................................................................................... 142 General References ..................................................................................................................... 159 CHAPTER 4. DISSERTATIONS ON MAGNESIUM ............................................................................. 161 Overview.................................................................................................................................... 161 Dissertations on Magnesium ..................................................................................................... 161 Keeping Current ........................................................................................................................ 168 CHAPTER 5. CLINICAL TRIALS AND MAGNESIUM........................................................................ 169 Overview.................................................................................................................................... 169 Recent Trials on Magnesium ..................................................................................................... 169 Keeping Current on Clinical Trials ........................................................................................... 173 CHAPTER 6. PATENTS ON MAGNESIUM ........................................................................................ 175 Overview.................................................................................................................................... 175 Patents on Magnesium .............................................................................................................. 175 Patent Applications on Magnesium .......................................................................................... 214 Keeping Current ........................................................................................................................ 254 CHAPTER 7. BOOKS ON MAGNESIUM ........................................................................................... 255 Overview.................................................................................................................................... 255 Book Summaries: Federal Agencies............................................................................................ 255 Book Summaries: Online Booksellers......................................................................................... 256 The National Library of Medicine Book Index ........................................................................... 264 Chapters on Magnesium ............................................................................................................ 265 CHAPTER 8. MULTIMEDIA ON MAGNESIUM ................................................................................. 267 Overview.................................................................................................................................... 267 Video Recordings ....................................................................................................................... 267 Bibliography: Multimedia on Magnesium................................................................................. 268 CHAPTER 9. PERIODICALS AND NEWS ON MAGNESIUM .............................................................. 269 Overview.................................................................................................................................... 269 News Services and Press Releases.............................................................................................. 269 Newsletter Articles .................................................................................................................... 274 Academic Periodicals covering Magnesium............................................................................... 277 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 279 Overview.................................................................................................................................... 279 U.S. Pharmacopeia..................................................................................................................... 279 Commercial Databases ............................................................................................................... 280 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 285 Overview.................................................................................................................................... 285
viii Contents
NIH Guidelines.......................................................................................................................... 285 NIH Databases........................................................................................................................... 287 Other Commercial Databases..................................................................................................... 290 The Genome Project and Magnesium ........................................................................................ 290 APPENDIX B. PATIENT RESOURCES ............................................................................................... 295 Overview.................................................................................................................................... 295 Patient Guideline Sources.......................................................................................................... 295 Finding Associations.................................................................................................................. 297 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 301 Overview.................................................................................................................................... 301 Preparation................................................................................................................................. 301 Finding a Local Medical Library................................................................................................ 301 Medical Libraries in the U.S. and Canada ................................................................................. 301 ONLINE GLOSSARIES................................................................................................................ 307 Online Dictionary Directories ................................................................................................... 308 MAGNESIUM DICTIONARY .................................................................................................... 311 INDEX .............................................................................................................................................. 401
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with magnesium is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about magnesium, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to magnesium, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on magnesium. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to magnesium, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on magnesium. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON MAGNESIUM Overview In this chapter, we will show you how to locate peer-reviewed references and studies on magnesium.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and magnesium, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “magnesium” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Magnesium Chloride Slows Gastric Emptying, But Does Not Affect Digestive Functions Source: Alimentary Pharmacology and Therapeutics. 16(8): 1571-1577. August 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: An inverse relationship has been established between serum magnesium and serum lipid levels. This article reports on a study in which, by means of breath tests, the authors tested the hypothesis that magnesium inhibits intraluminal lipid digestion and subsequently causes changes in lipid metabolism. The authors also investigated the influence of the administration of magnesium chloride on protein digestion and gastric
4
Magnesium
emptying. Five healthy volunteers performed simultaneous breath tests for gastric emptying and intraluminal lipid digestion, and six others for gastric emptying and protein digestion. Each test was performed in basal conditions and after the intake of 800 milligrams of magnesium chloride dissolved in water. The oral administration of a single dose of magnesium chloride resulted in a diminished rate of intraluminal lipid and protein digestion. The most pronounced effect of magnesium chloride, however, was a decreased gastric emptying rate of both test meals. After correction for gastric emptying, no differences were noted in intraluminal lipid or protein digestion. Therefore, the lower lipid levels noted after magnesium supplementation are unlikely to be the result of altered lipid assimilation. The authors conclude that magnesium chloride slows gastric emptying but does not influence lipid digestion. 8 figures. 2 tables. 20 references. •
Magnesium and Diabetes Source: Practical Diabetology. 10(2): 1-5. March-April 1991. Summary: Despite the frequency with which magnesium deficiency occurs in diabetes mellitus, symptoms are rarely present. This article describes the case example of a patient with uncontrolled diabetes mellitus and magnesium deficiency. Focal neuromuscular irritability, characterized by involuntary rhythmic myoclonic contractions, was caused by magnesium deficiency. The problem was resolved after magnesium repletion. Magnesium deficiency and its relationship to diabetes is reviewed within the context of this case. The author also discusses the clinical usefulness of a magnesium-loading test and gives a therapeutic outline. 2 tables.
•
Magnesium and Diabetes: A Call for Concern Source: Practical Diabetology. 14(1): 7-11. March 1995. Contact: Available from R.A. Rapaport Publishing, Inc. 150 West 22nd Street, New York, NY 10011. (800) 234-0923. Summary: In this article, the authors call attention to the problem of inadequate magnesium levels in people with diabetes mellitus. Topics covered include a description of magnesium and its role in the body's metabolism; magnesium deficiency; magnesium and glycemia; macrovascular disease, diabetes and magnesium; microvascular disease and magnesium; and magnesium intake. The author concludes that subtle magnesium deficiency may play a significant role in diabetes and its complications. The article concludes with an editorial comment by Dr. Joel Zonszein, who focuses on determining which patients with diabetes should receive magnesium replacement or supplementation. 2 tables. 16 references.
•
Magnesium Deficiency and Diabetes Source: Diabetes Educator. 18(1): 17-19. January-February 1992. Summary: Magnesium plays a key role in many enzyme systems in the body and is required for all enzymatic reactions involving the nucleotide adenosine triphosphate. This article discusses magnesium deficiency and diabetes. The authors report that magnesium deficiency is seen in as much as 25 percent of the diabetes population. The authors discuss magnesium loss and diabetes-associated complications, including hypertension, retinopathy, dyslipidemia, focal seizures, and reduced release of insulin. In addition, they note that magnesium deficiency may influence the binding of insulin to peripheral tissue and has been associated with ventricular arrhythmias and sudden
Studies
5
cardiac death. Two final sections cover hypomagnesemia with hypokalemia and magnesium repletion. 1 figure. 25 references. •
Serum and Dietary Magnesium and the Risk for Type 2 Diabetes Mellitus: The Atherosclerosis Risk in Communities Study Source: Archives of Internal Medicine. 159(18): 2151-2159. October 11, 1999. Contact: Available from American Medical Association. Subscriber Services Center, P.O. Box 10946, Chicago, IL 60610-0946. (800) 262-2350. Fax (312) 464-5831. E-mail:
[email protected]. Summary: This article describes a prospective cohort study that examined the association between serum magnesium level and dietary magnesium intake and the subsequent risk for incident type 2 diabetes in a cohort of 12,128 middle aged adults without diabetes from the Atherosclerosis Risk in Communities Study during 6 years of followup. Fasting serum magnesium level, categorized into six levels, and dietary magnesium intake, categorized into quartiles, were measured at the baseline examination. Incident type 2 diabetes was defined by self report of physician diagnosis, use of diabetic medication, fasting glucose level of at least 7.0 mmol/liter, or nonfasting glucose level of at least 11.1 mmol/liter. The study found that, among white participants, a graded inverse relationship between serum magnesium levels and incident type 2 diabetes was observed. From the highest to the lowest serum magnesium levels, there was an approximately two fold increase in incidence rate. This graded association remained significant after simultaneous adjustment for potential confounders, including diuretic use. Compared with individuals with serum magnesium levels of 0.95 mmol/liter or greater, the adjusted relative odds of incident type 2 diabetes rose progressively across the following lower magnesium categories: 1.13, 1.20, 1.11, 1.24, and 1.76. In contrast, little or no association was observed in African American participants. No association was detected between dietary magnesium intake and the risk for incident type 2 diabetes in African American or white participants. The article concludes that, among white participants, low serum magnesium was a strong, independent predictor of incident type 2 diabetes. That low dietary magnesium intake did not confer risk for type 2 diabetes implies that compartmentalization and renal binding of magnesium may be important in the relationship between low serum magnesium levels and the risk for type 2 diabetes. 1 figure. 5 tables. 52 references. (AAM).
•
In Review: Magnesium Deficiency and Celiacs Source: Celiac Disease Foundation Newsletter. 3(4): 1. Winter 1993. Contact: Celiac Disease Foundation. 13251 Ventura Boulevard, Number 3, Studio City, CA 91604. (818) 990-2354. Summary: This brief article reviews the role of magnesium deficiency in people with celiac disease. Topics addressed in the article include the metabolism of magnesium and how it is used by the body; current research; diagnostic tests used to determine magnesium absorption; and the role of magnesium in the prevention of osteoporosis, particularly in people with celiac disease. The article concludes with a description of a research study to establish baseline data on people with celiac disease, confirming that there is an increased incidence of osteoporosis in celiacs. The article includes the telephone number of the Celiac Disease Foundation for readers who are interested in obtaining more information about this study.
6
Magnesium
•
Role of Magnesium in Diabetes Mellitus: A Possible Mechanism for the Development of Diabetic Complications Source: Journal of Diabetes and Its Complications. 6(2): 143-149. April-June 1992. Summary: This review article investigates the role of magnesium as a possible mechanism for the development of complications in diabetes mellitus. Topics include magnesium homeostasis; hypomagnesium, insulin resistance, hypertension, and ischemic heart disease; hypomagnesemia and diabetes complications; possible mechanisms for the action of magnesium; mechanisms linking hypomagnesemia and diabetes complications; and magnesium and inositol transport. The authors conclude that the recognition that hypomagnesemia is associated with essential hypertension, insulin resistance, hyperinsulinemia, hyperlipidemia, and ischemic heart disease may provide mechanistic support for the currently proposed theory that the association of these conditions constitutes a distinct clinical syndrome. 72 references.
Federally Funded Research on Magnesium The U.S. Government supports a variety of research studies relating to magnesium. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to magnesium. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore magnesium. The following is typical of the type of information found when searching the CRISP database for magnesium: •
Project Title: ANALYSIS & CONTROL OF NONSYNAPTIC EPILEPTIFORM ACTIVITY Principal Investigator & Institution: Durand, Dominique M.; Professor; Biomedical Engineering; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001; Project Start 04-SEP-2001; Project End 31-AUG-2005 Summary: (provided by applicant): Epilepsy is characterized by the abnormal synchronization of large numbers of neurons. The synchronization and propagation of epileptic seizures are thought to rely on synaptic transmission. However, non-synaptic mechanisms such as neuronal swelling, electric field effects, potassium diffusion, gap junctions and glial cell function also contribute to the generation and spread of epileptiform activity. Non-synaptic epilepsy is generated by lowering calcium in the extracellular space thereby eliminating synaptic transmission. As a result, the clinical relevance of non-synaptic mechanisms has been questioned. We have recently generated
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
7
novel models of non-synaptic activity in the presence of normal calcium and normal synaptic transmission. We propose to analyze the role of non-synaptic mechanisms in neuronal synchronization in order to understand and potentially develop novel therapies to prevent abnormal neural activity. We have recently shown that the frequency, amplitude and duration of non-synaptic epileptiform events can be controlled independently suggesting that different mechanisms are responsible. In particular, preliminary experiments show that gap junctions are not responsible for the propagation of non-synaptic events generated in zero-calcium medium, but that potassium diffusion (potentially mediated by the activity of glial cells) plays a crucial role. The goal of this proposal is to analyze and control non-synaptic epileptiform activity. Specifically, we propose to 1) determine the common mechanisms underlying three models of non-synaptic epilepsy, 2) establish the conditions sufficient for the generation of non-synaptic epileptogenesis, 3) analyze the mechanisms underlying the propagation of non-synaptic epileptiform activity, 4) develop a computer model of nonsynaptic propagation to test hypotheses not directly testable by experimentation, and 5) develop methods for controlling epileptiform activity. Multi-disciplinary experimental approaches such as computer simulation and fluorescence imaging will be combined with pharmacology and in-vitro slice electrophysiology to achieve these goals. Current therapeutic agents are not capable of controlling seizure activity in 25 percent of all epileptic patients. The results of our studies should provide valuable insight into mechanisms underlying epileptogenesis as well as new tools for the control and suppression of epileptic seizures. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANALYSIS OF A KINASE DOMAIN WITHIN A NOVEL ION CHANNEL Principal Investigator & Institution: Nadler, Monica J.; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2002; Project Start 15-APR-2002; Project End 31-MAR-2007 Summary: Little is known of calcium channels underlying flux in lymphocytes and other non-excitable cells. I have recently cloned a novel ion channel, designated LTRPC7, that is expressed in many types of non-excitable cells including all immune system tissues. This channel is a member of the LTRPC TRP sub-family and is unique in that it contains a catalytic kinase domain homology to eEF-2K at its C-terminus. Preliminary data indicate that this protein is bi-functional: it is a cation channel that is permeable to calcium and magnesium, and it has kinase activity. We have observed that the ion permeability of LTRPC7 is sensitive to and suppressed by Mg-ATP. These data suggest that the kinase activity and/or changes in conformation of the kinase domain upon phosphorylation could be critical to the gating and/or modulation of this channel. Experiments are proposed to fully characterize the enzymatic potential of this domain (Aim 1). In addition, experiments are proposed to explore the regions of LTRPC7 that mediate and influence the Mg- ATP suppression effect (Aim 2). Finally, preliminary functional characterization of LTRPC7 demonstrates that over-expression of it in HEK293 cells is toxic and/or induces growth arrest. In addition, production of a double allele LTRPC7 knockout cell line in the DT-40 B-cell system results in lethality. These results suggest that LTRPC7 function is linked to basic cellular processes required for cell survival. Experiments to address the unique structural features of LTRPC7 that could account for these functional effects and assessment of its ability to affect intracellular calcium are also proposed (Aim 3). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
8
Magnesium
•
Project Title: RELEVANCE
AROMATIC
AMINE
DNA
STRUCTURES--MUTAGENIC
Principal Investigator & Institution: Broyde, Suse B.; Professor; Biology; New York University 15 Washington Place New York, Ny 10003 Timing: Fiscal Year 2001; Project Start 01-SEP-1997; Project End 31-AUG-2006 Summary: (provided by applicant) The human population is routinely exposed to a large number of environmental chemicals: some of them may initiate cancer while others, only slightly different in structure, are harmless. One prominent route by which carcinogens exert their effects is to react with DNA in a way that leads to a mutation in a vital cellular target. Insight into the mechanism by which a carcinogen-damaged DNA produces mutations is needed in order to identify potentially hazardous substances. In this project, intensive computer modeling is used to explore this process. Our efforts here are targeted particularly to frameshift mutations, whose contribution to carcinogenesis has perhaps been underemphasized. In particular, we will attempt to relate chemical structure to mutagenic effectiveness within the framework of the slippage/misalignment theory. This theory has successfully explained the sequence dependence of many frameshift mutations. We will work with four aromatic amines, members of a chemical class that has demonstrated an exceptional ability to induce frameshifts. Our selection includes acetylaminofluorene (AAF), chosen because of the extensive data based concerning its mutagenicity, 2-amino-1-methyl-6phenylimidazo(4,5-b)pyridine (PhIP) and 2-amino-3-methyl-imidazo(4,5-f)quinoline (IQ), carcinogens that are formed during the cooking of protein-rich foods, and 1aminopyrene (AP), the transformation product of a common pollutant present in diesel engine exhaust, urban air particulates, and a number of other sources. We will follow the behavior of modified DNA primer-template complexes as they proceed through the steps of extension, blockage, and/or misalignment within the active sites of selected polymerases for which suitable crystal structures are available. Our methods include the use of the programs DUPLEX (for molecular mechanics with modified DNA) and AMBER for molecular dynamics simulations with DNA in solution or in a polymerase. DUPLEX permits an extensive search of conformation space without the use of assumptions concerning the final structure. The molecular dynamics studies include explicit solvent and salt, and provide animation, but are more restricted in their search. Molecular dynamics trajectories yield ensembles of structures that will be used to compute free energy differences between conformers in solution, and binding free energies of polymerase-primer-template complexes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ASSEMBLY OF HIGHER ORDER STRUCTURE IN GROUP I RIBOZYMES Principal Investigator & Institution: Doudna, Jennifer A.; Professor; Molecular Biophysics & Biochem; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2001; Project Start 01-AUG-1997; Project End 31-JUL-2002 Summary: The three-dimensional structure of RNA is critical to its cellular function. Catalytic RNA molecules, called ribozymes, fold into complex globular structures to produce active sites that promote chemical reactions independent of protein facilitation. Although the molecular basis for such structures is currently unknown, their formation involves the assembly of short helical elements via direct RNA-RNA and metalmediated contacts. An understanding of the molecular interactions that give to correctly
Studies
9
folded RNAs is fundamental to understanding the structural and mechanistic principles of RNA catalysis. A detailed knowledge of the principles of higher order folding in RNA will enable rational design of efficient ribozymes for therapeutic purposes and will illuminate the role of RNA in such fundamental biological processes as protein biosynthesis and messenger RNA splicing. Like proteins, large catalytically active RNA molecules are often composed of independently folding structural domains. In the wellstudied group I self-splicing introns, the catalytic core is comprised of helical components residing in two separate domains. The crystal structure of one of these, the independently folding P4-P6 domain, revealed that conserved helices of the core lie parallel to helices in an extended subdomain. In addition to two specific sets of tertiary contacts, divalent metal ions and 2' hydroxyl groups of riboses in the RNA backbone stabilize this remarkably close helical packing. This exciting structure also provides tantalizing clues to the organization of the complete intron catalytic core, and is thus the basis for probing structural interactions both within the P4-P6 domain and between P4P6 and the rest of the intron. The specific aims of this proposal are threefold: 1. Determine the affinity and specificity of magnesium ion binding sites clustered in an adenosine-rich corkscrew motif, the A-rich bulge, that is central to P4-P6 domain folding. 2. Define the classes of divalent metal ion binding sites in the P4-P6 crystal structure, and correlate them with functional data for P4-P6 folding and intron catalysis. 3. Measure the energetic contributions of individual tertiary contacts within the P4- P6 domain, involving magnesium ions, ribose 2' hydroxyl groups and nucleotide bases, to domain structure and global intron folding and catalysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BICARBONATE REGULATED ADENYLYL CYCLASE Principal Investigator & Institution: Buck, Jochen; Pharmacology; Weill Medical College of Cornell Univ New York, Ny 10021 Timing: Fiscal Year 2001; Project Start 01-FEB-2001; Project End 31-JAN-2005 Summary: Mammalian soluble adenylyl cyclase (sAC) is structurally, biochemically, and physiologically distinct from G protein coupled transmembrane adenylyl cyclases. sAC activity is not regulated by the known modulators of transmembrane adenylyl cyclases activity, such as G proteins and forskolin, but it is directly stimulated by the bicarbonate- ion. Multiple physiological processes (i.e., breathing, blood flow, cerebrospinal fluid and aqueous humor formation, spermatocyte development) are modulated by carbon dioxide and/or bicarbonate. With this grant application we plan to test the hypothesis that sAC is the physiological bicarbonate/carbon dioxide sensor in biological systems. Aim 1 will study the direct interactions of bicarbonate with purified recombinant sAC protein using enzyme kinetics, binding assays, and limited proteolysis studies. Aim 2 will study whether bicarbonate activated sAC activity is present in bicarbonate/carbon dioxide regulated physiological systems. Aim 3 will determine with the help of sAC knockout studies in mice whether SAC activity is essential for bicarbonate/carbon dioxide regulated physiological systems in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BIOCHEMICAL INVESTIGATION OF P-GLYCOPROTEIN Principal Investigator & Institution: Senior, Alan E.; Professor; Biochemistry and Biophysics; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2001; Project Start 01-JAN-1994; Project End 31-DEC-2004
10
Magnesium
Summary: Multidrug-resistance is a situation encountered in cancer patients in which the tumor becomes resistant to a variety of cytotoxic anti-cancer chemotherapeutic agents. It often involves enhanced expression of P- glycoprotein (Pgp), a plasma membrane protein. Involvement of Pgp in resistance to anti-AIDS drugs is also stronglyindicated. Pgp consists of 1280 amino acids, arranged in two repeated halves, each of which contains six predicted transmembrane helices and one ATP-binding site. It acts in an ATP-dependent manner to exclude drugs and a wide range of other hydrophobic compounds from cells, displays substantial drug- stimulated ATPase activity, and is now widely-believed to act as an ATP- driven drug-efflux pump. A catalytic cycle involving alternating catalytic sites and a mechanism for coupling of ATP-hydrolysis to drug-transport, presented by our laboratory, has become widely-adopted as a working model. We recently made a breakthrough, namely the development of a large- scale method for preparation of pure, detergent-soluble, mouse and human Pgp, using Pichia. Not only wild-type but also mutant Pgp may now be obtained in quantity, facilitating a broader range of structural, biophysical and biochemical approaches. The aim of this proposal is to characterize structure and function of Pgp. Structure will be determined by electron-microscopy and X-ray crystallography. Catalytic mechanism will be studied by specific insertion of fluorescent probes to monitor nucleotide binding parameters and occupancy of catalytic sites, and by mutagenesis of critical catalytic site residues. Coupling of ATP hydrolysis to drug transport will be investigated. The two halves of Pgp will be purified separately and reconstituted, to facilitate understanding of interactions between catalytic sites and membrane domains. Basic knowledge of this kind will be invaluable in devising ways to disable P-glycoprotein and overcome drugresistance in patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOCHEMICAL METABOLISM
MECHANISMS
OF
POLYPHOSPHATE
IN
Principal Investigator & Institution: Kornberg, Arthur; Emeritus Professor of Biochemistry; Biochemistry; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2006 Summary: (provided by applicant): Inorganic polyphosphate (poly P), a polymer of hundreds of phosphate residues linked by high-energy bonds, is found in every cell in Nature-bacteria, fungi, plants and animals. Among poiy P functions are: kinase donor to glucose and nucleoside diphosphates, phosphate (P1) reservoir, divalent metal (Ca2+, Mg2+, Mn2+) chelator and component of a membrane complex in bacterial transformation. Our recent studies have disclosed three major roles: 1) "alarmone" in response to stresses and deficiencies, 2) adaptations for survival in the stationary phase and 3) virulence in some pathogens. Thus, poly P has a variety of functions depending on the cell and circumstances. The multiplicity of functions and the plasticity of microbial organisms has complicated the search for the biochemical mechanisms responsible for each action. The proposed research will focus on mechanisms of metabolic regulation. Based on promising preliminary studies, we intend to pursue two major lines: 1) Regulation of protein synthesis and turnover by the supply of amino acids by biosynthesis and protein turnover, and 2) Operations of phosphate uptake and efflux and concomitant divalent metal ion transport. In addition, we will be mindful of control of in vitro transcription of genes known to be activated by poly P in vivo and a possible role for poly P as a donor for protein kinases. The widespread conservation of the enzyme, poly P kinase (PPK), responsible for poiy P synthesis in bacteria, including many of the major pathogens, has led us to knockout ppk in several of these pathogens.
Studies
11
In Pseudomonas aeruginosa poly P is essential for motility, quorum sensing, bioflim formation and virulence in mice. We expect that the proposed biochemical studies will reveal mechanisms that will assist in the current search for antimicrobial drugs aimed at PPK as a target. The research may also provide clues to the biosynthesis and metabolism of poly P in eukaryotes about which little is known. In view of the ubiquity of poly P in animal cells and subcellular organelles (particularly nuclei), it seems likely that poly P serves multiple functions in human metabolism that affect growth, differentiation and disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOMATERIALS (MG/ZN/F-BCPS)FOR OSTEOPOROSIS THERAPY Principal Investigator & Institution: Legeros, Racquel Z.; Biomaterials and Biomimetics; New York University 15 Washington Place New York, Ny 10003 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Osteoporosis is a 'silent' progressive and debilitating disease characterized by bone loss, thinning cortical bone and disorganized trabecular bone leading to bone fragility and fracture. Osteoporosis results when the processes of bone formation and bone resorption become uncoupled and the rate of bone resorption becomes much greater than that of bone formation. FDA-approved pharmaceutical interventions have antiresorptiive properties. Some of these drugs have serious side effects. Fluoride (F) therapy as sodium fluoride is the only one shown to consistently increase bone mass, but was also reported to increase fracture risk. The goal of the proposed research is to develop novel materials incorporating magnesium (Mg), zinc (Zn), F ions in a calcium (Ca) phosphate system (Mg/Zn/F-BCP). Separately, these ions have been associated with bone formation, biomineralization and osteoporosis therapy. Specific aims are to: (1) prepare and characterize the crystallographic, morphologic, and chemical properties of a series of Mg/Zn/F-BCP materials; (2) determine the short and long term initial dissolution rates and release of Ca, Mg, Zn, P and F ions of the materials prepared in Aim 1; (3) determine in vitro response of bone forming (osteoblasts) and bone resorbing (osteoclasts) cells to Mg/Zn/F-BCPs of various compositions using human osteoblast-like cells and rat osteoclast-like cells; (4) determine the effect of orally administered various Mg/Zn/F-BCPs on (a) bone properties (mechanical strength, density, quality, composition, and histomorphometric parameters and bone mineral (crystallinity, composition and dissolution) of adult and aged female and male rats; and (b) on the development of osteoporosis (deficient-diet induced) in adult rats; and (5) determine therapeutic effect of various injected Mg/Zn/F-BCPs on ovariectomized rats using biomechanical, histomorphometric measurements and chemical analyses on bone and plasma analyses. Hypothesis: Biomaterials with Zn, Mg and F ions in a calcium phosphate matrix (used as dietary supplement and ion releasing injectible 'implants') will improve bone health. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CA2+DEPENDENT K+CHANNELS: ALLOSTERIC GATING Principal Investigator & Institution: Cui, Jianmin; Biomedical Engineering; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2006 Summary: (provided by applicant): The long-term objective of this research is to understand the molecular mechanism of the voltage, Ca2+, and Mg2+ dependent activation of large-conductance K+ channels (BK channels). BK channels have road
12
Magnesium
physiological functions, including the modulation of neurotransmitter release and the control of blood vessel diameters. As a consequence of these physiological functions BK channels are of significant clinical importance. For example, abnormal activity of BK channels has been associated with hypertension in animal models; their increased activity may reduce the incidence of ischemia- reperfusion-induced cardiac arrhythmia. In the activation of BK channels voltage induces movements of the voltage sensor in the channel, Ca2+ or Mg2+ binds to the channel to cause conformational changes in the channel protein to open he activation gate. Now the structure of the K+ channel pore has been solved; protein sequences underlying he activation gate, the voltage sensor, and the Ca2+ binding site have been identified. However, the manner n which voltage sensor movements, Ca2+ or Mg2+ binding are coupled to the opening of the activation gate remains unknown. Until the structural and energetic basis of these couplings is elucidated, how voltage, Ca2+ and Mg2+ sensitivities are modulated in various BK channels to subserve their physiological functions cannot be understood. Based on previous studies, we hypothesize that a structural domain of the channel protein that is physically close to the activation gate (the RCK domain for Regulating the conductance of K+ channels) is central in these couplings. Recently, the X-ray crystal structure of the RCK domain has been solved. Guided by the structural data we will perturb the channel structure using molecular biology and determine its impact on the energetic contribution of Ca2+, Mg2+, or voltage to channel opening using our recently developed electrophysiological approaches. We will also use approaches of protein biochemistry and nuclear magnetic resonance spectroscopy (NMR) to map specific intramolecular protein interactions that nay be altered during channel activation and hence control channel function. These experiments will provide a foundation for understanding how various BK channels play their role in physiological processes and define targets on BK channels for therapeutic purposes. They will also contribute to our understanding of ion channel gating in general. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CALCIUM ACTIVATED MEMBRANE TARGETING BY THE C2 DOMAIN Principal Investigator & Institution: Falke, Joseph J.; Professor; Chemistry and Biochemistry; University of Colorado at Boulder Boulder, Co 80309 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: Description (applicant's description): The conserved C2 domain has been recognized in over 500 proteins, where it plays a central role in targetting proteins to new cellular locations during Ca2+ signals. The most common type of targetting driven by this ubiquitous motif is Ca2+-triggered membrane docking, which initiates critical signaling processes including neurotransmitter and hormone release, activation or inactivation of phosphorylation and G protein signaling cascades, inflammation, and cell cycle control. The present new research proposal aims to develop a molecular picture of C2 domain function, mechanism and structure. The five broad goals of the research are as follows. (i) Distinct classes of C2 domains, differing in their Ca2+ activation parameters and even their mechanisms, will be resolved by comparative equilibrium and kinetic studies of isolated C2 domains from functionally diverse proteins. (ii) The mechanisms by which these different C2 domain classes dock to membranes will be elucidated, and residues essential for membrane docking will be identified. (iii) A medium resolution structure of the protein-membrane interface will be determined via a novel strategy. (iv) The mechanism by which Ca2+ triggers membrane docking will be investigated. Finally, (v) activation parameters and mechanistic models
Studies
13
developed by studies of isolated C2 domains will be tested in multi-domain proteins and in living cells. To achieve these goals, a range of methods will be employed. Equilibrium dialysis, fluorescence titrations and stopped flow kinetics will be used to quantitate the equilibrium and kinetic features of selected C2 domains. Scanning cysteine mutagenesis and careful solution measurements will identify critical residues and forces that drive membrane docking. A novel combination of EPR distance measurements and constraint-based modelling will reveal the structure of the proteinmembrane interface, and will probe the Ca2+ triggering mechanism. Finally, hypotheses arising from in vitro studies of isolated C2 domains will be tested in multi-domain proteins and in living cells. Overall, this research will provide the first detailed molecular portrait of one of the most prevalent signaling motifs in nature, and will develop new methods to probe the challenging protein-membrane interface. Furthermore, comparative studies of C2 domains will provide information crucial to genomic analyses of many signaling pathways. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELLULAR MAGNESIUM AND CALCIUM ION HOMEOSTASIS IN HEART Principal Investigator & Institution: Scarpa, Antonio; Professor and Chairman; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-DEC-2006 Summary: Despite the abundance of Mg2+ in the body and within tissues in the body and within tissues, little is known about the regulation of cellular and plasma Mg2+ homeostasis. Studies conducted during the last nine years of finding to this Project, as well as those many other laboratories, have shown that cellular Mg2+ homeostasis is very active, has sophisticated and multiple forms of regulation and may provide, directly or indirectly, a novel role in regulating cell function and metabolism. Specific hormonal stimulation and changes in intracellular second messenger level induce the transport of large and rapid amounts of Mg2+ from heart into the extracellular milieu and ultimately into the bloodstream, or vice versa. This proposal continues to use a large variety of models (perfused hearts, myocytes, other isolated cells, permeabilized cells, isolated organelles, purified proteins) and experimental approaches (31P NMR, Electron Probe, Microanalysis, cell imaging, isotopic potentiometric techniques to acquire or integrate the knowledge on MG1+ homeostasis in heart. The objective of this application is o test several major hypothesis: That in myocytes there is a multiplicity of Mg2+ transporters mediating Mg2+ uptake and release, as well as a redundancy of signaling pathways activating and inhibiting Mg2+ transport. That cellular Mg2+ release may be a major part of the alpha1 or beta adrenergic response. That Mg2+ efflux from myocytes increases interstitial Mg2+ concentration in the myocardium and stimulates adenosine production. That in the heart a fraction of the large efflux of Mg2+ is coupled to Ca2+ uptake through a novel Mg2+-Ca2+ anti-porter Hence, Mg2+ efflux stimulated by catecholamines may be an additional pathway of Ca2+ entry. That the accumulation of Mg2+ in heart and other tissues is unaffected by extracellular Mg2+ but is independently regulated by specific signaling pathways through protein kinase C. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CELLULAR MAGNESIUM DYSFUNCTION IN DIABETES Principal Investigator & Institution: Romero, Jose R.; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115
14
Magnesium
Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): This small grant application has been prepared by a new investigator in order to obtain the preliminary data necessary to prepare a competitive RO1 grant application on endothelial cell dysfunction in insulin resistantstates. The objective of this application is to identify the regulatory mechanisms involved in insulin-stimulated Na+/Mg2+ exchange activity in cells from normal and diabetic patients. Our long-term goal is to define the cellular mechanisms that lead to insulin resistance and diabetes. The central hypothesis for the proposed research is that low levels of Mg2+ attenuate the intracellular signal generated following insulin binding to its receptor or antagonize binding of insulin to the receptor. This hypothesis is based on preliminary findings obtained in human microvascular endothelial cells and red blood cells. We propose to test our central hypothesis and accomplish the overall objectives of this proposal through the following specific aims: Aim 1: Identify the role of insulin in cellular Mg2+ regulation in human microvascular endothelial cells. On the basis of our preliminary data, we hypothesize that insulin regulates cellular Mg2+ levels via activation of the exchanger, which in turn regulates nitric oxide production in human endothelial cells. We will characterize the intracellular signaling pathways that are downstream of PI3-kinase activation and modulate the activity of the exchanger as well as nitric oxide production in these cells Aim 2: Identify the mechanisms for insulinregulated Na+/Mg2+ exchange activity in ex vivo human red cells from normal subjects. Erythrocytes have been used as ex vivo models of what may occur in target tissue of insulin resistance's pathophysiology. We hypothesize that the insulin receptor is functionally coupled to the exchanger in human red cells via PI3-kinase activation. Therefore, our studies are designed to characterize PI3-kinase activity as well as phosphorylated Akt levels in erythrocytes upon activation with insulin. Aim 3: Identify the mechanisms for regulation of Na+/Mg2+ exchange activity in ex vivo human red cells from Type 2 diabetes mellitus patients. We hypothesize that elevated Na+/Mg2+ exchange activity in the red cells of diabetic patients in comparison to normal subjects explains the low cellular Mg2+ levels observed in patients with diabetes. This suggests an uncoupling between the insulin receptor and the exchanger in these patients. Therefore, we hypothesize that PI3-kinase activity is altered in diabetic red cells when compared to normal. We will compare PI3-kinase activity and phosphorylated Akt levels in erythrocytes from normal and diabetic subjects. We expect that these studies will identify novel cellular mechanisms underlying insulin resistance as well as characterize cellular Mg2+ regulatory mechanisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHARACTERIZATION OF THE STRUCTURE AND FUNCTION OF DMP2 Principal Investigator & Institution: George, Anne; Associate Professor; Oral Biology; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2002; Project Start 01-JAN-2002; Project End 31-DEC-2006 Summary: The proper mineralization of bones and teeth has great importance in normal human growth and development including musculo-skeletal functions. The mineral phase in these tissues contributes to the hardness and comprehensive strength of the structure and also has a major physiological role as the metabolic reservoir of calcium and magnesium. Problems in the mineralization process are evident in a number of skeletal pathologies. One of the most interesting questions in mineralized tissue research is how, within the physiological environments, circulating calcium and phosphate and other mineral phase ions can be concentrated in specific, localized organs or tissues. Up
Studies
15
until this point we have defined little about the process by which this cascade is initiated and regulated. However, the organic matrix has been implicated to have a major role in regulating the mineralization process. We have focussed our efforts primarily on dentin mineralization because it is a simpler system than bone, but the two mechanisms are probably closely related. Our basic hypothesis for matrix-mediated mineralization, is that acidic macromolecules first bind within the collagen matrix and these are responsible for nucleating and starting the mineralization cascade. Probably these acidic macromolecules also regulate the size of carbonated hydroxyapatite crystals. In the search for the gene encoding for the principle acidic noncollagenous protein (NCP) of dentin, namely phosphophoryn (PP) we identified 2 clones one representing phosphophoryn now named DMP2 (dentin matrix protein 2) and the other DMP3 (dentin matrix protein 3) which is a compound of dentin sialoprotein and a mini "phosphophoryn"like domain. The amino acid sequence deduced from the partial DMP2 cDNA is of special interest because it clearly represents an aspartic acid and serine rich acidic protein of the type to be expected of a dentin matrix component. This gene has been tightly localized to mouse chromosome 5q21, equivalent to human chromosome 4Q21. This chromosome location is especially interesting because of the linkage of human chromosome 4q13-21 with the dentin mineralization disorder dentinogenesis imperfecta type II. In order to expand our understanding of the DMP2 gene structure and its function we propose the following specific aims: (1) To determine the complete primary structure of rat DMP2 (2) To delineate DMP2 promoter sequences and identify elements involved in tissue -specific regulation (3) To clone the human DMP2 gene in order to ultimately identify gene alterations in patients with Dentinogenesis Imperfecta Type II (4) To examine the temporal and spatial patterns of DMP2 expression during tooth development (5) To determine the calcium binding property of DMP2. The longterm goal is to understand the regulatory mechanism of DMP2 in dentin mineralization. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CINCINNATI COMPREHENSIVE SICKLE CELL CENTER Principal Investigator & Institution: Joiner, Clinton H.; Professor; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2003; Project Start 11-JUL-2003; Project End 31-MAR-2008 Summary: The Cincinnati Comprehensive Sickle Cell Center, based in the Division of Hematology/Oncology. at Children's Hospital Medical Center and affiliated with the University of Cincinnati College of Medicine, provides a full range of clinical services to people affected by sickle cell disease. Building on the finding that elevated homocysteine (Hcy) in sickle cell patients is associated with pyridoxine deficiency, an inter-Center collaborative research proposal examines the correlation of elevated Hey with activation of coagulation and endothelial cells in patients, and tests whether pyridoxine supplementation corrects these abnormalities. An interactive research team with expertise in molecular biology, membrane transport, in vivo cell kinetics, and clinical research will pursue projects focused on SS RBC dehydration, a key factor in sickle cell pathology, which results from two abnormal transport pathways, KCl cotransport (KCC) and sickling-induced cation leaks. The clinical study of Project 2 tests the therapeutic potential of dipyridamole, which inhibits sickling-induced cation leaks, and magnesium, which inhibits KCC, to improve SS RBC hydration in vivo. Project 3 examines the rate and mechanisms of hydration changes of SS RBC in vivo, using biotin label techniques unique to this Center. Project 4 explores the molecular basis of posttranslational regulation of KCC by cell volume in normal and SS RBC. Project 5 focuses on the erythroid isoforms of KCC and their transcriptional regulation. A Clinical Core
16
Magnesium
includes Pediatric and Adult Progra ms to provide comprehensive services to over 375 patients, to support basic and clinical research efforts, and to participate in inter-Center collaborative trials. An Education and Patient Services Core provides educational and psychosocial support for patients and families, and includes a Transition Program bridging the Pediatric and Adult Clinical Programs, in collaboration with the Sickle Cell Awareness Group and the Urban League of Cincinnati. An Administrative Core provides overall fiscal and programmatic management and serves as the focal point for Center activities, programs, and communication. The projects and cores in this proposal will be integrated with independently funded programs of newborn hemoglobinopathy screening follow-up, education and counseling, a Hemoglobin Diagnostic Laboratory, and other basic science and clinical research projects. The Cincinnati comprehensive Sickle Cell Center is poised to lead in the national effort to develop and test new therapies for sickle cell disease to improve the lives of affected individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL RESEARCH IN PEDIATRIC SICKLE CELL DISEASE Principal Investigator & Institution: Mueller, Brigitta U.; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2005 Summary: Clinical research in cell disease (SCD) has reached a new developmental milestone. Ironically, the recent success of hydroxyurea and other new treatments makes the work of clinical investigation harder. In order to move the field forward, we now need to develop clinical investigators who excel in the arenas of clinical investigation and sickle cell disease. Dr. Brigitta U. Mueller is an ideal person to grow into this role. She is a pediatric hematologist/oncologist who early on focused on clinical trials related to pediatric HIV disease at the National Cancer Institute's (NCI) intramural program. We have recruited her to Children's Hospital so that she can shift her attention to sickle cell disease while expanding her training and experience in clinical investigation. The goal of our five-year development plan is for her to become an independent investigator - lead sickle cell clinical research at our institution, and direct multi-institutional studies. Dr. Mueller will pursue her career development under the mentorship of Dr. Orah S. Platt, an experienced investigator in sickle cell disease, and Dr. Carlo Brugnara, an expert in design of innovative therapies in sickle cell disease. She will focus her efforts in four major areas: 1) Throughout the 5 years she will see and discuss patients with Dr. Platt, and meet with Dr. Brugnara to discuss research ideas and review data. 2) She will conduct and analyze the proposed clinical trial - evaluating the effect of Mg, a known inhibitor of K-Cl cotransport, in patients with Hb SC disease. Our hypothesis is that oral Mg will block K- Cl cotransport, prevent cell dehydration, and reduce polymerization-induced vasoocclusive complications. 3) She will design and implement a research infrastructure that will be used as a resource for future proposals. 4) She will do course work at the Harvard School of Public Health and obtain the MPH degree, concentrating on research design, implementation; and analysis. The trial of Mg for the prevention of pain crises in patients with Hb SC disease that we propose, will serve as a template for bringing a variety of treatments designed in basic laboratories to clinical trial. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CONTROL OF CALCIUM RELEASE IN SKELETAL MUSCLE FIBERS Principal Investigator & Institution: Schneider, Martin F.; Professor; Biochem and Molecular Biology; University of Maryland Balt Prof School Baltimore, Md 21201
Studies
17
Timing: Fiscal Year 2001; Project Start 01-JUL-1985; Project End 31-DEC-2002 Summary: The overall objective of this project is to gain deeper understanding of the mechanism controlling Ca/2+ release from the sarcoplasmic reticulum (SR) in skeletal muscle. Depolarization of the transverse tubules (TT) in a muscle fiber activates SR Ca/2+ release channels at triad junctions. We have recently used the Ca/2+ indicator dye fluo-3 with laser scanning confocal microscopy to detect discrete SR Ca/2+ release events ("Ca/2+ sparks"), which may arise from the opening of a few SR Ca/2+ channels or perhaps even from a single channel in functioning muscle fibers. These events, which originate at triad junctions and can be discerned at low levels of SR release activation, can be gated either by fiber depolarization or by physiological cytosolic ligands. They thus offer a unique window into the operation of SR Ca/2+ release channels within the normal structural and molecular environment in the muscle. We will characterize the frequency and pattern of occurrence of Ca/2+ sparks under either ligand- or voltageactivation in order to determine the effects of cytosolic [Mg/2+] and [Ca/2+], which are major physiological modulators of both voltage- and ligand-gated events. By determining the concentration dependence and interaction of these two divalent cations on event frequencies and patterns we will develop and test gating schemes for both types of activation and determine whether the same mechanistic steps underlie both ligand- and voltage-gated events. Determining the frequency of sparks under various conditions in these studies will provide the first characterization of the opening rates of SR channels in functioning muscle fibers. We will also use a diffusion and binding model, including diffusion of Ca/2+, CaDye and the sarcomeric distribution of Ca/2+ binding sites, to stimulate sparks and to estimate the amount of Ca/2+ related in a spark. Finally, we will determine whether a spark is generated by the opening of more than one SR Ca/2+ channel. These studies will provide deeper insight into the cellular and molecular mechanisms underlying regulation of Ca/2+ release in skeletal muscle in various physiological states as well as under possible pathological conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROL OF NEMATODE DEVELOPMENT Principal Investigator & Institution: Lambie, Eric J.; Biological Sciences; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2002; Project Start 01-AUG-1993; Project End 31-AUG-2006 Summary: (provided by applicant): The general goal of this work is to understand how cell division, differentiation and survival are regulated in response to extracellular and intracellular signals. The specific focus of this work is to determine how these phenomena are regulated within the gonad of the nematode, Caenorhabditis elegans. The work described in this proposal will focus on a set of genes that mediate the response of the somatic gonad progenitor cells to growth regulatory signals. Two genes, gon-2 and gon-11, have been identified that are required for gonadal cell divisions, beginning in the first larval stage. gon-2 encodes a predicted protein of the TRP cation channel family. The molecular identity of gon-11 is not yet known. In addition, four different gem (gon-2 extragenic modifier) loci have been identified by screening for revertants of the temperature-sensitive allele, gon-2(q388). A convergent line of work has resulted in the discovery of a new gene, neg-1, mutation of which leads to pleiotropic defects that include necrotic death of the gonadal precursor cells. neg-1 and weak alleles of gon-2 can be suppressed by increasing the level of magnesium in the medium. However, gon-11 and strong alleles of gon-2 show little or no suppression by increased magnesium levels. gon-2 is proposed to be expressed within the somatic gonadal cells, where it is activated in response to developmental signals and mediates
18
Magnesium
the influx of Mg2+ and Ca2+ These cations would then act in combination to promote cell division and maintain cell viability. The activity and downstream effects of gon-2 are regulated by the gem loci, gon-11 and neg-1. There has been no genetic analysis of how LTRP channels are regulated or how they control cell proliferation/viability. Similarly, there has been no genetic analysis of the regulation of metazoan development in response to the increases in intracellular Mg2+ and Ca2t Therefore, this work will provide a framework for understanding which cellular components are involved in the regulation of LTRP activity and how cells respond to increases in intracellular Mg2+ and Ca2+. The molecules that regulate cell division in response to extracellular signals have been well conserved evolutionarily and aberrancies in their regulation contribute to the onset of cancer in humans. Therefore, the results of this work are likely to be highly significant with regard to the etiology of human disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--INTER CENTER COLLABORATIVE CLINICAL RESEARCH Principal Investigator & Institution: Steinberg, Martin H.; Proofessor of Medicine and Pediatrics; Boston Medical Center Gambro Bldg, 2Nd Fl, 660 Harrison Ave, Ste a Boston, Ma 02118 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-MAR-2008 Summary: At birth, about 1 in 830 African Americans has HbSC disease. These patients have the same vasoocclusive complications as sickle cell anemia---only less often. Clinical descriptions of HbSC disease abound and substantial insights into its distinct pathophysiology have been gained. Nevertheless, few published trials of its treatment exist. Perhaps this is clue to the mistaken perception that HbSC disease is benign or that its rarity precludes conclusive therapeutic trials. We submit that: HbSC disease complications often merit acute treatment; a safe preventive treatment might forestall the disease complications that develop with age; novel means of reversing the pathophysiology of this disorder are available; sufficient patients exist to carry out a successful therapeutic trial. HbSC disease exhibits a characteristic erythrocyte dehydration compared with sickle cell trait or HbC trait erythrocytes. Cell dehydration plays a crucial role in the pathophysiology of HbSC disease because it allows for the intracellular HbS to reach concentrations that induce clinically significant HbS polymerization and cell sickling. K-CI cotransport is highly expressed in HbSC erythrocytes and determines their characteristic microcytosis and dehydration. Thus, HbSC disease represents the ideal target for therapies aimed at preventing K-CI cotransport mediated cell dehydration. Pilot studies showed that hydroxyurea and Mg affect erythrocyte hydration in HbSC disease. Our hypothesis is that oral Mg and hydroxyurea will increase intracellular Mg, block K-CI cotransport, prevent cell dehydration, and reduce polymerization-induced vasoocclusive complications. Accordingly, we propose a double-blinded, placebo-controlled trial to examine the effectiveness of hydroxyurea, magnesium pidolate and hydroxyurea + magnesium pidolate in reducing cell density in HbSC disease. As a secondary endpoint, because of the required brevity of this trial, we will examine the effectiveness of this treatment in preventing sickle cell disease-related vasoocclusive episodes. Other secondary endpoints include HbF level, F-cell numbers and hematologic measurements. The cellular effects of hydroxyurea and magnesium should modulate favorably the course of this disorder and the results of this study will provide the framework for a definitive efficacy trial. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: PROTEINS
CRYSTALLOGRAPHIC
STUDIES
OF
ELECTRON
19
TRANFER
Principal Investigator & Institution: Rees, Douglas C.; Professor; None; California Institute of Technology Mail Code 201-15 Pasadena, Ca 91125 Timing: Fiscal Year 2003; Project Start 01-JAN-1991; Project End 31-MAR-2008 Summary: (provided by applicant): Nitrogen fixation, the reduction of atmospheric dinitrogen to ammonia catalyzed by the enzyme nitrogenase, is the sole biological process for replenishing the nitrogen that is used in the biosynthesis of cellular materials. This enzyme system consists of two metalloproteins, the Fe-protein and MoFe-protein, that mediate the coupling of ATP hydrolysis to substrate reduction. Nitrogenase is a prototypic example of an enzyme with multiple and varied iron-sulfur clusters that participate in electron transfer and substrate reduction, as well as providing an excellent model for energy transduction of ATP hydrolysis. We will utilize crystallographic, biochemical and spectroscopic approaches to investigate the enzymatic and metallocluster assembly mechanisms of nitrogenase. Special emphasis will be placed on establishing the atomic identity and mechanistic significance of the light-atom ligand we recently observed in the center of the FeMo-cofactor, and in assessing the structural framework for the nucleotide-mediated gating of electron transfer processes in nitrogenase. Towards these objectives, we will address: 1. Very high resolution (<1.2A) structures of the nitrogenase proteins, and particularly the associated metalloclusters, in defined oxidation states. This will include not only establishing the metric parameters of the clusters, but also the use of diffraction-based methods to assign the oxidation states to individual metal sites within each cluster, and to determine the orientation of the relevant EPR g-tensors with respect to the metallocluster structures. Intermediates in the incorporation of the FeMo-cofactor into the MoFe-protein will also be studied to address aspects of the biosynthetic mechanism of the nitrogenase metalloclusters. 2. The interactions of Fe-protein with MgATP and the site(s) of binding to the physiological electron donors for the reduction of substrates, ferredoxin and flavodoxin. 3. The mode of substrate and inhibitor binding to nitrogenase under turnover conditions, initially through spectroscopic methods and ultimately by crystallography. From these studies, we seek to establish molecular details of mechanistically relevant states of the nitrogenase proteins that are essential to defining a chemically explicit mechanism for substrate reduction. Broader implications will address nucleotide dependent transduction processes based on the similarities between Fe-protein and other nucleotide switch proteins involved in signal and energy transduction processes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT OF LOW-COST MGB2/SOLID N2 MRI MAGNETS Principal Investigator & Institution: Iwasa, Yukikazu E.; Research Professor; None; Massachusetts Institute of Technology Cambridge, Ma 02139 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): The specific aim of this program is to demonstrate the feasibility and practicality of a low-cost, i.e., commercially viable, superconducting magnetic resonance imaging (MRI) magnet system specifically targeted for use in small hospitals, rural communities, and underdeveloped nations. The MRI system incorporates Magnesium Diboride (MgB2) composite conductor and an innovative cryogenic design/operation concept. We achieve this specific aim by building and operating a 0.5 Tesla (T)/80 cm bore demonstration magnet that, except for its lack of an
20
Magnesium
MRI-grade spatial homogeneity, satisfies key operational requirements of 0.5 T/80 cm MRI magnet systems. We are confident that commercial MRI magnet manufacturers will base their design for such MRI magnets on the demonstration system proposed herein. The demonstration system introduces two important firsts to MRI superconducting magnet technology, both benefiting the operation of the next generation low-cost MRI magnet systems: 1) a trend-setting MgB2 magnet for the next-generation of MRI magnets; and 2) an innovative cryogenic design/operation concept that introduces a volume of solid nitrogen in the magnet housing. The presence of solid nitrogen in the system, maintained by a cryocooler, enhances the magnet's heat capacity enormously, enabling the magnet to maintain its operating field over a limited time period even with its cryocooler shut off as would be in case of a power outage, an event not rare in rural communities and underdeveloped nations. Only during this shut off period, the magnet and the solid nitrogen, otherwise kept at a nominal operating temperature of 10 K by its cryocooler, will warm up to a design limit of 15 K over a period of one day. These specific temperatures and shut off duration are for the proposed demonstration magnet and a full-scale MRI magnet, a reference design of which is included in the application. The significance of this proposed demonstration magnet system is that its successful operation is expected to spur commercial production (and demand) of low-cost MgB2based MRI systems. The innovative cryogenic design/operation concept coupled to this low-cost magnet enables the MRI system to perform reliably even under working conditions much less reliable than those tacitly assumed for standard MRI systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIET SALT, CALCIUM KIDNEY STONES, BONE IN STONE FORMERS Principal Investigator & Institution: Massey, Linda K.; Professor; Food Science & Human Nutrition; Washington State University 423 Neill Hall Pullman, Wa 99164 Timing: Fiscal Year 2001; Project Start 15-SEP-2001; Project End 31-DEC-2003 Summary: (Scanned from the applicant's description): Increases in dietary salt, i.e. sodium chloride (NaCI), increase urinary calcium over the range of intakes commonly consumed. Both salt loading studies and reports of within-population correlations find that increased urinary calcium losses are approximately 1 mmol (40 mg) for each 100 mmol (2300 mg) increase in dietary NaC1. Individuals with hypercalciuria and/or a history of calcium kidney stones appear to have 2 times greater proportional increases in urinary calcium per 100 mmol increase in salt intake. Thirty-two subjects with a history of at least one calcium oxalate kidney stone will be recruited; 16 with hypercalciuria, 16 normocalciuria. This study consists of two, seven-day periods. For all seven days of both dietary treatments, each participant will eat only the foods provided by the investigators, a nutritionally adequate diet prepared from common foods containing 50 mmol/d salt. The first five days of each treatment (adaptation), the participant will be free-living, the sixth and seventh in the WSU metabolic unit. One of the two weeks, 150 mmol supplemental salt will be added as tablets taken with each meal; the total of 200 mmol is the average consumption measured in previous studies of stone formers. The major outcome measures are urinary oxalate, calcium, magnesium, phosphate and citrate, and two measures of calcium salt saturation as indicators of risk of calcium salt precipitation. The two measures of calcium salt precipitability will be the Tiselius risk index, a measure of calcium oxalate precipitability from solution which includes the effects of volume, magnesium and citrate concentrations as well as calcium and oxalate, and Ap (CaP), a measure of calcium phosphate precipitability from solution, which includes the effects of volume, citrate and pH as well as calcium and phosphate. Because
Studies
21
increased urinary calcium loss from adding salt occurs, bone breakdown may be increased in compensation, so 4 markers of bone turnover will be measured, bone alkaline phosphatase, osteocalcin, deoxypyridinoline, and N-telopeptide. We will also compare the responsiveness of hypercalciuric vs normocalciuric participants for all the outcome variables, because the literature suggests that hypercalciuric stoneformers may be more sensitive to dietary salt effects on urinary calcium. Reduction of dietary NaC1 from typical intakes of 200 mmol/day to an intake of 50 mmol/day may decrease the risk of recurrence of calcium-containing kidney stones and slow rates of bone loss, thus reducing risk of osteoporosis as well. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIPYRIDAMOLE/MAGNESIUM TO IMPROVE SICKLE CELL HYDRATION Principal Investigator & Institution: Kalinyak, Karen A.; Medical Director; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2003; Project Start 11-JUL-2003; Project End 31-MAR-2008 Summary: Vaso-occlusivc episodesare common among patients with sickle cell anemia (SCA), causing pain and chronic organ damage. SCA is characterized by the presence of dense, dehydrated sickle red blood cells (SS RBC), which are rheologically abnormal and are selectively trapped during vaso-occlusion. Strategies to prevent cellular dehydration would offer important therapeutic options that might decrease vaso-occlusive episodes. SS RBC dehydration results from cation depletion mediated by two cation transport systems, a sickling-induced (SI) leak pathway and the KCI cotransporter (KCC). Previous work at this Center has shown that di-pyridamole inhibits the SI fluxes of Na, K and Ca in vitro. Increasing cellular magnesium inhibits KCC activity and increases cellular hydration in animal models of SCA. A small clinical study in SCA patients demonstrated that Mg supplementation increased cellular Mg, reduced KCC activity and improved red cell hydration. This study will test the hypothesis that significant reduction in SS RBC dehydration will be seen in patients with SCA treated with either dipyridamole or magnesium. An additive, and possibly synergistic, effect on dense cell formation is hypothesized in patients treated simultaneously with both agents. A prospective, randomized, crossover, repeated measures design will be conducted among 48 patients with SCA, ages 12 years and older. Patients will be recruited from the Cincinnati Comprehensive Sickle Cell Center and the Sickle Cell Program at Wayne State University in Detroit. This design will allow for efficient comparison of the three treatment options; dipyridamole alone, magnesium alone or a combination of both. We anticipate that these therapies will be well tolerated by the patients. Primary outcome measures include the number of dense cells, assessed by automated cell counting and phthalate density gradients, cellular cation content, cell volume and hemoglobin concentrations. Using the biotin label technique pioneered in Cincinnati, measurements of red cell survival and rate of dense cell formation will be made in six patients in each treatment group, and will shed light on the mechanisms underlying SS RBC dehydration and its postulated inhibition by dipyridamole and Mg. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECTS OF VITAMIN B3 ON TRAUMATIC BRAIN INJURY Principal Investigator & Institution: Hoane, Michael R.; Psychology; East Carolina University 1000 E 5Th St Greenville, Nc 27858 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2005
22
Magnesium
Summary: (provided by applicant): Annually, approximately 2 million Americans suffer a moderate to severe traumatic brain injury (TBI). These injuries produce enduring disabilities that include cognitive, sensory, motor, and emotional impairments. The associated health care costs from these injuries are staggering. Confounding this major public health issue is the fact that currently there are very few pharmacological treatment options for patients who have suffered TBI. In part, this occurs because many newly synthesized drugs fail in various stages of efficacy testing. Given the fact that newly synthesized drugs fail in clinical trials it seems reasonable to begin to examine the potential efficacy of more natural substances. It has recently been demonstrated that administration of vitamin B3 (B3) following experimentally induced stroke reduces the size of the infarct and can improve behavioral outcome in rats. In addition, the preclinical efficacy of magnesium pharmacotherapy has been well established. The proposed research will investigate the potential preclinical efficacy of B3 to lessen the physiological consequences of brain injury and improve behavioral outcome. We will use the rodent bilateral frontal cortical contusion injury model, which is similar to a frontal head injury sustained in a car accident. The specific aims of this study are to: 1) determine if administration of B3 following injury can significantly reduce the cognitive and sensorimotor impairments seen following TBI; 2) determine the best injections parameters (i.e., window of opportunity and dose response) for B3 pharmacotherapy following TBI; 3) determine if administration of B3 following injury can significantly decrease the amount of injury-induced edema and injury-induced magnesium depletion; 4) determine the effect of B3 pharmacotherapy on apoptosis and reactive gliosis following TBI. The research proposed here will determine if B3 holds any preclinical efficacy for the treatment of TBI and begin to define the parameters for the development of B3 as a clinical treatment for TBI. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: F1 ATPASE CHEMICAL MECHANICAL COUPLING MECHANISMS Principal Investigator & Institution: Frasch, Wayne D.; Professor; Botany and Microbiology; Arizona State University P.O. Box 873503 Tempe, Az 852873503 Timing: Fiscal Year 2001; Project Start 01-AUG-1996; Project End 31-MAR-2005 Summary: (Applicant's Description) The relationship between the chemistry of ATP hydrolysis and the mechanical events that result in rotation of the gamma subunit of the F1-ATPase will be examined. Catalytic function of F1 derives from the asymmetry of the catalytic sites that, in turn, depends on the gamma subunit and the Mg2+ cofactor. The driving force for gamma rotation is believed to result from the initial binding energy of the Mg2+-ATP complex and from the release of phosphate which is a Mg2+ ligand. The ability of the gamma subunit of F1 to rotate will be measured using a fluorescent microsphere attached to the gamma subunit as recorded using a CCD camera. The torque generated during gamma rotation as well as the dwell time between rotations will be as assessed with F1 that contains site-directed mutants or other treatments at locations that may affect the coupling between hydrolysis and gamma rotation. Three loci are targeted for investigation that include: (a) Switch 3, the gamma subunit Cterminus and the beta subunit greasy bearing which is close to the site of Mg2+ binding and phosphate release; (b) Switch 2, the interface between the gamma subunit and the beta subunit DELSEED sequence; and (c) Switch 1, where hydrogen bonds form between the gamma subunit and the betaE subunit catch loop. Experiments will examine the possibility that Switch 1 is part of an escapement mechanism that only allows gamma rotation when the catalytic sites are filled with metal-nucleotide complex.
Studies
23
Experiments are also designed to identify changes in metal ligands at the catalytic sites that are specifically associated with conformational changes linked to gamma rotation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FACTORS
FUNCTIONAL
SPLICEOSOME
AND
EXTRINSIC
SPLICING
Principal Investigator & Institution: Lin, Ren-Jang; Beckman Research Inst of City of Hope Helford Building Duarte, Ca 910103000 Timing: Fiscal Year 2003; Project Start 01-AUG-1988; Project End 31-MAR-2007 Summary: (provided by applicant): The majority of messenger RNA sequences in eukaryotes are in fragments that need to be correctly spliced in order to be translated into functional proteins. Defects in pre-mRNA splicing have been linked to many human diseases including neurological dysfunction and cancer. The broad, long-term objectives of this grant are to understand the structure and function of the large ribonucleoprotein complex, called the spliceosome, that carries out the pre-mRNA splicing reaction. The spliceosome field has made tremendous progress since its conception almost 20 years ago; however, it is still not clear what factors exist in the core of the spliceosome and how the core is activated or remodeled for catalysis. This proposal will investigate the role of the U6 small nuclear RNA in spliceosome catalysis as well as the function of extrinsic splicing protein factors at the spliceosome core. Specific aim 1 is to study the 3' intramolecular stem-loop (ISL) of yeast U6 snRNA, which binds a magnesium ion required for the first transesterification reaction. We will test whether the magnesium at the U6/3'ISL is at the 5' splice site of the pre-mRNA by using double sulfur substitutions and rescuing with a thiophilic metal ion. We will use crosslinking strategies to test whether the U6/3'ISL is held in the spliceosome core by RNA or by protein. Specific aim 2 is to study how an RNA helicase called Prp2 remodels the core of the spliceosome. We will investigate how a prp2-suppressor protein or an intermolecular U2/U6 helix RNA contributes to the spliceosome recognition by Prp2. We will also use crosslinking and yeast genetics approaches to test the interaction between Prp2 and the spliceosomal RNAs. The specific aim 3 is to investigate whether the activation of the spliceosome by Prp2 is conserved in human. We will inhibit DBP2 by expressing a small interference RNA (siRNA) or a dominant-negative mutant targeting DBP2 in human cells. We will analyze the splicing machinery when DBP2 function is impaired in vivo or in vitro. The proposed study shall reveal the dynamic features and the remodeling of the spliceosome core in yeast and human. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENOMIC ENZYMOLOGY: OMP DECARBOXYLASE SUPRAFAMILY Principal Investigator & Institution: Gerlt, John A.; Professor & Head; Biochemistry; University of Illinois Urbana-Champaign Henry Administration Bldg Champaign, Il 61820 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2007 Summary: (provided by applicant): We want to understand the structural origins of functional diversity in the (beta/alpha)8 barrel fold, the most commonly observed fold in enzymes. We have identified a group of homologous (beta/alpha)8-barrel fold enzymes that catalyze reactions with unrelated substrates and mechanisms in different metabolic pathways. Orotidine 5'-phosphate decarboxylase (OMPDC) is the best characterized member of this "suprafamily." We propose to determine structure/function relationships for other members of the OMPDC suprafamily so that
24
Magnesium
we can understand the structural strategies for using a homologous scaffold to catalyze unrelated reactions. These studies significantly expand the scope of functional diversity beyond those found in mechanistically diverse enzyme superfamilies, e.g., the enolase and crotonase superfamilies, in which homologous enzymes catalyze different reactions that share a common partial reaction. The four Specific Aims integrate mechanistic and structural studies: the mechanistic studies will be performed in Dr. Gerlt's laboratory at Illinois (P.I.); the structural studies will be performed in Dr. Rayment's laboratory at Wisconsin (Co-P.I.): 1) Structure/function relationships will be established for 3-keto-Lgulonate 6-phosphate decarboxylase that catalyzes Mg2+-dependent decarboxylation of beta-ketoacids via an enediolate intermediate. 2) Structure/function relationships will be established for D-arabino-hex-3-ulose 6-phosphate synthase that catalyzes Mg2+dependent aldol condensation via an enediolate intermediate. 3) Structure/function relationships will be established for D-ribulose 5-phosphate 3-epimerase that catalyzes divalent metal-independent 1,1-proton transfer via an enediolate intermediate. 4) A structural blueprint for functional diversity in the ((beta/alpha)8-barrel fold will be tested. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIGH TOUGHNESS TEXTURED DENTAL GLASS CERAMICS Principal Investigator & Institution: Denry, Isabelle L.; Associate Professor; Restorative/Prosthetic Dentrsy; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2001; Project Start 01-FEB-2000; Project End 31-JAN-2003 Summary: Dental ceramics are chemically durable, biocompatible and have the greatest potential for achieving superior esthetics. They are currently gaining new interest while metal-based restorative products are progressively being eliminated from the oral environment. During the past five years, a novel technique has been introduced in dentistry for fabricating all-ceramic dental restorations: hot-pressing. However, most of the currently available pressable ceramics have low fracture toughness, implying possible failure of all-ceramic restorations. The overall objective of the proposed research is to develop high-toughness textured glass-ceramics for hot-pressed allceramic restorations. The texture will be obtained during hot-pressing of the nucleated glass. This unique microstructure will be associated with an anisotropic increase in fracture toughness, due to the alignment of the plate-shaped crystals in the direction of pressing. The strategy is to investigate the effect of magnesium oxide on the thermal and mechanical properties of a glass-ceramic in the system Li2O-Na2O-K2O-CaO-MgOSiO2-F. The hypothesis to be tested is that increasing concentrations of magnesium will increase the fluidity of the glass and its working range. The nucleation and crystallization behavior of the glasses will be studied by x-ray diffraction, scanning and transmission electron microscopy and nuclear magnetic resonance spectroscopy. The thermal properties will be analyzed by differential thermal analysis and dilatometry. The biaxial flexural strength and fracture toughness will also be investigated. The study of thermal and mechanical properties will allow material selection for hot-pressing. Hotpressing studies will be divided in two steps, first a simplified, low fusing version of the glass-ceramic material studied will be hot-pressed as control. Second, the glass ceramic material itself will be hot-pressed. The optical scattering and absorption coefficients will be calculated from reflectance measurements. The mechanical properties of both materials will be tested in both the direction of pressing and the normal direction, the degree of texture will be characterized by SEM. The effect of annealing on the crack
Studies
25
healing behavior and flexural strength of the glass-ceramic developed will be investigated last. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HU AND MG COMBINATION THERAPY OF SCD--PHASE I /II TRIAL Principal Investigator & Institution: Wang, Winfred C.; Member; St. Jude Children's Research Hospital Memphis, Tn 381052794 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-MAR-2008 Summary: The use of combination chemotherapy has been developed successfully over several decades for the treatment of cancer and, more recently, HIV infection. However, the principles of treatment with multiple drugs that have distinct and additive or synergistic mechanisms of action and non-overlapping toxicity have not been applied to the treatment of sickle cell disease. We propose the combination ofhydroxyurea, which stimulates fetal hemoglobin synthesis, and magnesium, which improves red cell hydration, in Phase I and Phase II trials in children and adolescents with sickle cell disease. Patients eligible for this trial will have been treated with hydroxyurea for a minimum of 6 months before they are begun on oral magnesium pidolate. In Specific Aim 1, the Phase I trial, we will determine the maximum tolerated dose 0VITD) of magnesium pidolate, beginning at a dose of 0.5 mEq/kg/day. Specific Aim 2 is to determine the effect of combination treatment including magnesium at the previously determined MTD, on prevention or reversal of CNS complications in a preselected population of patients identified in a screening phase to have a silent infarct on MR/or a stenotic lesion on MRA. Patients in the Phase II study will be followed for 3 years, which will allow statistical power to detect decreases in the rate of new or more extensive silent infarcts and new overt strokes and improvement in stenotic lesions in the respective populations. In Specific Aim 3 we will determine the effect of the combination of hydroxyurea and magnesium on hematologic parameters and red cell characteristics by distributing serial blood samples to 4 investigators whose research laboratories will examine red cell metabolism, ionized magnesium levels, red cell adhesion, and whole blood viscosity. In particular, the studies of Dr. Carlo Brugnara will elucidate the combined effects ofhydroxyurea and magnesium on red cell K and Mg content, K-CI co-transport, and the fraction of dense red cells. In Specific Aim 4 we will examine the effect of the combination of hydroxyurea and magnesium on nutritional status looking at measures of dietary intake, growth, strength and endurance, protein metabolism, and in particular, resting energy expenditure (REE), which is consistently abnormal in sickle cell patients. In summary, through Phase I and II studies, Project 1 will determine the MTD of magnesium when used in combination treatment with hydroxyurea and will assess the efficacy of this combination on CNS and nutrition status and red cell physiology. These data in conjunction with Project N, the proposed Network study, will establish the feasibility and efficacy of combination drug treatment in patients with sickle cell disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IVMT FOR FIBROMYALGIA SYNDROME: A PILOT STUDY Principal Investigator & Institution: Katz, David L.; Director of Medical Studies; Griffin Hospital 130 Division St Derby, Ct 06418 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2004
26
Magnesium
Summary: (provided by applicant): Fibromyalgia syndrome (FMS) is a prevalent and debilitating condition for which definitive therapy is lacking and urgently needed. Characterized by widespread pain and muscle tenderness, the syndrome affects roughly 6 million people in the United States alone. Conventional therapies targeting a variety of theories regarding etiology and pathogenesis have largely proved ineffective. As a result, the great majority of FMS sufferers seek complementary/alternative medicine (CAM) therapies for palliation of their symptoms, but often with limited success. Intravenous micronutrient therapy (IVMT) with the Myer's Cocktail has emerged as a popular treatment for fibromyalgia. While the theoretical rationale for this treatment approach is limited, a therapeutic effect is plausible, and the empirical evidence supporting it appears to be strong. An on-line survey of treatment clinics representing 12,000 patient experiences with IVMT conducted exclusively in support of this application suggests that the therapy is very safe and often (60-80%) effective. Despite its popularity, and the increasing prevalence of its use, IVMT has not been subjected to formal investigation. We therefore propose a randomized, double-blind, placebocontrolled pilot study of IVMT for fibromyalgia with validated functional and pain measures as the outcomes of interest. The study will be conducted in 4 phases over a 12month period with assessment of treatment effect based primarily on the tender point index (TPI) derived from the examination of a dedicated, board-certified research rheumatologist blinded to the subjects' treatment status. The study will be conducted out of the Yale-Griffin Prevention Research Center, in collaboration with the Integrative Medicine Center in Derby, CT, a partnership already actively involved in CAM outcomes research with CDC funding. The proposed pilot study is designed to demonstrate feasibility and safety, and is adequately powered to provide evidence of treatment efficacy. Follow-up study will be indicated if pilot data are encouraging as anticipated; a consortium of sites (the Northeast Regional CAM Consortium) in which the applicant is a member has already expressed interest in participating in follow-up study pending results of the pilot. The identification of an effective, safe, inexpensive therapy for fibromyalgia would represent a great advance, and a major contribution to the public health. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: KINETIC/THERMODYNAMIC/STRUCTURAL STUDIES OF RNA FOLDING Principal Investigator & Institution: Pan, Tao; Associate Professor; Biochem and Molecular Biology; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2001; Project Start 01-AUG-1998; Project End 31-JUL-2002 Summary: The biological function of RNA is intimately related to its three-dimensional structure. How an RNA sequence specifies its tertiary structure is an ultimate goal of RNA structural biology. In order to understand how RNA folding is accomplished, it is essential to elucidate the thermodynamic stability of the RNA structure and the kinetic folding pathway. The long-term objective of this proposal is to determine the thermodynamics and the folding kinetics of two highly structured RNAs. In the first two aims, the ribozyme component from bacterial RNase P will be studied to understand folding of a large RNA containing multiple domains. The compactness and tertiary structure of two known thermodynamic/kinetic intermediates will be evaluated. The role of the domain-domain interactions in folding will be examined. Folding will also be studied during transcription under simulated cellular conditions to determine how large RNAs may fold in vivo. In addition, RNase P RNA variants will be isolated, whose folding pathway may be altered from that of the wild-type ribozyme. In
Studies
27
the third aim, transfer RNA will be studied as a model system to understand folding of a single, isolated tertiary structure. The tRNA studies will not only elucidate how tRNAs fold, but also more importantly, generate a conceptual framework in physico-chemical analysis for folding of all RNAs. The results from this proposal will deepen our understanding in how an RNA folds into a particular tertiary structure and establish the fundamental principles of RNA folding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAGNESIUM DEFICIENCY: EFFECT ON BONE AND MINERAL Principal Investigator & Institution: Rude, Robert K.; Medicine; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2005 Summary: The objective of this proposal is to increase our understanding of the role of magnesium (Mg) deficiency in the etiology of osteoporosis. While sex steroid deficiency is a major factor in postmenopausal osteoporosis, nutrition is also important. Dietary Mg intake has been associated with bone mass in aging and postmenopausal osteoporosis. Disorders in which Mg deficiency is common such as alcoholism, malabsorption syndrome and diabetes also have an increased risk of osteoporosis. The average dietary Mg intake in women is 68 percent of the RDA indicating that a large proportion of our population have substantial dietary Mg deficits. Severe Mg deficiency in the rat results in impaired bone growth, osteopenia and skeletal fragility. The level of dietary Mg intake that results in osteoporosis in rat or human is unknown. In our proposal, we will employ dietary Mg deprivation in the rat at 10 percent, 25 percent, and 50 percent of recommended nutrient requirement. This reduction in Mg intake reflects levels of dietary Mg inadequacy in our population. Our first specific aim is to determine the dietary intake that will result in Mg deficiency as assessed by bone Mg content. Another specific aim is directed at assessing the effect of these dietary Mg intakes on bone histology, histomorphometry and bone turnover; ie. at what level of Mg intake does osteoporosis occur and is it reflected by alteration in osteoblast and osteoclast activity. The mechanism for the previously observed osteoporosis in severe Mg deficiency is unclear but may involve systemic hormones or local factors regulating bone cell activity. Severe Mg deficiency in humans and rats result in low serum parathyroid hormone (PTH) and 1,25(OH)2-vitamin D which may contribute to reduced bone formation. We will quantify the effects of low Mg intake on calcium homeostasis by determining serum calcium, PTH and 1,25(OH)2-vitamin D levels. The cause of increased osteoclastic bone resorption in severe Mg deficiency is unclear. Cytokines can increase osteoclastic bone resorption and are implicated in postmenopausal osteoporosis. Mg deficiency in the rat results in an increase in serum substance P which in turn stimulates production of various cytokines. We will therefore measure serum substance P, TNFalpha, IL1beta, and IL6 in the Mg deficient rat and perform immunohistochemical staining of bone for these cytokines. Parallel studies will be performed in which a specific substance P receptor inhibitor will be administered to directly test whether generation of these cytokines are responsible for Mg deficiencyinduced bone loss. These studies should substantiate our hypothesis that Mg depletion contributes to osteoporosis and provide mechanistic explanations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MAGNESIUM DEFICIENCY: GLOBAL GENE EXPRESSION STUDY Principal Investigator & Institution: Schultheis, Patrick J.; Biological Sciences; Northern Kentucky University University Dr Highland Heights, Ky 41076
28
Magnesium
Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): Magnesium (Mg2+) is the second most abundant cation in cells. Because Mg2+ serves as a cofactor in hundreds of enzymatic reactions, it has a profound influence on many biological activities including DNA and protein synthesis, ion transport, intracellular signal transduction, and cell growth and differentiation. Consequently, it is not surprising that Mg2+ deficiency has been implicated in various disease states such as atherosclerosis, hypertension, diabetes, asthma, and alcoholism. Yet, our understanding of Mg2+ homeostasis lags far behind that of other cations such as Ca2+, Na+, K+, and H+, largely because the transporters of Mg2+ have not been identified at the molecular level. In addition, little work has been conducted concerning the effects of Mg2+ deficiency on gene expression, especially with respect to its role in various pathological conditions. Gene expression profiling using cDNA microarrays represents a powerful method for identifying genes involved in specific cellular or disease processes. We propose to use this technology to identify genes involved in magnesium homeostasis and to elucidate the mechanisms by which magnesium deficiency leads to various disease states. By comparing global gene expression patterns of select organs of normal mice to their counterparts in magnesiumdeficient mice, it should be possible to identify genes involved in magnesium homeostasis, such as those encoding magnesium transporters. Genes that are aberrantly expressed under magnesium-deficient conditions should also be identified. This should lead to a better understanding of magnesium's role in health and disease. In Aims 1 and 2 commercial cDNA microarrays will be used to investigate the effects of acute and chronic magnesium deficiency on gene expression, respectively. In Aim 3 suppression subtraction hybridization libraries will be constructed from various organs of magnesium-replete and magnesium-deficient mice. Clones from the library will then be used to construct custom cDNA microarrays for gene expression profiling. This combination of techniques should lead to the identification of all genes that are differentially expressed during magnesium deficiency. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAGNESIUM HOMEOSTASIS IN MICROORGANISMS Principal Investigator & Institution: Maguire, Michael E.; Professor; Pharmacology; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001; Project Start 01-JAN-1991; Project End 31-DEC-2002 Summary: Mg2+ is the most abundant intracellular divalent cation. Its chemistry is unique among the biological cations. Likewise, its various transport systems are also unique or are highly unusual members of existing families. Mg2+ also plays a fundamental regulatory role in prokaryotic cells and especially in bacterial pathogenesis. Our long-term goal is to understand both Mg2+ transport processes and Mg2+ regulation of gene expression to formulate an overall picture of Mg2+ homeostasis. CorA represents a new family of transport proteins lacking similarity to other known proteins. It is ubiquitous in the Bacteria and Archaea with homologs in yeast. Phylogenetic and structural studies suggest the various members of the family may differ in both function and membrane topology. All CorA's contain a large soluble N-terminal domain and a small C-terminal membrane domain, facilitating study of its structure through treatment as two separable structural domains. CorA has been shown to be oligomeric, the soluble domain has been purified and retains secondary structure, and a partial pathway for Mg2+ movement through the membrane has been identified. This renewal outlines continuing studies to define the functional structure of CorA. The 23 kDa MgtC protein is encoded by the first gene of a two gene operon along with the P-
Studies
29
type ATPase Mg2+ transporter MgtB. Operon transcription is controlled by extracellular Mg2+ concentration through the PhoPQ two component regulatory system. PhoPQ is an essential regulator of virulence in S. typhimurium. Insertional mutagenesis of the mgtCB operon renders S. typhimurium essentially avirulent, with the large majority of this decrease in virulence due to loss of mgtC. Expression of MgtC is unusual. Transcription of the operon is increased several thousand fold at low extracellular Mg2+ concentrations, but only MgtB protein is expressed. In contrast, if the mgtB gene is insertionally inactivated, MgtC is expressed in large amounts. MgtC has been purified to homogeneity and appears to be an oligomeric membrane protein. Preliminary data suggest that it alters cellular Ca2+ homeostasis. This renewal proposal seeks to determine the basis for its unusual expression and to investigate its possible role in Ca2+ homeostasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAGNESIUM SULFATE FOR NEUROPROTECTION AFTER BRAIN TRAUMA Principal Investigator & Institution: Winn, H Richard.; Professor and Chairman; Neurological Surgery; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001; Project Start 01-JUL-1983; Project End 31-JUL-2002 Summary: (Adapted from Applicant's Abstract): Traumatic brain injuries represent an important health problem; they occur with high frequency, the population affected contains many previously healthy young people, and they are associated with high mortality and morbidity. The proposed study continues on our 16 years of experience in conducting clinical trials evaluating treatments for preventing seizures following head injury (Dilantin Prophylaxis of Post-traumatic Seizures, Valproate for Prophylaxis of Post-traumatic Seizures) and in examining neurobehavioral outcome after head injury. Our previous trials showed that Dilantin prevents early seizures but is ineffective in preventing epilepsy following head trauma and that Valproate is possibly associated with higher mortality that short-term Dilantin. The trials and outcome studies found that epileptic seizures, serious cognitive difficulties, high unemployment, and inability to live independently are common among survivors of moderate or severe head injury. Using a randomized, double-blind design, the present study will evaluate magnesium sulfate as a neuroprotectant and anti-epileptogenic agent following head injury. Magnesium sulfate is a widely used, well-tolerated compound that has been shown in the laboratory to be effective in reducing seizures and also in limiting neuronal damage and in improving functional outcome following experimental head injury. Specifically, the study will test the hypothesis that magnesium sulfate, when given within 8 hours of a moderate or severe head injury, a) increases survival, b) decreases seizures, and c) improves neurobehavioral functioning. Additionally, the study will: assess the effects of timing of dosage (e.g. <4 hours vs. 4-8 hours), gender, and race; determine the rate of adverse events: and evaluate the time course and correlates of total and ionized magnesium concentrations. Patients with moderate or severe head injury (postresuscitation Glasgow Coma Scale 3-12) will be randomized to receive high doses of magnesium sulfate or placebo. Treatment will be started as soon as possible, and definitely within 8 hours of injury. The initial bolus of magnesium sulfate will be followed by a 7 day infusion to keep magnesium levels high during the period when secondary damage from the head injury is most likely. Patients will be closely monitored for survival and seizures over the first six months after injury and will have a comprehensive neurobehavioral assessment at six months after injury. In summary, this placebo-controlled, randomized clinical trial will determine the effects of magnesium
30
Magnesium
sulfate on survival, post-traumatic seizures, and the patients behavioral functioning following head injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAGNESIUM SULFATE FOR NEUROPROTECTION AFTER BRAIN TRAUMA Principal Investigator & Institution: Temkin, Nancy R.; Associate Professor; Neurological Surgery; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2002; Project Start 01-JUL-1983; Project End 31-AUG-2005 Summary: (provided by applicant): Traumatic brain injuries represent an important health problem: they occur with high frequency, the population affected contains many previously healthy young people, and they are associated with high mortality and morbidity. This study continues on our 20 years of experience in conducting clinical trials evaluating treatments for preventing seizures following head injury (Dilantin Prophylaxis of Post-traumatic Seizures. Valproate for Prophylaxis of Post-traumatic Seizures) and in examining neurobehavioral outcome after head injury. The trials and outcome studies found that epileptic seizures, serious cognitive difficulties, high unemployment, and inability to live independently are common among survivors of moderate or severe head injury the ongoing trial tests whether these consequence can be ameliorated by magnesium sulfate. Using a randomized, double-blind design, the present study evaluates magnesium sulfate as a neuroprotectant and anti-epileptogenic agent following head injury. Magnesium sulfate is a widely used, well tolerated compound that has been shown in the laboratory to be effective in reducing seizures and also in limiting neuronal damage and in improving functional outcome following experimental head injury. Specifically, the study will test the hypothesis that magnesium sulfate, when given 8 hours of a moderate or severe head injury, a) increases survival b) decreases seizures, and c) improves neurobehavioral functioning. Additionally, the study will: assess the effects of timing of dosage (e.g. <4 hours vs. 4-8 hours), gender, and race; determine the rate of adverse events; and evaluate the time course and correlates of total and ionized magnesium concentrations. Patients with moderate or severe head injury (post-resuscitation Glasgow Coma Scale 3-12 or having an early craniotomy) are randomized to receive moderate doses of magnesium sulfate or placebo. Treatment is started as soon as possible, and definitely within 8 hours of injury. The initial bolus of magnesium sulfate is followed by a 5 day infusion to keep the magnesium levels elevated during the period when secondary damage from the head injury is most likely. Patients are closely monitored for survival and seizures over the first six months after injury and have a brief neurobehavioral assessment at I and 3 months and a comprehensive neurobehavioral assessment at six months after injury. In summary, this placebo-controlled, randomized double-masked clinical trial will determine the effects of magnesium sulfate on survival, post-traumatic seizures, and the patients' functional status and neurobehavioral functioning following traumatic brain injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MAGNESIUM SUPPLEMENTATION TO PREVENT BONE LOSS Principal Investigator & Institution: Ryder, Kathryn M.; Medicine; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2006
Studies
31
Summary: PROPOSAL (Adapted from the applicant's abstract): The candidate is Assistant Professor of Medicine at the UTSM, Memphis. UTSM has a Clinical Research Center that provides resources through which the candidate can perform patientoriented clinical research. The Departments of Internal and Preventive Medicine have numerous ongoing experimental and observational trials. This provides opportunities for the candidate to collaborate with faculty. The candidate has proposed a five-year training plan, with the long- term goal of practicing medicine, performing patientoriented research and teaching residents and students. The candidate also plans to serve as a resource and mentor for faculty who wish to learn research design and literature interpretation. The candidate will complete a Master's degree in epidemiology and take advanced courses beyond the degree. She will attend research meetings in the Metabolic Bone Center, the Department of Preventive Medicine, and the St. Jude-LeBonheurUTSM Bone Coalition. Finally, the candidate will investigate the effect of magnesium (Mg) on bone loss in healthy older adults. Mg supplementation has attractive but unproven benefits in bone health. In uncontrolled and unblinded trials, Mg supplementation leads to large gains in bone density. The mechanism of action is not known. Severe Mg deficiency has an impact on calciotropic hormones, and changes in these hormones may have a direct effect on bone as well as an effect on gut calcium absorption. Whether Mg supplementation affects calciotropic hormones in healthy subjects without severe Mg deficiency is not known. Mild Mg deficiency may be common, since as many as 75% of the elderly do not meet the estimated average requirement for Mg. This study will test the following hypotheses: 1) Mg supplementation reduces bone resorption in healthy adults; 2) Mg supplementation increases gut calcium absorption; and 3) The increase in calcium absorption occurs through changes in circulating levels of calciotropic hormones. This will be a doubleblinded placebo-controlled trial of Mg (500 mg/day) in 92 healthy men and women between the ages of 55-75. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHANNEL
MAGNESIUM-NUCLEOTIDE
DEPLETION
ACTIVATED
ION
Principal Investigator & Institution: Fleig, Andrea; Queen's Medical Center 1301 Punchbowl St Honolulu, Hi 96813 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2006 Summary: (provided by applicant): Metal ions contribute to fundamental biological processes, including maintenance of protein architecture, determination of enzyme catalytic activity and signal transduction. Transport mechanisms for trace metal ions are not well characterized, and no ion channel with the ability to permeate significant amounts of these ions has yet been described. Recently, a superfamily of the putative calcium-permeable cation channel family TRPC (transient receptor potential channels) has been identified. Our data characterize a novel and widely expressed ion channel of this superfamily, LTRPC7, which has an intriguing selectivity profile for trace metal ions. LTRPC7 is regulated by intracellular levels of Mg.ATP and is non-redundantly essential for cell viability. The current proposal characterizes this novel ion channel using electrophysiological and molecular biology techniques. Specific Aim 1 focuses on the biophysical characterization of recombinant and native LTRPC7. First, the channel?s selectivity profile for trace metal ions will be analyzed. Second, since LTRPC7 is dependent on nucleotide triphosphates, these findings will be extended to include other phospho-nucleotides. Third, the involvement of phosphorylation in channel function will be tested. Specific Aim 2 concentrates on the functional and molecular analysis of
32
Magnesium
LTPRC7 and introduces targeted point mutations to evaluate the structural requirements that determine the selectivity and modulation of LTRPC7. Specific Aim 3 addresses the physiological significance of LTRPC7 currents. It is hypothesized that endogenous LTRPC7 contributes to calcium influx pathways normally attributed to the ICRAC conductance in immune cells. Therefore, experiments have been designed addressing the dissociation of these two currents. Finally, the role of enhanced LTRPC7 expression and metal ion entry in pro-apoptotic events and cell death is assessed. The studies proposed above are based on the unique ion channel LTRPC7. By virtue of this channel?s sensitivity to Mg ATP levels and unusual selectivity to divalent ions, LTRPC7 seems to link fundamental processes that adjust plasma membrane divalent cation fluxes according to the metabolic state of the cell. Disturbing this delicate balance may induce LTRPC7-dependent cell death. These features predestine LTRPC7 to be a prominent player in pathophysiological situations mediating the detrimental divalent ion entry in ischaemic events. Detailed understanding of LTRPC7 physiological function will open new and fascinating possibilities to influence cell survival. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAGNESIUM'S ANTIHYPERTENSIVE EFFECTS IN PREECLAMPSIA Principal Investigator & Institution: Standley, Cynthia A.; Physiology; Midwestern University 555 31St St Downers Grove, Il 60515 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Preeclampsia consists of hypertension and proteinuria in pregnancy and is the most common cause of maternal mortality if left untreated. Hypertension in preeclampsia is implicated in the constellation of symptoms including seizures, glomerular damage and intrauterine growth retardation. Inhibition of nitric oxide synthase (NOS) in pregnant rats is an established model of preeclampsia, as it replicates these symptoms. Magnesium sulfate is the standard treatment for preeclampsia. However, magnesium's anti-hypertensive effects remain poorly understood. Magnesium acts as a vasodilator, an action customarily attributed to its ability to antagonize calcium entry into vascular smooth muscle cells (VSMC). Emerging evidence suggests that magnesium may also regulate vascular nitric oxide (NO). Therefore, magnesium may mediate vascular relaxation and reduction of blood pressure by activating the vascular NO/cGMP/protein kinase G (PKG) signaling pathway. We hypothesize that magnesium and NO act synergistically at the level of the vasculature to cause vasodilation and a reduction in blood pressure. Specifically, magnesium's ability to reduce blood pressure in the nitric oxide-inhibited animal model of preeclampsia is due to its ability to upregulate vascular NO/cGMP/PKG signaling, effectively reducing total vascular resistance and consequently blood pressure. To test this hypothesis, we will use the NOS inhibitor, NGnitro-L-arginine methyl ester (LNAME), to induce hypertension in pregnant rats. Then, graded doses of magnesium sulfate via chronic infusions in vivo, and acute treatment of vascular tissues ex vivo, will be used to address the following specific aims: 1) Determine if magnesium predictably reduces blood pressure and proteinuria and alters plasma/urinary NOS signaling metabolite levels, and whether these measures can be used therapeutically to predict and track hypertension; 2) Determine magnesium's effects on vascular inducible NOS (iNOS) and endothelial NOS (eNOS) expression; 3) Investigate magnesium's effects on vascular NOS signaling such as NOS activity, NO-mediated guanylate cyclase activity and PKG expression, and 4) Investigate magnesium's ability to regulate vascular reactivity in response to NO-generating stimuli. Data derived from these experiments
Studies
33
will elucidate the anti-hypertensive effects of magnesium, its mode of action and the roles of NO and magnesium in preeclampsia and pregnancy-induced hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF POLYA TAIL FORMATION BY VACCINIA VIRUS Principal Investigator & Institution: Gershon, Paul D.; Associate Professor; Center for Genome Res; Texas A&M University Health Science Ctr College Station, Tx 778433578 Timing: Fiscal Year 2001; Project Start 01-AUG-1995; Project End 31-JUL-2003 Summary: The poly(A) tail is a virtually ubiquitous mRNA feature, yet neither its role(s) nor its mechanism(s) of synthesis are well characterized in any organism. Of the various tail-synthesizing enzymes (poly(A) polymerases of PAPs), the vaccinia virus enzyme provides a powerful tool with which to study important aspects of PAP mechanism. Thus, although it shares characteristics with the cellular PAPs. the viral enzyme participates in a relatively simple polyadenylylation process that is coupled to neither the interactions or auxiliary protein factors with multiple RNA signals, nor other cellular processes such as endonucleolytic cleavage, mRNA splicing or protein phosphorylation. I propose to capitalize upon the viral enzyme's directness of action to investigate mechanisms central the action of any PAP, namely catalysis, translocation and processivity. Mechanistic insights regarding PAP, of one of the simplest known RNAsynthetic enzymes, should contribute to a more general understanding of RNA synthesis and macromolecular machinery. The VP55 (catalytic) subunit of the heterodimeric vaccinia PAP abruptly ceases processive primer elongation after producing tails approximately 25-30 nt in length, and the VP39 subunit is a processivity factor for further elongation by VP55, the heterodimer and the heterodimer-RNA ternary complex will be investigated using various complementary techniques (such as site- specific photocrosslinking, crosslinking-SELEX, photocrosslinking with labeltransfer and an anchored 'chemical protease' approach) to identify topological constraints. For example, one aim is to establish whether VP39's polyadenylylationspecific RNA contact site(s) like within a 'fully' on the protein surface between two parts of an apparently bipartite dimerization interface. Initial attempts to improve VP55 overexpression should facilitate elucidation of its 3D structure. RNA determinants of VP55 translocation will be investigated using both discrete oligonucleotides and a novel selection scheme. The relationship between VP55 translocation, primer anchoring and processive tail synthesis will be established using covalently-photocross-linked PAPprimer complexes and flexibility in the relative positioning of the 3' OH-distal and proximal primer-PAP contact sites will be characterized using oligonucleotides designed to 'squeeze' and 'stretch' their relative positions. Finally, to investigate roles for metal ions at VP55's catalytic center, we will determine which of the two apparent divalent cation binding sites in the VP55.ATP complex is Mn2+-enhanced; identify roles for divalent metals in NTP binding and catalysis using co-valently photocrosslinked VP55-primer conjugates; quantify VP55-metal ion affinities by EPR; and address metal ion coordination using unusual, sulfur-substituted oligonucleotides. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISM OF THE RECBCD ENZYME FROM E. COLI Principal Investigator & Institution: Julin, Douglas A.; Associate Professor; Chemistry and Biochemistry; University of Maryland College Pk Campus College Park, Md 20742 Timing: Fiscal Year 2002; Project Start 01-APR-1989; Project End 31-MAR-2006
34
Magnesium
Summary: (provided by applicant): The RecBCD enzyme acts in homologous DNA recombination in Escherichia coil and other bacteria. Homologous recombination is essential for the repair of some types of DNA damage and is an important part of the DNA replication process. Bacteria with mutations in the recB or recC genes are deficient in their ability to carry out homologous recombination and they have low viability. That is, a large fraction of the cells are inviable after cell division as a result of the inability to repair chromosome breaks that arise during DNA replication. Homologous recombination is also important in DNA repair and replication in higher organisms including humans. Defects in these processes have significant negative health implications, as they can be a contributing factor in the development of diseases including cancer. RecBCD is also quite interesting as a multisubunit enzyme machine. It is a multifunctional enzyme that unwinds and degrades linear DNA as an ATPdependent exonuclease. The enzyme activity is regulated by a specific DNA sequence that has been called Chi (5'-GCTGGTGG). An encounter with Chi affects the rate and strand specificity of the nuclease reaction. All of these phenomena are critically dependent on the reaction conditions, especially the ATP and magnesium ion concentrations. The principal investigator has studied the enzyme by dissecting it into its subunits and protein domains and characterized the activities of those component parts. This proposal describes enzymological experiments to study how the enzyme activities and structure are affected by ligands including magnesium ion, DNA, and ATP, to learn more about the regulation of the enzyme activity that happens at the Chi sequence. He will also study in more detail the structure of a small domain of the RecB subunit that has the nuclease active site, how its activity is affected by the presence of the other proteins, and comparative experiments with another nuclease that has a similar active site sequence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF V(D)J RECOMBINATION Principal Investigator & Institution: Roth, David B.; Associate Professor; Microbiology and Immunology; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2001; Project Start 01-AUG-1994; Project End 31-JUL-2004 Summary: The work described in this proposal is a continuation of our long-term project aimed at a complete description of the mechanism of V(D)J recombination. Essential for proper immune system development, this specialized recombination process generates a diverse set of antigen receptors by assembling the variable regions of immunoglobulin and T cell receptor genes. If recombination is impaired, B and T cell differentiation is arrested at an early precursor stage, leading to a severe combined immunodeficiency (scid). Aberrant V(D)J rearrangements, on the other hand, lead to leukemias and lymphomas. To understand both normal immune system development and the molecular basis of oncogenic, aberrant recombination, we must carefully explore this sophisticated system. V(D)J recombination can be divided into two basic steps: DNA cleavage and rejoining of the broken ends. Efficient cleavages requires that a pair of specific DNA sequences, termed recombination signal sequences (RSS), be recognized, assembled into a synaptic complex, and cleaved by the RAG-1 and RAG-2 proteins. After cleavage, the broken ends remain associated with the RAG proteins in a post-cleavage complex. These ends can then e joined to form normal products of recombination. Recent in vitro work has shown that the ends can also participate in an aberrant reaction, transposition, which has been suggested as a cause of oncogenic chromosome rearrangements. The work proposed here will: 1) Dissect the active sites of the RAG proteins and define the role of these sites in the cleavage reaction. 2) Probe the
Studies
35
mechanism of RAG- mediated DNA cleavage and how cleavage is regulated by synapsis. 3) Delineate joining mechanisms in the context of the post-cleavage complex. 4) Determine whether RAG-mediated transposition occurs and examine regulatory mechanisms that limit this potentially dangerous reaction. Clearly, our best hope for therapeutic interventions is either scid or lymphoid malignancies rests on a detailed knowledge of normal immune system development and the molecular basis of oncogenic, aberrant recombination events. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF MITOCHONDRIAL FISSION AND FUSION Principal Investigator & Institution: Shaw, Janet M.; Professor; Biology; University of Utah 200 S University St Salt Lake City, Ut 84112 Timing: Fiscal Year 2001; Project Start 01-FEB-1996; Project End 31-JAN-2005 Summary: (applicant's description): Changes in mitochondrial morphology and copy number are associated with a variety of human diseases including neurological disorders and some types of cancer. Although the metabolic functions of mitochondria have been extensively studied, the molecular mechanisms that regulate mitochondrial membrane dynamics are not understood. In the current funding period, we characterized two different GTPases in S. cerevisiae that regulate mitochondrial morphology and copy number. Dnm1p is a dynamin-related GTPase that acts on the outer mitochondrial membrane to regulate fission. Fzo1p (fuzzy onions) is a transmembrane GTPase that regulates mitochondrial docking and/or fusion. Both GTPases have human homologues that, when mutated, cause defects in mitochondrial morphology. These findings illustrate how effectively yeast can be used as a tool to study the molecular mechanisms that control mitochondrial dynamics in human cells. During the next funding period, we will continue to study mitochondrial fission and fusion in yeast using a combination of genetic, molecular and biochemical approaches. Specifically, we propose: 1) to identify and characterize SFZ genes/proteins required for mitochondrial fission, 2) to determine the role of Fzo1p self-interactions in mitochondrial fusion, 3) to screen for binding partners that interact with Fzo1p in its GTP-bound state, and 4) to develop an in vitro assay for mitochondrial fusion. The studies we propose will provide new information about the molecular and biochemical basis of mitochondrial fission and fusion in eukaryotic cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: METAL SITES AND DYNAMICS IN LARGE RNA MOLECULES Principal Investigator & Institution: Derose, Victoria J.; Associate Professor; Chemistry; Texas A&M University System College Station, Tx 778433578 Timing: Fiscal Year 2002; Project Start 01-AUG-1998; Project End 31-JUL-2006 Summary: (provided by applicant): The overall goal of the proposed research is to investigate metal binding sites in large RNA molecules and their influence on RNA structure, stability, and dynamics. RNA displays a rich array of cellular functions through complex interactions with other nucleic acids and proteins. RNA-metal interactions are critical to both structure and function, and effective, direct probes of the influence of metal sites on the structural biology of RNA are required. In work carried out under this project, direct measurements of metal-binding in RNA systems will be measured using Mn2+ as an EPR-detectable spectroscopic probe. The influence of both Mg2+ and Mn2+ on metal binding, RNA structure, and thermodynamic parameters will be investigated. Insight into the conformational dynamics of RNA will be sought using
36
Magnesium
site-specific, EPR-active nitroxide spin labels. Taken together, these studies will provide important information about RNA structure and stability as a function of solution conditions, and will provide new tools for the investigation of more elaborate and conformationally dynamic RNA complexes.Specific aims of the current proposal include: Investigating the unique 'metal ion core' from the Group I Intron, with a goal of understanding specifically how metal ions contribute to folding and stability in this structural motif. Determining metal ion affinities and influence of metals on folding and catalysis in the hairpin ribozyme. Developing methods for site-specific EPR-active spin labels to study dynamics and distances in RNA, with application to metaldependent folding pathways in the hammerhead and Group I Intron P4-P6 subdomain. Investigating the influence of metal ions on folding and activity in a U2U6 RNA model system for the active site of the spliceosome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MFMU NETWORK (COLUMBIA UNIV. FACULTY @ SLRH AND CPMC) Principal Investigator & Institution: Malone, Fergal D.; Associate Professor; Obstetrics and Gynecology; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2003; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: The attached application proposes that the Maternal-Fetal Medicine Division of the Columbia University Medical Centers in New York City including St. Luke'sRoosevelt Medical Center (with it's Continuum partnership affiliate Beth Israel Medical Center) and Columbia Presbyterian Hospital Center be selected as a new member for the Cooperative Multicenter Network of Maternal Fetal Units (MFMU). Our hospitals are strategically placed throughout the Metropolitan New York area. They are closely associated with the respective surrounding communities, thus allowing targeted and improved delivery of Health Care, dependable relationships between patients and health care providers, and thereby creating an environment that facilitates patient recruitment to clinical trials. Over 15,000 primary and referral patients who represent a broad spectrum of social, economic, ethnic, racial and cultural backgrounds deliver in our facilities each year of whom more than 30% are high risk. The faculty of the Divisions of Maternal-Fetal Medicine in our institutions represents a team of highly motivated individuals who are enthusiastically approaching the prospect of becoming a new study center for the MFMU network. They are experienced investigators who have been highly successful in recruiting and retaining subjects in clinical trials. The faculty have a record of successful grant applications and contract awards. We are currently participating as an independent Center in the MFMU BEAM Study (Randomized Clinical Trial of the Beneficial Effects of Magnesium Sulfate) and as an affiliate of Thomas Jefferson University in two additional MFMU studies. The Department of OB/GYN at Columbia University currently ranks second place nationally for funding in Obstetrics and Gynecology by the NIH and is the leading center for the FASTER trial. The faculty of the St Luke's-Roosevelt Hospital Center, Columbia Presbyterian Center, Beth Israel Medical Center and their administrations are unanimous in their eagerness to participate in the MFMU trials and strongly support this grant application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MODELING THE ION AND SOLVENT ENVIRONMENT OF NUCLEIC ACIDS Principal Investigator & Institution: Quigley, Gary J.; Hunter College 695 Park Ave New York, Ny 10021
Studies
37
Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2002 Summary: The immediate objective of this research is to obtain the best procedures for stimulating the ion and solvent environment of crystalline DNA, initially and particularly z-DNA. This is a particular problem due to the high charge density and large surface area of nucleic acids. The longer range objective is to develop a protocol which will be applicable for stimulating the ion and solvent environment of nucleic acids in general in both crystalline and non-crystalline environments. The energies of the non-bonding interaction with the ion and solvent environment are typically greater than the internal non-bonding energies for nucleic acids. Accordingly, a reliable remodeling of the nucleic acid requires an accurate modeling of the solvent. The ability to understand and model the structure of the interactions of nucleic acids will lead to more reliable drug design, a better understanding of the modes of interactions of the numerous proteins that interact with nucleic acids and of the folding and compaction of nucleic acids. Crystalline Z-DNA has been selected for these initial studies since we have extensive, very high resolution x-ray diffraction data on the crystals data on the crystals which has provided us with a much more detailed view of the ion and solvent environment than is available for other structures. This in turn will provide a reliable basis for assessing the quality of our simulations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR ACTIONS OF VOLATILE ANESTHETICS ON GPROTEINS Principal Investigator & Institution: Rebecchi, Mario J.; Associate Professor; Anesthesiology; State University New York Stony Brook Stony Brook, Ny 11794 Timing: Fiscal Year 2001; Project Start 01-FEB-2000; Project End 31-JAN-2004 Summary: (adapted from applicant's abstract): Volatile anesthetics perturb the coupling of metabotropic receptors to specific heterotrimeric guanine nucleotide-binding proteins (G-proteins), but the relevance to anesthesia and its molecular basis are not understood. Heterotrimeric G-proteins, consisting of alpha, beta, and gamma subunits, are GTPdriven molecular switches that couple metabotropic receptors to downstream effectors, including ion channels. In the inactive state, the G-protein is a heterotrimer with GDP tightly bound to the Galpha subunit. Binding of agonist to the receptor triggers exchange of GTP for bound GDP, hydrolyzing the former in the presence of Mg2+. The GTP-charged alpha subunit dissociates from betagamma and may be free to diffuse some distance on the membrane surface. Either the alpha subunit bound to GTP or the free betagamma heterodimer or both regulate effector enzymes such adenyl cyclase (AC) and phospholipase C, or modulate ion channels, thereby amplifying the initial receptor stimulus. Thus, alpha subunits function as on/off switches based on the occupant of the nucleotide binding site, GTP or GDP, such that alterations in nucleotide exchange, like those induced by volatile anesthetics, modulate signal output. To test for correlation between clinical potency and inhibition of GDP/GTP exchange, various anesthetic compounds, as well as non-immobilizing drugs, will be tested on Galpha subunits. Similar experiments will be performed on living cells in which the pathways are reconstructed by expression of the signaling components: receptors, G-protein subunits and effectors. The hypothesis that volatile agents disrupt receptor/effector coupling by locking the Galpha subunit into a complex with Gbetagamma will be tested on artificial membranes by measuring the lateral interactions of these proteins using fluorescence resonance energy transfer. To understand the molecular basis of the anesthetic effect, intrinsic fluorescence and isothermal titration microcalorimetry will be used to measure the binding of these drugs to soluble Galpha subunits. Finally, regions
38
Magnesium
essential to the actions of anesthetics will be established by swapping homologous portions of sensitive and insensitive alpha subunits. These studies will generate predictions for future experiments to be conducted on animals exposed to anesthetic agents. Completion of the proposed study will also form the basis for future crystallographic work on the nature of interactions between anesthetics and these potential protein targets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR CRYSTALLIZATION
MODULATION
OF
CALCIUM
OXALATE
Principal Investigator & Institution: De Yoreo, James J.; Senior Scientist; Materials Science & Technology; University of Calif-Lawrnc Lvrmr Nat Lab Lawrence Livermore National Lab Livermore, Ca 94550 Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 31-JUL-2006 Summary: (provided by applicant): Urinary tract stone disease (urolithiasis) is a common clinical disorder that frequently leads to hospitalization. The objective of this proposal is to advance the understanding of the pathogenesis of urolithiasis by determining the physical mechanisms through which important inhibitors that include small urinary molecules, such as magnesium and citrate that are currently used in the treatment of urinary tract stone disease and urinary macromolecules, such as osteopontin control the nucleation, growth, aggregation, and phase transformations of calcium oxalate (CaOx) precipitates. This objective will be accomplished by investigations focusing on 1). the mechanisms of modulation of CaOx nucleation and growth by small urinary molecules and urinary macromolecules, 2). the mechanisms by which urinary modulators affect the sequence of events during phase transformations of CaOx crystals and 3). the surface interactions and events underlying urinary protein modulation of CaOx aggregation. The proposed research will use in situ atomic force microscopy to follow the evolution of CaOx crystal surfaces and quantify the impact of growth modulators on the thermodynamic and kinetic factors controlling the dynamics of atomic steps on those surfaces. This work will lead to new insights that integrates an understanding of the specific stereochemical interactions on the crystal surface with the quantitative impact on kinetics and morphology. The atomic force microscopy measurements will be correlated with concurrently performed constant composition measurements of growth kinetics and contact angle measurements of interfacial energies. The knowledge derived from our studies will assist in the design of inhibitory molecules that are potentially useful in therapy of stone disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MR ASSESSMENT OF MAGNESIUM IN ACUTE STROKE Principal Investigator & Institution: Kidwell, Stella M.; Assistant Clinical Professor; Neurology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 02-APR-1999; Project End 31-MAR-2004 Summary: The objectives of this project are to demonstrate that 1) intravenous magnesium is beneficial in acute ischemic stroke as evidenced by decrease in the growth of infarct volume over time as measured by diffusion weighted magnetic resonance imaging (DWI); 2) DWI is a valuable surrogate outcome measure in acute ischemic stroke clinical trials; 3) diffusion/perfusion mismatch is a useful entry criterion for neuroprotective treatment in acute stroke clinical trials; and 4) intravenous
Studies
39
magnesium is safe and potentially beneficial in intracerebral hemorrhage. During the first phase of the project, objectives 1-3 will be assessed by conducting a randomized, double-blind, placebo controlled trial to evaluate the efficacy of intravenous magnesium as a neuroprotective agent in acute ischemic stroke. The trial will use diffusion/perfusion magnetic resonance imaging as a surrogate outcome marker. 150 patients will be enrolled within 12 hours of symptom onset at 3 UCLA-associated hospitals. The second phase of this project will be a parallel pilot randomized, doubleblind, placebo-controlled trial to evaluate the safety and explore the efficacy of intravenous magnesium in acute intracerebral hemorrhage, enrolling 40 patients. Additional data will be collected to assess the diffusion/perfusion MR signature of acute intracerebral hemorrhage. The findings of this project will have direct relevance to future treatment of acute ischemic and hemorrhagic stroke as well as to the design of future trials of neuroprotective agents. The results will help establish the utility of novel diffusion/perfusion MR techniques as demonstrating physiologic, objective changes that can be used as entry and outcome criteria in evaluating stroke patients. During the award period, in addition to serving as the principal investigator of these trials, Dr. Kidwell will pursue in-depth didactic multidisciplinary training in biostatistics, epidemiology, clinimetrics and magnetic resonance radiology. She will be mentored by Drs. Jeffrey Saver, Sidney Starkman, Jeffry Alger, and Barbara Vickrey. At the completion of this training, Dr. Kidwell will have acquired all requisite experience and skills to function as an independent investigator in clinical studies of novel magnetic resonance stroke imaging techniques, pivotal trials of promising therapeutic agents, and studies of the pathophysiology of acute human cerebral ischemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Miodovnik, Menachem; Obstetrics and Gynecology; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: The attached application proposes that the Maternal-Fetal Medicine Division of the Columbia University Medical Centers in New York City including St. Luke'sRoosevelt Medical Center (with it's Continuum partnership affiliate Beth Israel Medical Center) and Columbia Presbyterian Hospital Center be selected as a new member for the Cooperative Multicenter Network of Maternal Fetal Units (MFMU). Our hospitals are strategically placed throughout the Metropolitan New York area. They are closely associated with the respective surrounding communities, thus allowing targeted and improved delivery of Health Care, dependable relationships between patients and health care providers, and thereby creating an environment that facilitates patient recruitment to clinical trials. Over 15,000 primary and referral patients who represent a broad spectrum of social, economic, ethnic, racial and cultural backgrounds deliver in our facilities each year of whom more than 30% are high risk. The faculty of the Divisions of Maternal-Fetal Medicine in our institutions represents a team of highly motivated individuals who are enthusiastically approaching the prospect of becoming a new study center for the MFMU network. They are experienced investigators who have been highly successful in recruiting and retaining subjects in clinical trials. The faculty have a record of successful grant applications and contract awards. We are currently participating as an independent Center in the MFMU BEAM Study (Randomized Clinical Trial of the Beneficial Effects of Magnesium Sulfate) and as an affiliate of Thomas Jefferson University in two additional MFMU studies. The Department of
40
Magnesium
OB/GYN at Columbia University currently ranks second place nationally for funding in Obstetrics and Gynecology by the NIH and is the leading center for the FASTER trial. The faculty of the St Luke's-Roosevelt Hospital Center, Columbia Presbyterian Center, Beth Israel Medical Center and their administrations are unanimous in their eagerness to participate in the MFMU trials and strongly support this grant application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Carpenter, Marshall W.; Associate Professor; Women and Infants Hospital-Rhode Island 101 Dudley St Providence, Ri 02905 Timing: Fiscal Year 2001; Project Start 03-APR-2001; Project End 31-MAR-2006 Summary: (provided by applicant): WIH and the Department of Obstetrics and Gynecology at Brown University School of Medicine have the capability to participate actively as a new member of the Cooperative Multicenter Maternal-Fetal Medicine Units Network. WIH operates one of the nation?s larger obstetrical services. All obstetric care is supported by insurance in Rhode Island. Consequently, the State?s ethnic and racial diversity is reflected among both private and clinic patients. Providing care to 74 percent of the State s patients, WIH s demographic and clinical statistics wholly reflect those of Rhode Island. During fiscal year 1999, 9023 deliveries were performed at WIH, 2099 among WIH Clinic and Maternal-Fetal Medicine patients. Of the total WIH deliveries, 174 had ruptured membranes before 35 weeks, 556 delivered prior to 35 weeks, 207 had multi-fetal pregnancies, 179 had gestational or chronic diabetes, 794 had hypertensive disorders in pregnancy, 539 had asthma or other respiratory disease and 163 had cardiac or vascular disease. The academic faculty and private practice community have had a consistently collaborative relationship providing access to the entire obstetrical population for cohort studies. Consequently, WIH is particularly suited for performance of clinical trials. The Maternal-Fetal Medicine Division is composed of six board-certified and one active candidate for the Maternal-Fetal Medicine boards, all of whom will support Network research protocols. The Division also employs two research nurses and a sonographer, all presently supported by NICHD funding, and three additional clinical nurses, all with extensive experience in cohort research. The Division has successfully enlisted patients (53-100 percent enlistment rates) in complex tocolysis trials and exercise, and metabolic and hemodynamic cohort studies with retention rates of 79-93 percent. The Division has maintained strong clinical and investigational relationships with local and regional private obstetricians, reflected in the proportions of private patients in Divisional cohort studies of 54-80 percent. The Division is presently engaged in three multicenter cohort studies funded by NICHD. It was selected by the Network in April 2000 to participate in the Beneficial Effects of Antenatal Magnesium (BEAM) Study to increase patient enlistment in this protocol and is presently beginning to enroll subjects. The Division has been funded as one of five North American sites in an international study of the maternal and perinatal impact of maternal glucose intolerance, the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study. The Division is also a participant in the First and Second Trimester Evaluation of Risk (FASTER) Study examining combined biochemical and sonographic first trimester screening for Down syndrome. WIH and the Maternal-Fetal Medicine Division will enlist subjects for all Network protocols and actively participate in proposing, planning and executing Network studies. Local infrastructure available for participation in multicenter clinical trials at WIH include (1) a large patient volume and highly involved full-time and voluntary obstetrical faculty;
Studies
41
(2) robust clinical patient, laboratory, anatomic pathology, and pharmacy databases; (3) a strong history of collaboration between Maternal-Fetal Medicine and Neonatology Divisions; (4) decades-old perinatal tissue samples and anatomic pathology; and (5) a strong Departmental commitment to outcomes research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Leveno, Kenneth J.; Professor; Obstetrics and Gynecology; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2001; Project Start 05-MAY-1996; Project End 31-MAR-2001 Summary: This proposal describes the qualifications and experience of the MaternalFetal Medicine faculty and research team at the University of Texas Southwestern Medical Center and Parkland Hospital and the facilities and patient population available to them for carrying out clinical protocols to be designed by the NICHD Maternal-Fetal Medicine Units Network. UT Southwestern's Division of Maternal-Fetal Medicine include 11 physicians, 9 of whom are board-certified in Maternal-Fetal Medicine. A total of 6 research nurses experienced in perinatal research lead by a research nurse coordinator with 12 years experience in protocol development and implementation are available for participation in MFM Units Network protocols. A computerized perinatal database that has been operational since late 1982 is a centerpiece in perinatal research team efforts at UT Southwestern Medical Center Parkland Hospital. The perinatal research team has successfully completed several randomized trials and submitted with this application is an example of such effort in 2,138 women with pregnancy-induced hypertension who were randomized to receive magnesium sulfate or phenytoin for eclampsia prophylaxis during labor. In 1994 there were 13,935 deliveries at Parkland Hospital and approximately 55% were high-risk. Pregnancy complications of particular interest to the MFM Units Network, e.g. preterm birth and gestational diabetes are well represented in the obstetric population at Parkland Hospital. Importantly the maternal-fetal medicine physicians at Parkland Hospital are philosophically committed to rigorous controlled trials intended to objectively evaluate principals of obstetrical care before adoption of these interventions into clinical practice. Other resources brought to the MFM Units Network include support of UT Southwestern's NIH General Clinical Research Center, the Cecil H. and Ida Green Center for Reproductive Biology Sciences and collaboration with the NICHD Neonatal Unit Network through support of the local neonatal network principle investigator. The perinatal research team now described is committed to collaborative participation consistent with the goals of the MFM Units Network. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS Principal Investigator & Institution: Shankaran, Seetha; Professor; Pediatrics; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-APR-1991; Project End 31-MAR-2006 Summary: (Provided by Applicant) The Wayne State University School of Medicine at the Detroit Medical Center is submitting an application for renewal in the NICHD Multicenter Neonatal Research Network. The Division of Neonatal-Perinatal Medicine has both an inborn service at Hutzel Hospital (6000 deliveries, 55 bed
42
Magnesium
NICU/Progressive Care Nursery) and an outborn service at Children?s Hospital of Michigan (45 bed NICU). The Division of Maternal-Fetal Medicine at Wayne State is currently a member of the NICHD Multicenter Materna/-Fetal Research Network (MFM). The Division of Clinical Pharmacology at Wayne State is currently a member of the NICHD Pediatric Pharmacology Research Unit (PPRU). The Wayne State site has additional capabilities of including two more Detroit Medical Center inborn hospitals (Sinai-Grace Hospital, 4000 deliveries and Huron Valley Hospital, 2000 deliveries) into the Neonatal Research Network with the site PI who is the Regional Director of the Detroit Medical Center?s Neonatal Programs. The Wayne State site has actively participated in the current NICHD Neonatal Research Network studies by contributing a greater number of subjects than the average enrollment per site. These studies include 1134 subjects enrolled in the Generic Database Study, 366 in the Follow-up Study, 28 in the Erythropoiten Study, 157 in the Magnesium Sulfate Study, and 61 in the Vitamin A Study. In two studies, the Wayne State site has far exceeded enrollment. These include the Early Inhaled Nitric Oxide Study, Wayne State has enrolled 32 of 203 subjects and the Network study on Hypothermia for Encephalopathy where Wayne State has enrolled 4 of 22 subjects. In the Maternal Lifestyle Study (4 sites), Wayne State has enrolled 43% of all infants enrolled in Phase II and III of the study. I n the current grant period, the Principal Investigator at the Wayne State University site, Dr. Seetha Shankaran, served as PI for the Antenatal Phenobarbital to Prevent IVH Study and is currently PI of the Induced Hypothermia for Encephalopathy Study. Strengthens of the Wayne State site include neonatal imagining abilities (PET and MRI), obstetric imaging capabilities, the fetal diagnosis and therapy program and ongoing collaboration with the NICHD MFMU Network and the NICHD PPRU Network. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS Principal Investigator & Institution: Lemons, James A.; Pediatrics; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2001; Project Start 01-APR-1991; Project End 31-MAR-2006 Summary: Indiana University Medical Center has been an active member of the Neonatal Research Network since 1991. Particular strengths of the Indiana Center include a large patient population, design of new randomized trials for the Network, effective enrollment of subjects in Network protocols, eighteen neonatology faculty with extensive experience and expertise in basic and clinical research, an established newborn follow-up program, excellent infrastructure and support staff, and important collaborative research programs with other departments and university centers. Since 1995 (starting year of the second competitive renewal of the Network grant) the faculty within the Section of Neonatal-Perinatal Medicine has had 20 NIH grants and 49 other extramural awards, and has published over 200 manuscripts during that period. Indiana University School of Medicine is the only medical school and the site of the only comprehensive children's hospital in Indiana. The Medical Center serves as the principal referral center for pediatric subspecialty care for the entire state, which has a population of 5.9 million and 87,000 births annually. Further, the Indiana Center expanded in 1997 when Methodist Hospital (a large community hospital with a high risk obstetric service and NICU) merged with the Medical Center. Indiana has a strong record of participation in and contribution to the Neonatal Research Network. During the past four years Indiana enrolled an average of 334 VLBW infants yearly in the generic data base, and 390 infants in 1999 (the largest of any center). Indiana has participated in 12
Studies
43
trials since 1995, contributing 34/235 subjects to the Neonatal Inhaled Nitric Oxide Study 45/170 and 24/115 infants to the two Erythropoietin trials, 3/16 infants to date in the Hypothermia and Hypoxic Ischemic Encephalopathy study, and 65 of 300 to date in the Glutamine Trial. Indiana faculty chaired and developed the Newborn Follow-up Program, the Glutamine Trial, the Magnesium Sulfate Subcommittee and the Protocol Review Subcommittee, chaired the GDB Subcommittee, and served on nine other subcommittees. The clinical and basic research of the neonatology faculty is focused on molecular immunology, developmental hematopoiesis, and fetal/neonatal nutrition and metabolism. These research programs lend themselves to ancillary studies of the Neonatal Network; one currently active and six other ancillary studies were designed and initiated by Indiana faculty. Collaborative support has been provided by other investigators, departments and centers when additional expertise and/or resources could benefit Network protocols. Indiana University brings to the Neonatal Network a large patient population, a uniquely balanced program of clinical service and research, and a strong record of participation and accomplishment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NMR AND FLUORESCENCE STUDY OF LI+ INTERACTIONS IN CELLS Principal Investigator & Institution: Mota De Freitas, Duarte E.; Professor; Chemistry; Loyola University of Chicago Chicago, Il 60611 Timing: Fiscal Year 2001; Project Start 01-SEP-1990; Project End 31-JUL-2004 Summary: Lithium salts continue to be the most promising drugs in the treatment of acute episodes and the prevention of relapses in patient suffering from manic depression or bipolar illness. Even though lithium salts have been used clinically in the treatment of bipolar patients for fifty years, their pharmacologic mode of action is unclear. The main goals of the research proposed in this applications are: (i) to advance the understanding at the molecular and cellular levels of the pharmacologic action of the Li+ ion in the treatment of bipolar disorder by analyzing the binding and transport properties of Li+, Mg2+ ions in human neuroblastoma and lymphoblatoma cells, and in purified wild-type and mutated guanine nucleotide-binding (G) proteins by using nuclear magnetic resonance (NMR) spectroscopy, and fluorescence spectroscopy and imaging; and (ii) to test the application of these spectroscopic and imaging methods to the identification of bipolar patients who are likely to respond to lithium treatment or are most susceptible to experiencing lithium toxicity. The proposed spectroscopic and imaging methods will test two interrelated mechanisms of actions Li+: a cell membrane abnormality, and a competition mechanism between Li+ and Mg2+ ions for membrane binding sites (in particular, anionic phospholipids and the metal-binding domain of G proteins). Our preliminary studies with cultured cells and G proteins indicate that the spectroscopic and imaging methods proposed in this study provide new information on Li+ interactions with cell components; this new information could not have been obtained with other techniques routinely used for Li+ analysis. In addition to contributing to an advancement of the understanding at the molecular and cellular levels of the pharmacologic action of the Li+ ion in the treatment of bipolar illness, the results of this study may also be useful in the diagnosis and prognosis of bipolar patients. More precisely defined molecular parameters, such as Li+ binding constants to the lymphoblastoma membranes from bipolar patients and their phospholipid composition, may by useful for predicting the success of Li+ therapy and the likelihood of Li+ toxicity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
44
Magnesium
•
Project Title: NMR OF HIV REVERSE TRANSCRIPTASE PRIMERS Principal Investigator & Institution: Davis, Darrell R.; Professor; Medicinal Chemistry; University of Utah 200 S University St Salt Lake City, Ut 84112 Timing: Fiscal Year 2001; Project Start 01-AUG-1996; Project End 31-MAR-2005 Summary: (Provided by the applicant): RNA hairpin oligonucleotides will be synthesized which contain the three modified nucleosides found in the anticodon domain of human tRNA LYS3, the primer for HIV reverse transcriptase. The solution structures of these RNA hairpins will be determined using NMR spectroscopy. The high-resolution structures will be used to understand how the modified nucleosides rncm5s2U, ms2t6A, and pseudouridine provide structural stability to the anticodon domain of tRNA and why this is important for proper function of tRNALYS3 as the reverse transcriptase primer. Binding studies between the modified RNA hairpins and HIV reverse transcriptase will be done to elucidate how modification affects reverse transcriptase recognition. NMR spectroscopy will be used to localize the divalent metal ion binding sites in E.coli and human tRNALYS3. Paramagnetic manganese relaxation studies and NOE measurements of cobalt hexanimine complexed with the tRNA hairpins will be used as analogs of the magnesium ions that we have shown bind specifically to the modified RNAs. The solution structure of the RNA complex formed between tRNA and the A-rich loop of HIV genomic RNA will be determined using heteronuclear multidimensional NMR. The fully modified anticodon domain of human tRNA will be used to form the RNA-RNA complexes in order to understand how the natural modifications contribute to structural stabilization and to provide a structural target for therapeutic development. NMR spectroscopy will be used to study the solution structure of the entire tRNA isoacceptor from E.coli in its fully modified form. These structural studies will elucidate the nature of the folded core of tRNALYS and the structural basis for reverse transcriptase recognition elements in the D stem and loop of tRNALYS Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NMR STUDIES OF CYTOSOLIC METAL IONS AND OXIDATIVE STRESS Principal Investigator & Institution: Gupta, Raj K.; Professor; Physiology and Biophysics; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2003; Project Start 01-MAY-1982; Project End 31-AUG-2007 Summary: (provided by applicant): Our long-range goal is to elucidate the role of intracellular mineral ions (Na+, K+, free Mg2+ & free Ca2+) and oxidative stress in the pathophysiology of essential hypertension and type 2 diabetes. We seek to understand how the regulation of intracellular concentrations of essential metal ions and membrane lipids goes astray in health disorders, especially hypertension and diabetes. Our main research tool is NMR spectroscopy. Our laboratory played a key role in the development of NMR methods for measuring various intracellular cations and we also have considerable expertise in the use of 1H NMR for analyzing membrane phospholipid composition and the degree of membrane fatty acid unsaturation (double bonds) and average chain length. Oxidative stress, which may play a contributory role in the pathogenesis of diabetes as well as hypertension, causes peroxidative degradation of membrane lipids resulting in a loss of fatty acid double bonds that can be quantitated by 1H NMR. The following specific aims will be pursued: (1) To investigate the mechanism of altered renal sodium homeostasis in salt-sensitive hypertension; (2) To demonstrate that oxidative stress, which results in overproduction of reactive oxygen species (ROS),
Studies
45
can cause loss of unsaturation in fatty acyl chains of membrane phospholipids as measured by 'H NMR, and to test the hypothesis that peroxidative degradation of lipids as measured by loss of membrane fatty acid unsaturation during oxidative stress results in intracellular ionic changes similar to those seen in essential hypertension; (3) To investigate a possible protective role of magnesium against oxidative stress and whether there is a decrease in antioxidant capacity, as measured by glutathione (GSH) levels, in tissues exposed to low Mg environment; (4) To test the hypothesis that a deficit in membrane fatty acid unsaturation is associated with human essential hypertension and to investigate if there is an alteration in sphingomyelin-ceramide pathway in hypertension; (5) To find out if impairment of nitric oxide synthesis by inhibition of nitric oxide synthase, which causes hypertension in a normal rat, produces membrane lipid changes similar to those seen in essential hypertension; (6) To test the hypothesis that hyperglycemia causes peroxidative degradation,of membrane lipids as measured by 1H NMR, especially in vascular tissue, and, if so, whether hyperglycemia associated loss of fatty acid unsaturation and intracellular ionic alterations can be reversed by dietary antioxidants such as vitamin C and E; (7) To investigate increased vulnerability of hypertensive as well as hyperglycemic kidney and myocardium to ischemic damage and its relationship to increased perexidative degradation of membrane lipids; and (8) To design, develop and test a method for non-invasive measurement of "intracellular sodium using triple-quantum filtered (TQ)23 Na NMR. The proposed NMR investigations of intracellular ions and oxidative stress in hypertension and hyperglycemia condition may eventually lead to better strategies for the management of these health disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NORTHERN CALIFORNIA COMPREHENSIVE SICKLE CELL CENTER Principal Investigator & Institution: Mentzer, William C.; Professor; Pediatrics; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 01-APR-1978; Project End 31-MAR-2003 Summary: The objectives of the Northern California Comprehensive Sickle Cell Center (NCCSCC) are 1) to sponsor and facilitate hemoglobinopathy research at both fundamental and clinical levels and 2) to provide hemoglobinopathy detection, counseling, and education to affected populations using the most modern methods. To pursue these objectives, we have established a CORE hemoglobin structure and diagnosis laboratory at Childrens' Hospital Oakland Research Institute (CHORI) and CORE clinical research programs in the West Bay (UCSF/San Francisco General Hospital) and in the East Bay (Childrens' Hospital Oakland, Highland Hospital). These programs provide hemoglobinopathy detection, counseling and education as well as a stable, well characterized group of over 500 patients with sickle cell disease (SCD) who participate in NCCSCC research projects. Clinical research projects aim to a) test the efficacy of core decompression in the management of aseptic necrosis of bone, b) see whether an acute rise in serum secretory phospholipase AD heralds the acute chest syndrome and justifies early therapeutic intervention, and 3) evaluate the efficacy of potential new therapies (hydroxyurea + phenyl butyrate or clotrimazole, isobutyramide, oral magnesium, oral chelation and various forms of stem cell transplantation). More basic cell and molecular biology research projects will a) exploit our newly developed transgenic mouse model of SCD (which completely lacks mouse globin chains) to explore the pathophysiology of SC and evaluate potential new treatments, b) employ a genome a genome-wide scan to identify genes unlinked to the globin cluster that alter
46
Magnesium
SCD severity and globin chain switching in inbred strains of mice, c) use a human b globin YAC specific transgenic mouse model to define the role of cis-acting regulatory sequences that direct tissue-and stage-specific expression of the human b globin gene family, and d) establish a collaborative research venture to explore the effects of complement, thrombin, and other agonists on the adherence of sickle RBC to vascular endothelium with the ultimate goal of defining a potential role for these interactions in sickle vaso-occlusion. These projects will be carried out at the 2 CORE clinical facilities, CHORI, and laboratories at UCSF and Lawrence Berkeley National Laboratory. Programs will be coordinated by Center staff and evaluated by both internal and external review bodies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: 'OPTICAL NANOSENSORS FOR SUBCELLULAR CHEMICAL IMAGING' Principal Investigator & Institution: Kopelman, Raoul; Professor; Chemistry; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 01-JAN-1994; Project End 31-AUG-2005 Summary: Developing real-time, non-invasive, high-resolution chemical imaging of live mammalian cells, with high sensitivity and selectivity, is the objective. The tools to be employed are the smallest ever chemical and biochemical nanosensors, cell- implantable spheres, with a radius of 10-100 nm, called PEBBLEs (probes encapsulated by biologically localized embedding). Based on fluorophore molecules embedded in a variety of biocompatible matrices, the suggested methodologies will use, in tandem, optically silent ionophores and enzymes, so as to apply these sensors to a wide range of intracellular ions, free radicals and molecules, simultaneously, with high speed, sensitivity and selectivity. The list of subcellular analytes includes potassium, sodium, magnesium, zinc, copper, chloride, nitrite, carbonate and phosphate ions; oxygen, glucose and other enzyme substrates and reactive oxygen species -- singlet oxygen, nitric oxide, hydrogen peroxide, superoxide and hydroxyl radicals. Methods for controlling the size, shape and biocompatibility will be developed, as well as for steering the nanosensors (e.g., magnetically) and for targeting them to specific cell locations, with the help of molecular recognition. Validation and application examples of the subcellular real-time chemical imaging will be carried out on neural, liver, macrophage and other mammalian cell lines. Such refined chemical imaging is expected to accelerate biomedical research in many areas. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PHYSIOLOGY OF THALAMOCORTICAL RHYTHMICITY IN VITRO Principal Investigator & Institution: Coulter, Douglas A.; Associate Professor; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 01-JUL-1992; Project End 31-MAY-2003 Summary: GABAergic inhibition plays an atypical "pro-oscillatory" role in the thalamocortical (TC) system. Unlike most other brain areas, where inhibition checks excessive synchronous activation, in the TC system, inhibition synchronizes and drives rhythmic oscillatory behavior involving the tightly interconnected synaptic circuit comprised of thalamus, nucleus reticularis thalami (NRT), and neocortex. Within this circuit, the GABAergic NRT neurons are pacemakers, synchronizing TC rhythms via their powerful inhibitory connections onto neighboring thalamic neurons. TC oscillations normally occur during slow wave sleep, and pathological variants of these
Studies
47
rhythms include the spike wave discharges of Generalized Absence epilepsy, and generalized tonic clonic seizures characteristic of most convulsive forms of epilepsy. In these normal and pathological TC oscillations, the nature of cellular activity is fundamentally dissimilar, and these differences may reflect the added contributions of the neocortex to pathological rhythms. The central hypothesis underlying the research to be conducted in this proposal is that mechanisms involved in determining these distinct patterns of activity in pathological and nonpathological TC oscillations fundamentally depend on the cellular and regional properties of GABAergic inhibition within the TC system. Studies proposed in this application are designed to investigate and test this hypothesis through research centered on 3 specific aims: 1. Characterize inhibitory synaptic activity recorded under normal and pathological conditions in thalamic and NRT neurons; 2. Determine how intrinsic thalamic interneurons contribute to generation of TC rhythms; and 3. Investigate how chronic epilepsy-associated alterations in GABAergic inhibition in the TC system contribute to enhanced seizure susceptibility. Results of this research could provide important insight at cellular, synaptic, and molecular levels into mechanisms critically involved in GABAergic regulation of normal and pathological TC rhythmicity. This provides new directions to exploit in therapeutic intervention to control epileptic TC oscillations, as well as new insight into processes potentially altered in genetic forms of epilepsy involving pathological function of the TC system. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT--EXPRESSION AND REGULATION OF A PUTATIVE MG TRANSPORTER IN KIDNEY Principal Investigator & Institution: Walder, Roxanne Y.; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: Magnesium is an essential mineral in vertebrates and involved in many biochemical and physiological functions. Magnesium homeostasis is regulated between the overall requirements of the body, and the renal and intestinal reabsorption and excretion. Despite extensive study, the molecular mechanisms of magnesium regulation are poorly understood. Since 1997, we have studied an autosomal recessive disorder, familial hypomagnesemia with secondary hypocalcemia (HSH). Patients affected with this disease show severe hypomagnesemia and hypocalcemia, which leads to tetany and seizures, which can be lethal if left untreated. The disorder has been thought to be caused by a defect in the intestinal absorption of magnesium, rather than by abnormal renal loss of magnesium because HSH patients have low to normal levels of magnesium in their urine, prior to treatment. High-dose magnesium supplementation, which is needed as a life-long treatment, can overcome the apparent defect in magnesium absorption and in serum concentrations of calcium. We initially mapped the gene locus to chromosome 9q in three large inbred kindreds from Israel. The HSH locus was subsequently narrowed to approximately 2 Mb, flanked by D9S1115 and D9S 175. We recently demonstrated that mutations in TRPM6, a candidate gene within the narrowed interval, caused HSH. TRPM6 is highly homologous to a bifunctional protein, TRPM7, which can act as an ion channel for divalent cations and as a serine/threonine protein kinase. We also observed that patients carrying mutations in TRPM6 have abnormal renal magnesium excretion. These findings indicate that TRPM6 plays an important role in magnesium homeostasis in the kidney, as well as in the intestine. We would like to extend these studies to determine the precise locations of TRPM6 expression in the kidney, and to compare it with expression of TRPM7. TRPM6 is
48
Magnesium
selectively expressed in colon and in kidney, whereas TRPM7 is widely expressed, and also expressed in the kidney. We will develop specific, non-cross-reacting antibodies to the two proteins for immunolocalization and Western studies. We will examine the possibility of co-localization of the two proteins. TRPM6 and TRPM7 expression will be examined in mice made hypomagnesemic with magnesium deprivation diets to test if expression is regulated in hypomagnesemia and hypocalcemia. The expression of the two TRP channels will also be examined in mice on calcium deprivation diet. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POST TRAUMATIC NONCONVULSIVE EPILEPTIFORM ACTIVITY Principal Investigator & Institution: Vespa, Paul M.; Surgery; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 06-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): The main aim of this proposal is to study the incidence of epileptiform discharges and seizures that occur during coma after traumatic brain injury, possible mechanisms of generating epileptiform activity and the neurochemical consequences of this activity. The investigator has made exciting preliminary observations that post-traumatic nonconvulsive seizure activity on continuous electroencephalography (EEG) occurs frequently, is associated with adverse neurochernical changes and increases mortality. Previous animal brain injury models have documented neurochernical and ionic perturbation with an energy crisis and compensatory hyperglycolysis. At the same time there is a selective loss of neuronal inhibition (GABA, y-amino-butyric acid, containing cells) and reduced extracellular magnesium that leads to a decrease in seizure threshold. As a consequence of early post traumatic seizures, cellular energy demand may be increased and lead to secondary injury of cells that survived the initial trauma. Preliminary studies demonstrate an increased incidence of EEG-defined seizures. and epileptiforin activity, however the relationship between early post-traumatic epileptiform activity, the disordered neurochernical state, increased glucose metabolism and secondary cellular injury remain unknown. Thus the central hypothesis of this grant is that early post-traumatic nonconvulsive epileptiform activity is common and leads to further hyperglycolytic neurochernical events (increased lactate, glutamate and decreased glucose) and additional neuronal membrane injury. The specific aims of this proposal will be: (1) delineate the incidence rate, type and duration of early EEG-defined post-traumatic epileptiform activity (TEEA); (2) define the mechanistic influence of impaired neuronal inhibition in generating TEEA; (3) determine if TEEA results in a hyperglycolytic response; and (4) determine if TEEA leads to additional brain tissue membrane injury, as determined by time-locked increases in extracellular glycerol. The application is intended to pen-nit the candidate to gain important didactic education in research and statistical methods and experience in conducting a human-based basic research paradigm complemented by future animal models. The hypothesis and unique approach come at a crucial time of failed clinical trials and address an important new therapeutic target. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROBING THE 3' LOOP OF U6 SNRNA IN SPLICEOSOME CATALYSIS Principal Investigator & Institution: Dery, Kenneth J.; City of Hope National Medical Center Duarte, Ca 91010
Studies
49
Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): Significant insight has emerged from the analyses of phylogenetics, compensatory base-pair mutations, and photochemical crosslinking that indicate a specific catalytic role for U6 small nuclear RNA (snRNA) in pre-messenger RNA splicing. This notion has been strengthened by our recent discovery that the 3' intramolecular stem-loop of U6 snRNA binds a magnesium ion that is critical for the chemistry of splicing (Yean et al., Nature 408:881). It is unclear, however, whether the magnesium that we have identified is at the catalytic site and how the 3' stem-loop of U6 interacts with the rest of the spliceosome. The objectives of this pre-doctoral grant application arc two-fold: (1) test a metal-ligand interaction that would involve juxtaposing the 3' intramolecular stem loop (ISL) of U6 snRNA with the 5' splice site (SS) and (2) to investigate what protein factors stabilize, assist, or mediate RNA folding that leads to catalysis within the context of the assembled spliceosome. These interactions, once defined, would help our understanding of how the different sites of chemistry become tightly linked during spliceosome catalysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: QUANTITATIVE ARRAY PIEZOELECTRIC MICROCANTILEVER SENSORS Principal Investigator & Institution: Shih, Wan Y.; Materials Engineering; Drexel University 3201 Arch Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): Objective: The goal of proposed research is to fabricate and use highly piezoelectric microcantilever arrays for ultrasensitive, in-situ, rapid, simultaneous multiple analyte quantification in small sample volumes using electrical means with unprecedented sensitivity (10 -15 g). The proposed piezoelectric microcantilevers with antibodies specific to the target antigen immobilized at the cantilever tip will measure the presence of proteins or pathogens with femtogram (smaller than the mass of a single cell) sensitivity. This represents the ability to detect a single cell or about 1000 molecules in a small volume. We will demonstrate the application with (1) transient protein expression of a recombinant protein, alkaline phosphatase (SEAP) in Chinese Hamster Ovary cells (CHO) during growth in a bioreactor, and (2) early detection of streptococcus at ultra low concentrations , 100 10,000 number/ml. Approaches: The device consists of a highly piezoelectric lead magnesium niobate-lead titanate solid solution (PMN-PT) cantilever smaller than 50 um in length coupled to antibody immobilized at the cantilever tip. Binding of target antigens is detected by monitoring the resonance frequency shift. Because of the small sizes, the cantilevers will be capable of detecting a single cell or some 1000 molecules in a small volume. The resonance frequency shift transient will be used to quantify the amount of antigens present in a small volume. In the model CHO bioreactor, the SEAP expression quantification is used as an example to illustrate the proposed methodology. For pathogen detection, microcantilevers developed under this program have the potential to detect streptococcus at a concentration of 100 to 10,000 bacterial/ml, significantly enhancing detection capability. Experiments will be designed to explore lower level of detection in the range of 100 to 10,000 cells/ml. Because the proposed piezoelectric cantilever sensors use electrical signal for actuation and detection, the sensor and all necessary electronics can be organized in a compact form and easily usable in such broad ranging applications such as early disease detection and genomicsinspired proteomics. Results: It is anticipated that as a result of the proposed study, ultra sensitive, rapid, specific, multiple analyte quantification in ultra low concentrations and
50
Magnesium
small sample volumes will be achieved using arrays of highly piezoelectric PMN-PT micro cantilevers of less than 50 um in length with better than10-15 g/Hz sensitivity coupled with antibodies specific to the target antigen immobilized at the cantilever tip with simple electrical means, which has wide ranging applications such early disease detection and genomics-inspired proteomics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RECOGNITION AND CATALYSIS IN RNASE III PROCESSING Principal Investigator & Institution: Nicholson, Allen W.; Professor & Chair; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2002 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REGULATION OF CITRATE TRANSPORT Principal Investigator & Institution: Hamm, L Lee.; Chief, Nephrology and Hypertension; Medicine; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2001; Project Start 15-APR-2000; Project End 31-MAR-2004 Summary: Urinary citrate is one of the most important known endogenous inhibitors of calcium nephrolithiasis. Urinary citrate excretion is primarily determined by its fractional reabsorption in the proximal tubule. Previously, a major impediment to studies of citrate transport has been the lack of a suitable cell culture model. However, we have now clearly identified a method to study citrate reabsorption in a proximal tubule cell line (see preliminary data). In addition, the recent cloning of an apical dicarboxylate transporter from the proximal tubule by Pajor allows new insight into the regulation of citrate transport. This with our new culture model will allow us to examine several critical issues in the molecular regulation of citrate transport. The specific aims are to characterize both acute and chronic regulation of citrate absorption in the proximal tubule. Acute regulation of citrate transport by pH and divalent cations, in particular will be addressed. Although a variety of previous studies have addressed the influence of pH on citrate transport, our proposed studies will be able to directly address simultaneously the role of intracellular pH (to be measured with fluorescent probes) as well as extracellular pH. In regards to divalent cations, our preliminary data demonstrate dramatic effects of extracellular calcium and magnesium on citrate transport. Our findings suggest that changes in luminal calcium and magnesium concentrations within the ranges seen clinically may be important in determining urinary citrate excretion. The proposed studies will also address chronic regulation of citrate reabsorption. Our cell culture method will allow us to directly examine the mechanism of chronic regulation by pH, hypokalemia, and starvation. We hypothesize that changes in citrate reabsorption with each of these result from changes in the abundance and/or cellular distribution of the citrate transporter. In the proposed studies we will be able to measure the direct in vitro effects of these stimuli on citrate transport in polarized cells, and on mRNA and protein levels and cellular distribution of the dicarboxylate transporter. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
51
Project Title: REVERSIBLE MAGNESIUM PRECIPITATION FOR HOT-START PCR Principal Investigator & Institution: Rowlyk, Katherine R.; Scientist; Dna Polymerase Technology, Inc. 1508 S Grand Blvd St. Louis, Mo 63104 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JAN-2004 Summary: (provided by applicant): We have been investigating strategies for novel methods of hot start for PCR. One such strategy involves the sequestering of a critical component of the reaction until the reaction temperature is sufficient to ensure selective annealing of PCR primers. We have investigated reversible precipitates of Mg as a method of sequestering Mg2+ ions, which are a critical component of PCR. Many PCR analyses benefit from or require a hot start, particularly those with rare targets or those with compromised DNA templates, such as diagnostic or forensic analyses. In a normal (room temperature) start, the primers can bind to non-specific sequences, or each other, during reaction setup, which can result in the amplification of competitive or inhibitory products. Current methods of achieving a hot start are tedious, expensive, and/or unreliable. We have identified a precipitated form of Mg that is solublized by thermocycling, but is stable enough at room temperature to inhibit polymerase activity. We have also determined that PCR reactions performed with this reversibly precipitated Mg have the benefit of a hot start. We are proposing to simplify and optimize this reversible precipitate technology for standard PCR and extend it to specialized PCR applications, multiplex PCR, Long and Accurate PCR, and even those applications that use other Mg2+ ion dependent enzymes, such as cDNA synthesis by reverse transcriptases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RIBOSOMAL PROTEIN S4 INTERACTIONS WITH MRNA AND RRNA Principal Investigator & Institution: Draper, David E.; Professor; Chemistry; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-JAN-1998; Project End 31-DEC-2001 Summary: Complexes of RNA and protein (RNPs) carry out many essential functions in the cell, including translation. How proteins within these complexes recognized specific sites, promote RNA folding, and contribute to function are important questions. The goal of this project is to explore these question for a ribosomal protein, S4, that has dual functions: it is a key protein in ribosome assembly, binding and organizing a approximately 500 nucleotide domain of the small subunit RNA, and also binds a 110 nucleotide pseudoknot structure in the alpha mRNA, where it represses translation by a novel "entrapment" mechanism. The protein is organized into at least three regions: an N-terminal segment (42 residues) is not required for ribosome assembly: a middle domain is highly conserved and mostly responsible for RNA recognition; a C-terminal domain may contribute to both RNA and protein interactions. The structure of a fragment containing the middle and C-terminal regions (159 residues), derived from Bacillus stearothermophilus S4, will be determined by NMR methods. Site- directed mutagenesis, selection approaches, and thermodynamic and kinetic measurements will be used to explore the following aspects of S4-RNA interactions: Determination of conserved surface residues involved in mRNA or rRNA binding; Comparison of the ways in which S4 binding is linked to folding of the ribosomal and messenger RNA recognition domains, paying particular attention to the role of Mg/2+ in promoting RNA folding and protein binding; Resolution of the translational repression mechanism by studies of S4 and 30S subunit interactions with the mRNA ribosome binding site;
52
Magnesium
Studies of the cooperatively between S4 and other ribosomal proteins (S20 and S16) assembling with the 16S rRNA 5' domain. Results from these studies should contribute to a basic understanding of protein-RNA recognition mechanisms and RNA folding, as well as elucidation of specific S4 roles in translational regulation and ribosome assembly. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF PROTEIN PHOSPHATASES IN INSULIN SECRETION Principal Investigator & Institution: Kowluru, Anjaneyulu; Associate Professor; Pharmaceutical Sciences; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: (From applicant's abstract) While a majority of extant studies have focused since on the protein kinases, very little is known of the regulation and roles of protein phosphatases (PPases) in physiologic insulin secretion from the pancreatic beta cell. The catalytic activity of certain enzymes of intermediary metabolism is influenced by their phosphorylation status. For example, acetyl CoA carboxylase (ACC), a lipogenic enzyme, is modulated by phosphorylation (inactive)- dephosphorylation (active). Here in the investigators describe a novel cytosolic, okadaic acid-sensitive (PP2A-like) PPase that dephosphorylates and activates ACC in the beta cell. Activity of this PPase is augmented by methylation at its C-terminal leucine. Further, the methylated form is converted to its inactive, demethylated form by a cytosolic serine esterease-like enzyme, also localize in the beta cell. Physiologic concentrations of glutamate and magnesium stimulate the carboxyl methylation as well as the catalytic activity of this PPase and concomitantly increase ACC activity. Effects of glutamate and magnesium are specific for ACC-phosphatase, but not ACC-kinase. Insulinotropic concentrations of glucose or glutamine stimulate the carboxyl methylation of this PPase in intact beta cells. More importantly, activity of this ACC-PPase is abolished in islet derived from the GK rat, a model for NIDDM, compared to islets from the control Wistar rats. Using isolated rat islets and pure beta (HIT-T15 and INS-1) cells, the investigators propose to study the regulation of this PPase, and thereby ACC, at 3 cellular levels (i.e. subcellular fractions, intact islets, and purified proteins in reconstituted systems). The investigators will also purify this PPase using microcystin -sepharose affinity columns to determine changes in the (A, B and C) subunit composition of PP2A under various experimental conditions, to establish a link between the carboxyl methylation of the C-subunit and the assembly of PP2A haloenzyme. The investigators will characterize the methylating and demethylating enzymes of PP2 Ac and study the interaction of ACC with its putative PPase. Using similar approaches, the investigators will examine the abnormalities in ACC-phosphatase in the diabetic GK islet and investigate if such a defect is reversed by treatment of diabetic rats with insulin or phlorizin. The proposed studies should establish a link between ACC activation and physiologic insulin secretion from isolated beta cells. These studies will also identify the locus that is causal to the observed defect in ACC-phosphatase and ACC activation signaling cascade in the diabetic beta cell, leading to abnormal insulin secretion demonstrable in this model for NIDDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SAR OF NOVEL TOPO I INHIBITOR AGAINST PROSTATE CANCER Principal Investigator & Institution: Lee, Yue-Wei D.; Associate Professor of Psychiatry/ Harva; Mc Lean Hospital (Belmont, Ma) Belmont, Ma 02478 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-DEC-2003
Studies
53
Summary: Prostate cancer is the most common cancer and the second leading cause of cancer mortality in men. An estimated 317,000 cases of prostate cancer were diagnosed, and 41,000 were expected to be fatal in the U.S. in 1996. Many cytotoxic chemotherapeutic agents have proven ineffective against metastatic prostate cancer, with only estramustine, suramin, and mitoxanthrone showing low levels of efficacy. During the course of searching for anti-cancer agents from traditional herbal medicine, we isolated alpha-Boswellic acid acetate from Olibanum (Boswellia carterii Birdw), a folk medicine used in the treatment of inflammatory diseases in China and the Middle East without overt toxicity. Alpha-Boswellic acid acetate shows excellent inhibitory activity against the DNA topoisomerase I enzyme: It is 3 times more potent than the standard, camptothecin, in the topoisomerase I relaxation assay. Because the levels of topoisomerase I are significantly higher in human cancerous prostate tissues than in normal tissues, and appear to remain constantly high throughout cell growth, compounds targeted at this enzyme could have the advantages of selectivity and specificity. The effectiveness of alpha-Boswellic acid acetate (as NSC624807) against cancer were evaluated several times by NCI using an in vitro assay system consisting of 57 human tumor cell lines. The compound was effective against several prostate cancer cell lines (androgen-independent PC-3: GI50=3.77x10-7M; DU-145: GI50=3.97x10-7 M) and cell strains derived from fresh surgical specimens of prostate tumor (GI50=3.9x107M). In view of its favorable toxicity profile (LD50 greater than 2.0 g/kg) and encouraging preliminary clinical efficacy in brain tumor, we propose to study the structural requirements of this unique natural product, which has a pentacyclic ring system, for topoisomerase I inhibition, and to evaluate its synthetic analogs for improved physical and biological activity. The specific aims are (1) to isolate a quantity of alpha-Boswell acid and its acetate from Boswellic carterii Birdw by high speed countercurrent chromatography, (2) to establish structure-activity relationship by chemical modifications of the alpha-Boswellic acid molecule, and (3) to evaluate the synthetic analogs in vitro in the topoisomerase I assay and against three prostate tumor cell lines: androgen-independent PC-3 and DU-145, and androgen-dependent LNCaP. These biochemical studies are critical for assessing (1) what structural features are essential for activity, (2) whether these alpha-Boswellic acid acetate analogs act as topoisomerase I inhibitors, and (3) whether we have any new alpha-Boswellic acid acetate analogs with enhanced activity against prostate cancer cells. We believe that these studies are important in providing a better understanding of alpha-Boswellic acid acetate and in identifying the most promising topo-I inhibitors for in vivo experiments and for further development as non-hormonal chemotherapy for prostate cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SCOPE AND CAUSES OF STILLBIRTH Principal Investigator & Institution: Saade, George R.; Associate Professor; Obstetrics and Gynecology; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2003; Project Start 26-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The University of Texas Medical Branch at Galveston (UTMB) has the capability to participate actively as a member of the NIH multisite Stillbirth Network. PI George R. Saade, MD, offers extensive experience within several NIH multisite clinical trials og: First and Second Trimester Evaluation of Risk of Aneuploidy (FASTER); First Trimester Nuchal Translucency and the Risk of Congenital Heart Disease; Twin-Twin Transfusion Syndrome Trial; and Beneficial Effects of Antenatal Magnesium Sulfate Study (BEAM). We have achieved successful patient
54
Magnesium
recruitment and retention by frequent involvement with UTMB's extensive Regional Maternal & Child Health Program (RMCHP). All of RMCHP's clinics follow protocols established by the Maternal-Fetal Medicine division, and the patients are delivered at UTMB in Galveston. Pregnant women in two counties served by UTMB--Galveston and Brazoria--will constitute the geographic-based population. More than 90% of these patients are cared for at a UTMB clinic and deliver at John Sealy Hospital. If needed, this target population can be expanded to other RMCHP clinics based on zip codes or counties, as appropriate. Further, the Department's Electronic Medical Record captures antepartum and intrapartum information, entered on-line, that is readily available for query by authorized investigators. In like manner, our Department's Tissue Bank has added broad efficiencies to clinical investigation. The excellent and productive collaboration between PI and Co-I, Radec Bukowski, MD, PhD, offers further benefits to the Stillbirth Network. In addition, our Department's genetics counselor, Jennifer Lee, who will serve as our site's outreach worker, brings considerable experience as an established grief counselor. Our Department has a very productive and well-funded basic science research group with expertise in many areas of relevance to the RFA, such as infection, vascular physiology, placental function, and fetal growth. Finally, we have well-established collaborative ties with our University's Department of Pathology and divisions of Genetics and Neonatology (see letters of support). In particular, UTMB has a highly regarded Perinatal Pathology division with expertise in various areas of interest to this RFA, including neuropathology and placental pathology. Following on our current interest in DNA microarray technology, our proposed study concept is to determine a single nucleotide polymorphism (SNP) marker profile particular to stillbirth. We accept the capitation and participatory stipulations of this RFA and stand ready to become a contributinq member of the NIH Stillbirth Network. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SPECTROSCOPIC METHODS TO STUDY METAL BINDING IN URIDINE Principal Investigator & Institution: Basti, Mufeed; North Carolina Agri & Tech St Univ 1601 E Market St Greensboro, Nc 27411 Timing: Fiscal Year 2001; Project Start 01-JUN-1977; Project End 31-JUL-2005 Summary: (provided by applicant): My long-term objective is to identify the roles of posttranscriptional modifications in the coordination of selective metal ions to several modified nucleosides and oligonucleotides. Oligonucleotides containing selected modified nucleosides will coordinate to a certain metal strongly and this may enhance their catalytic activity, i.e., their ability to function as ribozymes or coenzymes. Ultraviolet (UV) spectrophotometry, fluorescence, and NMR will be used to study the coordination of Mg+2, Mn+2, Cd+2, Pb+2, and Hg+2 to uridine (mostly as control) and to several of its naturally-occuring modifications. The roles of water of hydration, and the phosphate group of oligonucleotides in metal coordination will be examined. The generated data will guide the synthesis of short oligonucleotides which, by the inclusion of selected modified nucleosides, will coordinate tightly to certain metal ions. Metal coordination to oligonucleotides will also assist in explaining some of the heavy metals toxic biological effects as they bind to RNAs. Specifically my aims are: 1) Mg+2, Mn+2, Cd+2, Pb+2, and Hg+2 binding constants and the identification of these metals' coordination sites to uridine (mostly as a control) and several modified uridines will be determined. 2) By carrying out the metal coordination study in dimethylsulphoxide (DMSO) and comparing it with that in water, this study will explain the role of water of hydration. Steric and pH effects will be investigated. 3) Role of the phosphate group,
Studies
55
among other aspects, in metal coordination to short oligonuceotides that contain selected modified nucleosides will be surveyed. 4) This broad metal coordination study may then assist in designing oligonucleotides whose tight metal binding may enhance their catalytic activity, i.e., their ability to function as ribozymes or coenzymes. In light of their toxic effects, this broad study will also correlate the coordination of heavy metals to a specific RNA (tRNA, snoRNA) molecule to the presence of certain modified nucleosides. The different possible biological pathways resulting from such binding will be examined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SPECTROSCOPIC STUDIES OF ENZYME/SUBSTRATE COMPLEXES Principal Investigator & Institution: Reed, George H.; Professor; Institute for Enzyme Research; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2001; Project Start 01-JAN-1986; Project End 31-DEC-2002 Summary: The objectives of the project are to gain a better understanding of the mechanisms of enzymatic catalysis and of the means by which inorganic cations contribute to the catalytic processes. Pyruvate kinase and enolase, enzymes from the glycolytic pathway, are of central importance to carbohydrate metabolism in all living organisms. Both enzymes require specific activation by two equivalents of divalent cation, and pyruvate kinase requires activation by potassium as well. Each enzyme exhibits one or more instances of general acid-base catalysis during the catalytic cycle. The roles of magnesium and other divalent cations in enzymatic catalysis are poorly understood. General acid-base catalysis is a topic of current interest in enzymology. Studies of enolase and pyruvate kinase hold promise for revealing fundamental concepts in these areas. The specific aims of the project focus on key aspects of activation by metal ions and of general acid-base catalysis that have been revealed in previous studies. X-ray crystallography, site-directed mutagenesis, spectroscopic, and kinetic methods are proposed to approach the specific aims which include experiments to: 1) determine the pKa's of the general acid-base catalysts in the active site of enolase; 2) probe the basis for metal specificity in the steps of enolase catalysis; 3) correlate structure and function of wild type and site specific mutant enolases; 4) search for the group or groups responsible for general acid-base catalysis and for a potential proton relay network in the active site of pyruvate kinase; 5) probe the structural outcome of a Glu to Lys mutation in pyruvate kinase that eliminates the requirement for activation by potassium and probe the structural changes induced by an allosteric effector. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STRATEGIES TO LIMIT DEFIBRILLATION AND REPERFUSION INJUR Principal Investigator & Institution: Kerber, Richard E.; Professor of Medicine; Internal Medicine; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2001; Project Start 01-JUL-1995; Project End 31-MAY-2003 Summary: Nitric oxide plays a major role in oxygen-derived free radical generation in defibrillation and reperfusion injury; nitric oxide reacts with the superoxide radical to form peroxynitrite, which is toxic in itself and also forms further strongly oxidizing species resembling the hydroxyl radical. By limiting nitric oxide availability, nitric oxide synthase inhibitors may limit this process and ameliorate defibrillation/ reperfusion toxicity. Magnesium also has a role to play: it can also limit oxygen-derived free radical generation via its actions as a "physiologic calcium antagonist", which include limiting
56
Magnesium
the formation and release of endothelial-derived nitric oxide. The combination of NO synthase inhibitors and magnesium may be particularly effective. We will emphasize the direct detection of ascorbate radical to examine a series of testable hypotheses. Our overall hypotheses that the nitric oxide/superoxide/peroxynitrite pathway is a major source of free radicals that contribute to both defibrillation and reperfusion injury. Modulation of nitric oxide will alter bury from defibrillation and ischemia-reperfusion. The specific, testable hypotheses are: 1) Nitric oxide synthase inhibitors, by limiting the NO available to react with superoxide (forming peroxynitrite), reduce free radical generation and thereby ameliorate defibrillation and reperfusion injury. This preserves left ventricular function after defibrillation and/or reperfusion (i.e., less "stunning"). 2) Conversely, NO donors (SIN-1), by providing more NO substrate to react with superoxide and form toxic peroxynitrite, will increase free radical generation after defibrillation and/or reperfusion, worsening left ventricular function. 3) Magnesium, which we have already shown to reduce free radical generation in reperfusion injury, will be similarly cardioprotective in ameliorating defibrillation injury, reducing radical generation and deserving ventricular function. 4) The combination of nitric oxide synthase inhibitors and magnesium, which alter two different mechanisms/pathways to limit free radical generation, will be especially cardioprotective, ameliorating defibrillation and reperfusion injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURAL STUDIES OF NUCLEOTIDE DEPENDENT ENZYMES Principal Investigator & Institution: Holden, Hazel M.; Professor; Institute for Enzyme Research; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2001; Project Start 01-JUN-1994; Project End 31-MAY-2002 Summary: Nucleotides serve important roles in virtually all biochemical processes where they provide building blocks for DNA and RNA, act as currencies of energy in various metabolic pathways, serve as modulators of enzymatic activity, and function as transient electron acceptors and donors. The objective of this research program is to understand, on a molecular level, the role of nucleotides in the overall catalytic mechanisms of four protein systems: acetyl-CoA carboxylase which is Mg(II)-ATP dependent, kanamycin nucleotidyltransferase which can employ ATP, GTP, or UTP as a substrate, UDP-galactose 4-epimerase which requires tightly bound NAD for activity, and L-phenylalanine dehydrogenase which binds NAD or NADH reversibly. Kanamycin nucleotidyltransferase catalyzes the inactivation of various aminoglycoside antibiotics often employed in the treatment of serious infections due to aerobic Gramnegative bacteria. UDP-galactose 4- epimerase plays a key role in proper galactose metabolism, and indeed, one form of galactosemia arises from a deficiency in this enzyme. Acetyl-CoA carboxylase catalyses the first and absolutely critical step in the biosynthesis of long chain fatty acids. Finally, L-phenylalanine dehydrogenase catalyzes the oxidative deamination of L-phenylalanine. For the proposed studies, a combination of site-directed mutagenesis, x- ray crystallography, and kinetic measurements will be employed. Taken together, these studies will provide a detailed description of the role of nucleotides in the enzymatic functions of these proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STRUCTURAL STUDIES OF U6 SNRNA Principal Investigator & Institution: Butcher, Samuel E.; Biochemistry; University of Wisconsin Madison 750 University Ave Madison, Wi 53706
Studies
57
Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: (provided by applicant): Accurate and efficient nuclear pre-mRNA splicing is essential to eukaryotic life. Aberrant pre-mRNA splicing has been linked to a number of diseases. These include breast, colorectal, epithelial and ovarian cancer, as well as neurodegenerative diseases such as Parkinson's and Alzheimer's. Our objective is to develop an atomic-level understanding of the structure and function of a key component of the pre-mRNA splicing machinery, that of U6 snRNA. Currently, there is a profound lack of structural information about U6 snRNA. We hypothesize that the U6 snRNA structure functions to coordinate a magnesium ion cofactor during splicing, and that proteins and other RNAs are not required for magnesium binding. We will use NMR spectroscopy to investigate the structure, function, dynamics and metal binding properties of U6 snRNA. We anticipate that this research will provide a basis for the interpretation of genetic and biochemical data compiled on this region of U6 snRNA over the past decade. Our specific aims are: 1. Define metal ion interactions with the U6 snRNA stem-loop. We will use NMR to test our hypothesis that the U6 stem-loop is sufficient for coordination of the catalytically essential metal ion. 2. Determine the structure and investigate the dynamics of the S. cerevisiae U6 snRNA intramolecular stem-loop by NMR. The corresponding human U6 and U6atac structures will also be investigated. 3. Investigate the structural basis for U6 mutant phenotypes. We will correlate structural effects with well studied S. cerevisiae mutant phenotypes. 4. Investigate the influence of surrounding U6 snRNA sequences and the splicoesomal protein Prp24 on the U6 snRNA sem-loop structure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURE, FUNCTION AND REGULATION OF PRIMASE Principal Investigator & Institution: Godson, G N.; Biochemistry; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2001; Project Start 01-AUG-1986; Project End 31-MAR-2004 Summary: DNA replication cannot take place without active primase. The broad longterm goal of this proposal is to learn enough about primase to develop it as a target to inhibit DNA replication in cancer cells. This proposal continues our studies of the structure, function and mechanism of primer RNA synthesis by E. coli primase and extends our studies to human primase. In the revised proposal, Specific Aim #1 is to study mechanism of movement of E. coli primase on DNA template. A hypothesis of a periodic, punctuated synthesis of pRNA by E. coli primase will be tested by measuring the processivity of primase and dissociation and rebinding of primase to the template after each step of synthesis (10/11 nt, 21/22 nt and 24/25 nt). A primase elongation mutant will be used for these experiments. Specific Aim #2 is to analyze the active center of pRNA synthesis of E. coli primase. We will use Fe2+ cleavage and site-directed mutagenesis to localize amino acids that bind Mg2+ at the catalytic center and Zn2+ at the zinc finger. The DNA template binding sites will be analyzed using template oligonucleotides containing UV photoreactive nucleotides incorporated in specific positions. The exit pathway of the growing primer RNA chain will be similarly mapped by using photoreactive oligonucleotide primers. Changes in the conformation of primase during pRNA synthesis will be analyzed. In Specific Aim #3, we will continue to study the role of SSB in pRNA synthesis. A primase/SSB physical interaction will be trapped by biochemical methods. The yeast two-hybrid system will be used to further analyze primase/SSB interaction. Interaction sites on both primase and SSB will be identified. In Specific Aim #4, we will establish the domain structure of the human primase P49 and 58 subunits of DNA polymerase alpha. The active center of this two-
58
Magnesium
protein system will be identified by ATP affinity cross-linking technique plus chemical cleavage. The function of these regions will be explored by site-directed mutagenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURE/FUNCTION OF THE 790 LOOP IN RIBOSOMAL RNA Principal Investigator & Institution: Cunningham, Philip R.; Associate Professor; Biological Sciences; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-JAN-1998; Project End 31-DEC-2002 Summary: The long term objective of this proposal is to understand the role played by ribosomal RNA in protein synthesis. The fundamental processes involved in protein synthesis are believed to be the same in all organisms and several studies have indicated direct involvement of highly conserved ribosomal RNA sequences in translation. The goal of this project is to determine the functional significance and structure of a loop in the small subunit ribosomal RNAs of all organisms and located at position 790 in E. coli 16S RNA. A combined genetic, biochemical and structural approach will be employed. In vivo genetics and in vitro biochemistry will be employed to determine function, and NMR will be used to determine the key structural features of the loop. The presence of multiple rRNA genes in most organisms has complicated genetic analysis of ribosome function. To circumvent these problems, a genetic system has been constructed which does not interfere with normal cellular function. In this system, the chloramphenicol acetyltransferase (CAT) reporter message is translated exclusively by plasmid encoded ribosomes which cannot translate normal cellular messages. Consequently, cells containing this construct are chloramphenicol resistant and the level of this resistance is dependent on the amount of functional CAT protein produced by plasmid derived ribosomes. Thus, deleterious rRNA mutations in plasmid encoded ribosomes will inhibit translation of only the CAT message and therefore decrease chloramphenicol resistance without affecting translation of other cellular messages. Three specific aims are: 1. Identification of key functional elements within the loop. Random mutations will be constructed simultaneously at each of the nine nucleotides in the 790 loop and functional an nonfunctional mutants will be selected. Mutants will be sequenced to identify elements within the loop required for function. Nonfunctional mutants will be analyzed biochemically to determine which aspect of protein synthesis is affected. 2. Identification of sites which functionally interact with the 790 loop. Nonfunctional mutants from 1 will be used to select second-site functional revertants. These will be cloned by complementation and identified. 3. Identification of key structural elements within the 790 loop. Loop structure will be determined using NMR. Key structural elements of the loop will be revealed by structure determination of highly substituted yet functional mutants from 1. Proposed structure/function relationships will be tested by site-directed mutagenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THERMODYNAMICS OF BIOCHEMICAL SYSTEMS Principal Investigator & Institution: Alberty, Robert A.; Chemistry; Massachusetts Institute of Technology Cambridge, Ma 02139 Timing: Fiscal Year 2001; Project Start 01-AUG-1994; Project End 31-MAR-2002 Summary: (Adapted from applicant's abstract) The long term objective is to increase the usefulness of equilibriumcalculations on biochemical reactions. Thermodynamics determine whether a reaction goes in the forward or reverse direction and whether it will absorb or evolve heat. More specifically, thermodynamics makes it possible to
Studies
59
calculate equilibrium compositions and heat evolutions using data that often comes from other reactions. Knowledge of the thermodynamics of a reaction and knowledge of the kinetics of the forward reaction make it possible to calculate the kinetics of the reverse action. Chemical equilibrium in biological systems is complicated by the fact that apparent equilibrium constants depend on pH and pMg, as well as on temperature, pressure and ionic strength. A better understanding of these effects will facilitate the interpretation of metabolism and problems that are encountered in certain diseases. Thermodynamic information on biochemical reactions is currently stored as equilibrium constants and heats of specific reactions. These data can be interpreted by the use of recently developed techniques to obtain thermodynamic properties of individual reactants, which can then be used to calculate equilibrium constants and heats of reactions that have not even been studied previously. One objective of this project is to prepare thermodynamic tables on the properties of reactants so as to increase the usefulness of current knowledge. Another objective is to use new concepts in biochemical thermodynamics to investigate coupling of reactions by enzymes, missing reactions in systems like glycolysis, muscle, and chemosmotic theory. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TOWARDS A HEAT-LABILE CHELATOR FOR HOT-START PCR Principal Investigator & Institution: Kermekchiev, Milko B.; Dna Polymerase Technology, Inc. 1508 S Grand Blvd St. Louis, Mo 63104 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 31-OCT-2002 Summary: (applicant's abstract): Many PCR analyses, particularly those with rare targets or those with compromised DNA templates (such as forensic analyses), benefit from a hot start. In a normal (room temperature) start, the primers can prime at non-specific sequences, or on each other, during reaction setup. The result can be competitive or inhibitory product produced at the expense of the desired product. In a hot start, a critical component is kept inactive or separate from the reaction until the temperature is at least 65C, at which temperature the primers are properly selective. Current methods of achieving a hot startare tedious, expensive, and/or have shortcomings. We propose to develop heat-labile chelators of Mg++ ion as hot-start reagents for PCR. The DNA polymerases used in PCR reactions are Mg++ dependant, and the Mg++ chelator EDTA inhibits PCR. The ideal hot-start chelator would be stable at room temperature in PCR reaction buffer for at least an hour, but will inactivate and release the Mg++ ion during the first PCR heat cycle, yet not inhibit the PCR reaction itself. To perform hot-start with these reagents, sequestered Mg++ ions (in the form of soluble Mg-chelate) would be added to PCR reactions in place of MgCI2 as a source of Mg++ ions. We propose three lead groups of compounds that have the structural characteristics of Mg++ chelators, and can be inactivated under controlled conditions. PROPOSED COMMERCIAL APPLICATION: Methods for hot-start PCR have proven to be impartant-- even critical-for many PCR procedures, such as forensic analysis, food and blood product contamination assays. Although most PCR applications benefit from hot-start methods, they are underused because they add significant cost and effort, and they have inadequacies. The labile Mg-chelating reagents we propose to develop and test will be inexpensive, easy to use, and will likely be more effective mediators of hot-start than current methods. They may in fact be inexpensive enough to become standard reagents for PCR used by thousands of laboratories world wide. Such labile chelators may also have applications for other biotechnology and chemical processes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
60
Magnesium
•
Project Title: VERY HIGH RESOLUTION STRUCTURES OF THE FFH GTPASE Principal Investigator & Institution: Freymann, Douglas M.; Assistant Professor; Mol Pharm & Biol Chemistry; Northwestern University Office of Sponsored Programs Chicago, Il 60611 Timing: Fiscal Year 2001; Project Start 01-FEB-1999; Project End 31-JUL-2002 Summary: All cells contain mechanisms by which proteins are targeted to different cellular compartments. Co-translational targeting of proteins to cell membranes is mediated by the signal recognition particle (SRP), which recognizes the amino-terminal signal sequence of the nascent polypeptide and targets the translating ribosome to a membrane receptor. Structural and functional elements of the SRP ribonucleoprotein are highly phylogenetically conserved. One protein component of the particle, SRP54 or Ffh (in prokaryotes), is of particular interest because it provides specific recognition of the hydrophobic signal peptide and is also a GTPase which interacts directly with the membrane receptor. GTPases are a ubiquitous family of proteins which use the binding and hydrolysis of GTP to elicit various cellular functions - well studied GTPases are involved in translation, cell regulation, and signal transduction. This proposal is directed towards detailed protein structural understanding of the NG GTPase domain of Ffh. The results will contribute to our understanding of the role of this specific GTPase in the SRP pathway, and, more generally, give insight into how different GTPases build on a common core protein structure to elicit different cellular function. The project has three crystallographic objectives. To obtain highly refined ultra-high (1.0 Angstroms) resolution structural models of the apo- and GDP-bound NG GTPase from crystals now in hand. To improve existing MgGDP-form crystals so that we can describe that structure at a similar level of detail. And, to crystallize the MgGTP-bound NG GTPase using nonhydrolyzable nucleotide analogs or GTP, and to solve its crystal structure as well. The structural data, spanning the ligand states of the GTPase, will provide the basis for detailed and accurate analysis of the interaction between the protein, water, magnesium, and nucleotide. They should also reveal whether structural phenomena not resolved in structures at lower resolution - deviations of the protein stereochemistry, packing imperfections, and conformational substrates - may be relevant to GTPase function. The analyses will address the chemistry of the GTPase and the protein design principles which facilitate mobilization of different structural motifs during the cycle of GTP binding and hydrolysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “magnesium” (or synonyms) into the search box. This search gives you access to 3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
61
full-text articles. The following is a sample of items found for magnesium in the PubMed Central database: •
A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection. by Huycke MM, Naguib MT, Stroemmel MM, Blick K, Monti K, Martin-Munley S, Kaufman C.; 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90026
•
A Mutation that Alters Magnesium Block of N-Methyl-D-Aspartate Receptor Channels. by Sharma G, Stevens CF.; 1996 Aug 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38629
•
A Novel Family of Magnesium Transport Genes in Arabidopsis. by Li L, Tutone AF, Drummond RS, Gardner RC, Luan S.; 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=139487
•
ATPases and phosphate exchange activities in magnesium chelatase subunits of Rhodobacter sphaeroides. by Hansson M, Kannangara CG.; 1997 Nov 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24312
•
Characterization of a family of chlorophyll-deficient wheat (Triticum) and barley (Hordeum vulgare) mutants with defects in the magnesium-insertion step of chlorophyll biosynthesis. by Falbel TG, Staehelin LA.; 1994 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=159242
•
Charge-to-Alanine Mutagenesis of the Adeno-Associated Virus Type 2 Rep78/68 Proteins Yields Temperature-Sensitive and Magnesium-Dependent Variants. by Gavin DK, Young SM Jr, Xiao W, Temple B, Abernathy CR, Pereira DJ, Muzyczka N, Samulski RJ.; 1999 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112978
•
Chlorophyll Biosynthesis. Expression of a Second Chl I Gene of Magnesium Chelatase in Arabidopsis Supports Only Limited Chlorophyll Synthesis. by Rissler HM, Collakova E, DellaPenna D, Whelan J, Pogson BJ.; 2002 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=148938
•
Comparison of sufentanil with sufentanil plus magnesium sulphate for sedation in the intensive care unit using bispectral index. by Memis D, Turan A, Karamanlijoglu B, Oguzhan N, Pamukcu Z.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=270723
•
Constraints on nebular dynamics and chemistry based on observations of annealed magnesium silicate grains in comets and in disks surrounding Herbig Ae /Be stars. by Hill HG, Grady CA, Nuth JA III, Hallenbeck SL, Sitko ML.; 2001 Feb 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33388
•
Crystal Structure of Fructose-1,6-Bisphosphatase Complexed with Fructose 6Phosphate, AMP, and Magnesium. by Ke H, Zhang Y, Lipscomb WN.; 1990 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54299
•
Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial. by Bradford A, Lees K.; 2000; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=56206
62
Magnesium
•
Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity. by Engelman A, Craigie R.; 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189473
•
Electron Probe Microanalysis of Calcium Release and Magnesium Uptake by Endoplasmic Reticulum in Bee Photoreceptors. by Baumann O, Walz B, Somlyo AV, Somlyo AP.; 1991 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50889
•
Evidence for a hydroxide ion bridging two magnesium ions at the active site of the hammerhead ribozyme. by Hermann T, Auffinger P, Scott WG, Westhof E.; 1997 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=146905
•
Ferrous iron uptake by a magnesium transport system is toxic for Escherichia coli and Salmonella typhimurium. by Hantke K.; 1997 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=179529
•
Free Magnesium Levels in Normal Human Brain and Brain Tumors: 31P ChemicalShift Imaging Measurements at 1.5 T. by Taylor JS, Vigneron DB, Murphy-Boesch J, Nelson SJ, Kessler HB, Coia L, Curran W, Brown TR.; 1991 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52178
•
Functional Similarity between Archaeal and Bacterial CorA Magnesium Transporters. by Smith RL, Gottlieb E, Kucharski LM, Maguire ME.; 1998 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=107238
•
Hexahydrated magnesium ions bind in the deep major groove and at the outer mouth of A-form nucleic acid duplexes. by Robinson H, Gao YG, Sanishvili R, Joachimiak A, Wang AH.; 2000 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=102818
•
HLA- and H-2-Associated Variations of Intra- and Extracellular Magnesium Content. by Henrotte JG, Pla M, Dausset J.; 1990 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53590
•
Low-magnesium calcite produced by coralline algae in seawater of Late Cretaceous composition. by Stanley SM, Ries JB, Hardie LA.; 2002 Nov 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137715
•
Magnesium Adenosine 5[prime]-Triphosphate-Energized Transport of GlutathioneS-Conjugates by Plant Vacuolar Membrane Vesicles. by Li ZS, Zhao Y, Rea PA.; 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=157260
•
Magnesium and Manganese Content of Halophilic Bacteria. by Medicis ED, Paquette J, Gauthier JJ, Shapcott D.; 1986 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203574
Studies
63
•
Magnesium and the Role of mgtC in Growth of Salmonella typhimurium. by Moncrief MB, Maguire ME.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108421
•
Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. by Stahlmann R, Forster C, Shakibaei M, Vormann J, Gunther T, Merker HJ.; 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=162873
•
Magnesium deficiency: effect on bone mineral density in the mouse appendicular skeleton. by Gruber HE, Rude RK, Wei L, Frausto A, Mills BG, Norton HJ.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155646
•
Magnesium Dietary Intake Modulates Blood Lipid Levels and Atherogenesis. by Altura BT, Brust M, Bloom S, Barbour RL, Stempak JG, Altura BM.; 1990 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53579
•
Magnesium is required for specific DNA binding of the CREB B-ZIP domain. by Moll JR, Acharya A, Gal J, Mir AA, Vinson C.; 2002 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=101231
•
Magnesium limitation and its role in apparent toxicity of ethanol during yeast fermentation. by Dombek KM, Ingram LO.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=239160
•
Magnesium Sensitizes Slow Vacuolar Channels to Physiological Cytosolic Calcium and Inhibits Fast Vacuolar Channels in Fava Bean Guard Cell Vacuoles. by Pei ZM, Ward JM, Schroeder JI.; 1999 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59462
•
Magnesium Transport in Bacillus subtilis W23 During Growth and Sporulation. by Scribner H, Eisenstadt E, Silver S.; 1974 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=246605
•
Magnesium transport in Salmonella typhimurium: mgtA encodes a P-type ATPase and is regulated by Mg2+ in a manner similar to that of the mgtB P-type ATPase. by Tao T, Snavely MD, Farr SG, Maguire ME.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=176934
•
Magnesium Uptake by CorA Is Essential for Viability of the Gastric Pathogen Helicobacter pylori. by Pfeiffer J, Guhl J, Waidner B, Kist M, Bereswill S.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=128062
•
Magnesium-Chelatase from Developing Pea Leaves Characterization of a Soluble Extract from Chloroplasts and Resolution into Three Required Protein Fractions. by Guo R, Luo M, Weinstein JD.; 1998 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=35118
•
Magnesium-dependent alternative foldings of active and inactive Escherichia coli tRNA(Glu) revealed by chemical probing. by Madore E, Florentz C, Giege R, Lapointe J.; 1999 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=148604
64
Magnesium
•
Magnesium-dependent folding of self-splicing RNA: Exploring the link between cooperativity, thermodynamics, and kinetics. by Pan J, Thirumalai D, Woodson SA.; 1999 May 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26850
•
Magnesium-induced conformational change of packaging RNA for procapsid recognition and binding during phage phi29 DNA encapsidation. by Chen C, Guo P.; 1997 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191077
•
Molecular basis of the magnesium deprivation response in Salmonella typhimurium: identification of PhoP-regulated genes. by Soncini FC, Garcia Vescovi E, Solomon F, Groisman EA.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=178303
•
Pharmacokinetics of Gatifloxacin and Interaction with an Antacid Containing Aluminum and Magnesium. by Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89112
•
Probing the Pore Region of Recombinant N-Methyl-D-Aspartate Channels Using External and Internal Magnesium Block. by Kupper J, Ascher P, Neyton J.; 1996 Aug 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38727
•
Quantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions. by Kube DM, Srivastava A.; 1997 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=146885
•
Quinolone Binding to DNA is Mediated by Magnesium Ions. by Palu G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M.; 1992 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50194
•
Reconstitution of an Active Magnesium Chelatase Enzyme Complex from the bchI, D, and -H Gene Products of the Green Sulfur Bacterium Chlorobium vibrioforme Expressed in Escherichia coli. by Petersen BL, Jensen PE, Gibson LC, Stummann BM, Hunter CN, Henningsen KW.; 1998 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106941
•
Regulation of Bacillus subtilis macrofiber twist development by ions: effects of magnesium and ammonium. by Mendelson NH, Favre D.; 1987 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=211808
•
Role of Magnesium Chelatase Activity in the Early Steps of the Tetrapyrrole Biosynthetic Pathway. by Papenbrock J, Mock HP, Tanaka R, Kruse E, Grimm B.; 2000 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=58950
•
Synergistic Effect of Ofloxacin and Magnesium Deficiency on Joint Cartilage in Immature Rats. by Lozo E, Riecke K, Schwabe R, Vormann J, Stahlmann R.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127237
Studies
65
•
The C-terminal carboxy group of T7 RNA polymerase ensures efficient magnesium ion-dependent catalysis. by Lykke-Andersen J, Christiansen J.; 1998 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=148041
•
The influence of calcium and magnesium in drinking water and diet on cardiovascular risk factors in individuals living in hard and soft water areas with differences in cardiovascular mortality. by Nerbrand C, Agreus L, Lenner RA, Nyberg P, Svardsudd K.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=198279
•
The RNA-binding domain of ribosomal protein L11 recognizes an rRNA tertiary structure stabilized by both thiostrepton and magnesium ion. by Blyn LB, Risen LM, Griffey RH, Draper DE.; 2000 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=102817
•
Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. by Goldgur Y, Dyda F, Hickman AB, Jenkins TM, Craigie R, Davies DR.; 1998 Aug 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21307
•
Three semidominant barley mutants with single amino acid substitutions in the smallest magnesium chelatase subunit form defective AAA + hexamers. by Hansson A, Willows RD, Roberts TH, Hansson M.; 2002 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=129802
•
Transcription of the SsrAB Regulon Is Repressed by Alkaline pH and Is Independent of PhoPQ and Magnesium Concentration. by Miao EA, Freeman JA, Miller SI.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=134869
•
Ultrastructure of Achilles Tendons of Rats Treated with Ofloxacin and Fed a Normal or Magnesium-Deficient Diet. by Shakibaei M, Pfister K, Schwabe R, Vormann J, Stahlmann R.; 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89668
•
Use of magnesium to increase sensitivity of Limulus amoebocyte lysate for detection of endotoxin. by Tsuji K, Steindler KA.; 1983 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=242461
•
Variability within individuals of plasma ionic magnesium concentrations. by Newhouse IJ, Johnson KP, Montelpare WJ, McAuliffe JE.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113254
•
Vibronic Energy Map and Excited State Vibrational Characteristics of Magnesium Myoglobin Determined by Energy-Selective Fluorescence. by Kaposi AD, Vanderkooi JM.; 1992 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50552
66
Magnesium
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with magnesium, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “magnesium” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for magnesium (hyperlinks lead to article summaries): •
A comparative study on the analgesic effect of tramadol, tramadol plus magnesium, and tramadol plus ketamine for postoperative pain management after major abdominal surgery. Author(s): Unlugenc H, Gunduz M, Ozalevli M, Akman H. Source: Acta Anaesthesiologica Scandinavica. 2002 September; 46(8): 1025-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12190807&dopt=Abstract
•
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. Author(s): Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. Source: The New England Journal of Medicine. 2003 January 23; 348(4): 304-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540643&dopt=Abstract
•
A compartmental model of magnesium metabolism in healthy men based on two stable isotope tracers. Author(s): Sabatier M, Pont F, Arnaud MJ, Turnlund JR. Source: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2003 September; 285(3): R656-63. Epub 2003 May 29. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12775558&dopt=Abstract
•
A family of autosomal dominant hypocalcemia with a positive correlation between serum calcium and magnesium: identification of a novel gain of function mutation (Ser(820)Phe) in the calcium-sensing receptor. Author(s): Nagase T, Murakami T, Tsukada T, Kitamura R, Chikatsu N, Takeo H, Takata N, Yasuda H, Fukumoto S, Tanaka Y, Nagata N, Yamaguchi K, Akatsu T, Yamamoto M. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 June; 87(6): 2681-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12050233&dopt=Abstract
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
67
•
A low dose (“Dhaka”) magnesium sulphate regime for eclampsia. Author(s): Begum R, Begum A, Johanson R, Ali MN, Akhter S. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2001 November; 80(11): 9981002. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11703195&dopt=Abstract
•
A new approach to evaluate magnesium status: determination of exchangeable Mg pool masses using Mg stable isotope. Author(s): Feillet-Coudray C, Coudray C, Gueux E, Mazur A, Rayssiguier Y. Source: Magnes Res. 2002 December; 15(3-4): 191-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635871&dopt=Abstract
•
A new in vitro blood load test using a magnesium stable isotope for assessment of magnesium status. Author(s): Feillet-Coudray C, Coudray C, Gueux E, Mazur A, Rayssiguier Y. Source: The Journal of Nutrition. 2003 April; 133(4): 1220-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12672946&dopt=Abstract
•
A novel family of magnesium transport genes in Arabidopsis. Author(s): Li L, Tutone AF, Drummond RS, Gardner RC, Luan S. Source: The Plant Cell. 2001 December; 13(12): 2761-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11752386&dopt=Abstract
•
A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients. Author(s): Margolin A, Kantak K, Copenhaver M, Avants SK. Source: Journal of Addictive Diseases : the Official Journal of the Asam, American Society of Addiction Medicine. 2003; 22(2): 49-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12703668&dopt=Abstract
•
A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Author(s): Hassan TB, Jagger C, Barnett DB. Source: Emergency Medicine Journal : Emj. 2002 January; 19(1): 57-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11777881&dopt=Abstract
•
A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. Author(s): Bessmertny O, DiGregorio RV, Cohen H, Becker E, Looney D, Golden J, Kohl L, Johnson T. Source: Annals of Emergency Medicine. 2002 June; 39(6): 585-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12023699&dopt=Abstract
68
Magnesium
•
A survey of peri-operative use of magnesium sulphate in adult cardiac surgery in the UK. Author(s): Roscoe A, Ahmed AB. Source: Anaesthesia. 2003 April; 58(4): 363-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12688270&dopt=Abstract
•
Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption. Author(s): Green JH, Booth C, Bunning R. Source: European Journal of Clinical Nutrition. 2003 January; 57(1): 61-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548298&dopt=Abstract
•
Adenosine triphosphate-magnesium chloride: relevance for intensive care. Author(s): Nalos M, Asfar P, Ichai C, Radermacher P, Leverve XM, Froba G. Source: Intensive Care Medicine. 2003 January; 29(1): 10-8. Epub 2002 November 02. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12528016&dopt=Abstract
•
Alteration of myocardial mechanics in marginal magnesium deficiency. Author(s): Nair RR, Nair P. Source: Magnes Res. 2002 December; 15(3-4): 287-306. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635885&dopt=Abstract
•
An effective use of magnesium sulfate for intraoperative management of laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient. Author(s): Minami T, Adachi T, Fukuda K. Source: Anesthesia and Analgesia. 2002 November; 95(5): 1243-4, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401602&dopt=Abstract
•
Analysis method for lipoproteins by high-performance liquid chromatography with sulfopropyl-ligand column and magnesium ion-containing eluents. Author(s): Hirowatari Y, Kurosawa H, Yoshida H, Doumitu KI, Tada N. Source: Analytical Biochemistry. 2002 September 15; 308(2): 336-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12419348&dopt=Abstract
•
Analysis of antioxidant enzyme activity and magnesium level in chronic obstructive pulmonary disease (COPD). Author(s): Kurys E, Kurys P, Kuzniar A, Kieszko R. Source: Ann Univ Mariae Curie Sklodowska [med]. 2001; 56: 261-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11977322&dopt=Abstract
Studies
69
•
Anesthesia for one-stage bilateral pheochromocytoma resection in a patient with MEN type IIa: attenuation of hypertensive crisis by magnesium sulfate. Author(s): Niruthisard S, Chatrkaw P, Laornual S, Sunthornyothin S, Prasertsri S. Source: J Med Assoc Thai. 2002 January; 85(1): 125-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12075713&dopt=Abstract
•
Anion transport in normal erythrocytes, sickle red cells, and ghosts in relation to hemoglobins and magnesium. Author(s): Teti D, Venza I, Crupi M, Busa M, Loddo S, Romano L. Source: Archives of Biochemistry and Biophysics. 2002 July 15; 403(2): 149-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12139963&dopt=Abstract
•
Annual changes of the incidence and clinical characteristics of magnesium ammonium phosphate urinary stones. Author(s): Ogata T, Akakura K, Mizoguchi K, Mikami K, Nozumi K, Ito H. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 2003 January; 10(1): 1-5; Discussion 6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12534916&dopt=Abstract
•
Antiarrhythmic effect of magnesium sulfate after open heart surgery: effect of blood levels. Author(s): Kiziltepe U, Eyileten ZB, Sirlak M, Tasoz R, Aral A, Eren NT, Uysalel A, Akalin H. Source: International Journal of Cardiology. 2003 June; 89(2-3): 153-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12767537&dopt=Abstract
•
Ask the doctor. I've been diagnosed with atrial fibrillation. My daughter gave me a clipping from a natural health magazine that says the most common reason for this heart rhythm problem is magnesium deficiency. Is there any truth to this? Author(s): Lee TH. Source: Harvard Heart Letter : from Harvard Medical School. 2002 April; 12(8): 8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11959519&dopt=Abstract
•
Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Author(s): Mittendorf R, Dambrosia J, Dammann O, Pryde PG, Lee KS, Ben-Ami TE, Yousefzadeh D. Source: The Journal of Pediatrics. 2002 May; 140(5): 540-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12032519&dopt=Abstract
70
Magnesium
•
Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Author(s): Usta IM, Nassar AH. Source: American Journal of Obstetrics and Gynecology. 2003 August; 189(2): 614-5; Author Reply 615-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14524364&dopt=Abstract
•
Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Author(s): Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, Tomich PG. Source: American Journal of Obstetrics and Gynecology. 2002 June; 186(6): 1111-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12066082&dopt=Abstract
•
Association between use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Author(s): Mittendorf R, Pryde PG, Lee KS. Source: American Journal of Obstetrics and Gynecology. 2003 August; 189(2): 613. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14524362&dopt=Abstract
•
Association between use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Author(s): Rouse DJ, Hirtz DG, Thom E. Source: American Journal of Obstetrics and Gynecology. 2003 January; 188(1): 295. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548234&dopt=Abstract
•
Association between use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Author(s): McElrath TF. Source: American Journal of Obstetrics and Gynecology. 2003 January; 188(1): 294; Author Reply 294-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548232&dopt=Abstract
•
Audit can ensure the safe and effective introduction of seizure prophylaxis with magnesium sulphate in obstetric practice. Author(s): Owen P. Source: Health Bull (Edinb). 2000 September; 58(5): 414-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12813796&dopt=Abstract
Studies
71
•
Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. Author(s): Higgins JP, Spiegelhalter DJ. Source: International Journal of Epidemiology. 2002 February; 31(1): 96-104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11914302&dopt=Abstract
•
Bi-functional, substrate mimicking RNA inhibits MSK1-mediated cAMP-response element-binding protein phosphorylation and reveals magnesium ion-dependent conformational changes of the kinase. Author(s): Hamm J, Alessi DR, Biondi RM. Source: The Journal of Biological Chemistry. 2002 November 29; 277(48): 45793-802. Epub 2002 September 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12235136&dopt=Abstract
•
Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Author(s): Ranade VV, Somberg JC. Source: American Journal of Therapeutics. 2001 September-October; 8(5): 345-57. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11550076&dopt=Abstract
•
Bioavailability of US commercial magnesium preparations. Author(s): Firoz M, Graber M. Source: Magnes Res. 2001 December; 14(4): 257-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11794633&dopt=Abstract
•
Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of magnesium depletion. Author(s): Durlach J, Pages N, Bac P, Bara M, Guiet-Bara A. Source: Magnes Res. 2002 March; 15(1-2): 49-66. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030424&dopt=Abstract
•
Brain copper, iron, magnesium, zinc, calcium, sulfur and phosphorus storage in Wilson's disease. Author(s): Faa G, Lisci M, Caria MP, Ambu R, Sciot R, Nurchi VM, Silvagni R, Diaz A, Crisponi G. Source: Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (Gms). 2001; 15(2-3): 155-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11787982&dopt=Abstract
72
Magnesium
•
Breast engorgement and galactorrhea during magnesium sulfate treatment of preterm labor. Author(s): Lurie S, Rotmensch S, Feldman N, Glezerman M. Source: American Journal of Perinatology. 2002 July; 19(5): 239-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12152141&dopt=Abstract
•
Calcitonin gene- and parathyroid hormone-related peptides in preeclampsia: effects of magnesium sulfate. Author(s): Halhali A, Wimalawansa SJ, Berentsen V, Avila E, Thota CS, Larrea F. Source: Obstetrics and Gynecology. 2001 June; 97(6): 893-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11384692&dopt=Abstract
•
Calcium, magnesium, phosphorus and vitamin D fortification of complementary foods. Author(s): Abrams SA, Atkinson SA. Source: The Journal of Nutrition. 2003 September; 133(9): 2994S-9S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12949399&dopt=Abstract
•
Calcium, phosphorus and magnesium balance: FM 85 fortification of human milk does not meet mineral needs of extremely low birthweight infants. Author(s): Loui A, Raab A, Obladen M, Bratter P. Source: European Journal of Clinical Nutrition. 2002 March; 56(3): 228-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11960298&dopt=Abstract
•
Calcium-phosphorus-magnesium homeostasis in pregnant women after renal transplantation. Author(s): Czajkowski K, Wojcicka-Bentyn J, Grymowicz M, Smolarczyk R, Malinowska-Polubiec A, Romejko E. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2003 February; 80(2): 111-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12566182&dopt=Abstract
•
Cell-associated magnesium and QT dispersion in hemodialysis patients. Author(s): Averbukh Z, Rosenberg R, Galperin E, Berman S, Cohn M, Cohen N, Modai D, Efrati S, Weissgarten J. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2003 January; 41(1): 196-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12500237&dopt=Abstract
Studies
73
•
Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. Author(s): Brewer RP, Parra A, Lynch J, Chilukuri V, Borel CO. Source: Journal of Neurosurgical Anesthesiology. 2001 July; 13(3): 202-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426093&dopt=Abstract
•
Characteristics of improved NOVA magnesium ion-selective electrode: changes of ionized magnesium values and reference interval in healthy children. Author(s): Hoshino K, Ogawa K, Hishitani T, Kitazawa R. Source: Magnes Res. 2001 September; 14(3): 203-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11599553&dopt=Abstract
•
Chronopathological forms of magnesium depletion with hypofunction or with hyperfunction of the biological clock. Author(s): Durlach J, Pages N, Bac P, Bara M, Guiet-Bara A, Agrapart C. Source: Magnes Res. 2002 December; 15(3-4): 263-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635882&dopt=Abstract
•
Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Author(s): Goren MP. Source: Medical and Pediatric Oncology. 2003 September; 41(3): 186-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12868117&dopt=Abstract
•
Combination of sotalol and magnesium prevents atrial fibrillation after coronary artery bypass grafting. Author(s): Forlani S, De Paulis R, de Notaris S, Nardi P, Tomai F, Proietti I, Ghini AS, Chiariello L. Source: The Annals of Thoracic Surgery. 2002 September; 74(3): 720-5; Discussion 725-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12238830&dopt=Abstract
•
Combined vitamin B6-magnesium treatment in autism spectrum disorder. Author(s): Nye C, Brice A. Source: Cochrane Database Syst Rev. 2002; (4): Cd003497. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519599&dopt=Abstract
•
Commentary: biostatistics, biological mechanisms and Bayes: lessons from the magnesium trials. Author(s): Woods KL. Source: International Journal of Epidemiology. 2002 February; 31(1): 105-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11914303&dopt=Abstract
74
Magnesium
•
Comparing nutrient intake from food to the estimated average requirements shows middle- to upper-income pregnant women lack iron and possibly magnesium. Author(s): Turner RE, Langkamp-Henken B, Littell RC, Lukowski MJ, Suarez MF. Source: Journal of the American Dietetic Association. 2003 April; 103(4): 461-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12669009&dopt=Abstract
•
Comparison of magnesium and zinc levels in blood in end stage renal disease patients treated by hemodialysis or peritoneal dialysis. Author(s): Pietrzak I, Bladek K, Bulikowski W. Source: Magnes Res. 2002 December; 15(3-4): 229-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635877&dopt=Abstract
•
Comparison of stable-isotope-tracer methods for the determination of magnesium absorption in humans. Author(s): Sabatier M, Keyes WR, Pont F, Arnaud MJ, Turnlund JR. Source: The American Journal of Clinical Nutrition. 2003 May; 77(5): 1206-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12716673&dopt=Abstract
•
Comparison of sufentanil with sufentanil plus magnesium sulphate for sedation in the intensive care unit using bispectral index. Author(s): Memis D, Turan A, Karamanlioglu B, Oguzhan N, Pamukcu Z. Source: Critical Care (London, England). 2003 October; 7(5): R123-8. Epub 2003 August 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12974980&dopt=Abstract
•
Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants. Author(s): Rantone TH, Gronlund JU, Jalonen JO, Ekblad UU, Kaapa PO, Kero PO, Valimaki IA. Source: Clinical Physiology and Functional Imaging. 2002 January; 22(1): 13-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12003092&dopt=Abstract
•
Comparison of the potentiometric, (31)P NMR, and zero-point titration methods of determining ionized magnesium in erythrocytes. Author(s): Malon A, Wagner B, Bulska E, Maj-Zurawska M. Source: Analytical Biochemistry. 2002 March 15; 302(2): 220-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11878800&dopt=Abstract
•
Concentrations of copper, zinc, manganese, rubidium, and magnesium in thoracic empyemata and corresponding sera. Author(s): Domej W, Krachler M, Goessler W, Maier A, Irgolic KJ, Lang JK. Source: Biological Trace Element Research. 2000 Winter; 78(1-3): 53-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11314988&dopt=Abstract
Studies
75
•
Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. Author(s): Oladapo OO, Falase AO. Source: Afr J Med Med Sci. 2000 September-December; 29(3-4): 265-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11714003&dopt=Abstract
•
Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations. Author(s): Morimatsu H, Uchino S, Bellomo R, Ronco C. Source: Int J Artif Organs. 2002 June; 25(6): 512-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12117290&dopt=Abstract
•
Contraindication of magnesium sulfate in a pregnancy complicated with late-onset diabetes mellitus and sensory deafness due to mitochondrial myopathy. Author(s): Hosono T, Suzuki M, Chiba Y. Source: The Journal of Maternal-Fetal Medicine. 2001 October; 10(5): 355-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11730501&dopt=Abstract
•
Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Author(s): Boska MD, Welch KM, Barker PB, Nelson JA, Schultz L. Source: Neurology. 2002 April 23; 58(8): 1227-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11971091&dopt=Abstract
•
Contribution of mineral waters to dietary calcium and magnesium intake in a French adult population. Author(s): Galan P, Arnaud MJ, Czernichow S, Delabroise AM, Preziosi P, Bertrais S, Franchisseur C, Maurel M, Favier A, Hercberg S. Source: Journal of the American Dietetic Association. 2002 November; 102(11): 1658-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12449291&dopt=Abstract
•
Copper, zinc and magnesium levels in type-1 diabetes mellitus. Author(s): Zargar AH, Bashir MI, Masoodi SR, Laway BA, Wani AI, Khan AR, Dar FA. Source: Saudi Med J. 2002 May; 23(5): 539-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12070576&dopt=Abstract
•
Correction of ionized plasma magnesium during cardiopulmonary bypass reduces the risk of postoperative cardiac arrhythmia. Author(s): Wilkes NJ, Mallett SV, Peachey T, Di Salvo C, Walesby R. Source: Anesthesia and Analgesia. 2002 October; 95(4): 828-34, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12351253&dopt=Abstract
76
Magnesium
•
Correlation between Na, K-ATPase activity and potassium and magnesium contents in skeletal muscle of renal stone patients. Author(s): Prasongwatana V, Tavichakorntrakool R, Sriboonlue P, Wongkham C, Bovornpadungkitti S, Premgamone A, Reungjuiy S. Source: Southeast Asian J Trop Med Public Health. 2001 September; 32(3): 648-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11944732&dopt=Abstract
•
Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients. Author(s): Thakur V, Kumar R, Dhawan IK. Source: Annals of Clinical Biochemistry. 2002 January; 39(Pt 1): 70-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11853195&dopt=Abstract
•
Cyclosporine A neurotoxicity in a patient with idiopathic renal magnesium wasting. Author(s): West LJ. Source: Pediatric Neurology. 2002 April; 26(4): 329. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11992767&dopt=Abstract
•
Decreased serum magnesium and zinc levels: atherogenic implications in type-2 diabetes mellitus in Nigerians. Author(s): Anetor JI, Senjobi A, Ajose OA, Agbedana EO. Source: Nutr Health. 2002; 16(4): 291-300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12617280&dopt=Abstract
•
Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Author(s): Lodi R, Iotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V, Soriani S, Montagna P, Barbiroli B. Source: Brain Research Bulletin. 2001 March 1; 54(4): 437-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11306197&dopt=Abstract
•
Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Author(s): Mori Y, Nagamine K, Tomita N, Notomi T. Source: Biochemical and Biophysical Research Communications. 2001 November 23; 289(1): 150-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11708792&dopt=Abstract
•
Determination of trace elements (Cu, Zn, Mn, Pb) and magnesium by atomical absorption in patients receiving total parenteral nutrition. Author(s): Papageorgiou T, Zacharoulis D, Xenos D, Androulakis G. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 January; 18(1): 32-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11827761&dopt=Abstract
Studies
77
•
Determination of trace elements and magnesium by atomical absorption in patients receiving total parenteral nutrition. Author(s): Buchman AL. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2002 January; 18(1): 93-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11827776&dopt=Abstract
•
Dialysate/infusate calcium and magnesium. Author(s): Vitale C, Marangella M, Ramello A. Source: Contrib Nephrol. 2002; (137): 350-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12101977&dopt=Abstract
•
Dietary intake of calcium, magnesium and phosphorus in an elderly population using duplicate diet sampling vs food composition tables. Author(s): Moreno-Torres R, Ruiz-Lopez MD, Artacho R, Oliva P, Baena F, Baro L, Lopez C. Source: J Nutr Health Aging. 2001; 5(4): 253-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11753488&dopt=Abstract
•
Dietary magnesium depletion affects metabolic responses during submaximal exercise in postmenopausal women. Author(s): Lukaski HC, Nielsen FH. Source: The Journal of Nutrition. 2002 May; 132(5): 930-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11983816&dopt=Abstract
•
Dietary magnesium intake in a national sample of US adults. Author(s): Ford ES, Mokdad AH. Source: The Journal of Nutrition. 2003 September; 133(9): 2879-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12949381&dopt=Abstract
•
Dietary magnesium intake in type 2 diabetes. Author(s): Walti MK, Zimmermann MB, Spinas GA, Jacob S, Hurrell RF. Source: European Journal of Clinical Nutrition. 2002 May; 56(5): 409-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12001011&dopt=Abstract
•
Dietary magnesium, potassium, sodium, and children's lung function. Author(s): Gilliland FD, Berhane KT, Li YF, Kim DH, Margolis HG. Source: American Journal of Epidemiology. 2002 January 15; 155(2): 125-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11790675&dopt=Abstract
78
Magnesium
•
Differential effects of magnesium on the hydrolysis of ADP and ATP in human term placenta. Effect of substrates and potassium. Author(s): Martinez F, Uribe A, Milan R, Teresa Espinosa-Garcia M, Gracia-Perez C, Flores-Herrera O. Source: The International Journal of Biochemistry & Cell Biology. 2002 August; 34(8): 1004-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12007638&dopt=Abstract
•
Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Author(s): Magpie Trial Collaboration Group. Source: Lancet. 2002 June 1; 359(9321): 1877-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12057549&dopt=Abstract
•
Does ketamine or magnesium affect posttonsillectomy pain in children? Author(s): O'Flaherty JE, Lin CX. Source: Paediatric Anaesthesia. 2003 June; 13(5): 413-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12791115&dopt=Abstract
•
Does magnesium dysbalance participate in the development of insulin resistance in early stages of renal disease? Author(s): Sebekova K, Stefikova K, Polakovicova D, Spustova V, Dzurik R. Source: Physiological Research / Academia Scientiarum Bohemoslovaca. 2002; 51(6): 605-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12511185&dopt=Abstract
•
Does magnesium sulphate have a role in the management of paediatric status asthmaticus? Author(s): Markovitz B. Source: Archives of Disease in Childhood. 2002 May; 86(5): 381-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11970943&dopt=Abstract
•
Does magnesium therapy early in acute MI reduce mortality? Author(s): Phillips J, Krist A. Source: The Journal of Family Practice. 2003 March; 52(3): 195, 199. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12620172&dopt=Abstract
•
Dominant isolated renal magnesium loss is caused by misrouting of the Na+,K+ATPase gamma-subunit. Author(s): Meij IC, Koenderink JB, De Jong JC, De Pont JJ, Monnens LA, Van Den Heuvel LP, Knoers NV. Source: Annals of the New York Academy of Sciences. 2003 April; 986: 437-43. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12763862&dopt=Abstract
Studies
79
•
Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Author(s): Magnesium in Coronaries (MAGIC) Trial Investigators. Source: Lancet. 2002 October 19; 360(9341): 1189-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401244&dopt=Abstract
•
EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Author(s): Waters RS, Bryden NA, Patterson KY, Veillon C, Anderson RA. Source: Biological Trace Element Research. 2001 December; 83(3): 207-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11794513&dopt=Abstract
•
Effect of albumin on neonatal serum ionized magnesium in vitro. Author(s): Dollberg S, Kupietz M, Mimouni FB. Source: Magnes Res. 2002 December; 15(3-4): 237-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635878&dopt=Abstract
•
Effect of gestational age on cord blood plasma copper, zinc, magnesium and albumin. Author(s): Perveen S, Altaf W, Vohra N, Bautista ML, Harper RG, Wapnir RA. Source: Early Human Development. 2002 October; 69(1-2): 15-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12324179&dopt=Abstract
•
Effect of gutta-percha solvents at different temperatures on the calcium, phosphorus and magnesium levels of human root dentin. Author(s): Dogan H, Tasman F, Cehreli ZC. Source: Journal of Oral Rehabilitation. 2001 August; 28(8): 792-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11556962&dopt=Abstract
•
Effect of intra-operative magnesium sulphate on pain relief and patient comfort after major lumbar orthopaedic surgery. Author(s): Levaux Ch, Bonhomme V, Dewandre PY, Brichant JF, Hans P. Source: Anaesthesia. 2003 February; 58(2): 131-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562408&dopt=Abstract
•
Effect of intravenous magnesium on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers. Author(s): Mikkelsen S, Dirks J, Fabricius P, Petersen KL, Rowbotham MC, Dahl JB. Source: British Journal of Anaesthesia. 2001 June; 86(6): 871-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11573598&dopt=Abstract
80
Magnesium
•
Effect of low magnesium concentration and cholestane-3beta, 5alpha, 6beta-triol on levels of LDL receptor in cultured fibroblasts. Author(s): Zhou Q, Yuan C, Wei T, Kummerow FA. Source: Magnes Res. 2002 March; 15(1-2): 3-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030421&dopt=Abstract
•
Effect of magnesium lithospermate B on calcium and nitric oxide in endothelial cells upon hypoxia/reoxygenation. Author(s): Luo WB, Dong L, Wang YP. Source: Acta Pharmacologica Sinica. 2002 October; 23(10): 930-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12370098&dopt=Abstract
•
Effect of magnesium sulfate, isradipine, and ritodrine on contractions of myometrium: pregnant human and rat. Author(s): Kantas E, Cetin A, Kaya T, Cetin M. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 September; 81(9): 825-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12225296&dopt=Abstract
•
Effect of oral and injectable contraceptives on serum calcium, magnesium and phosphorus in women. Author(s): Hameed A, Majeed T, Rauf S, Ashraf M, Jalil MA, Nasrullah M, Hussan A, Noreen R. Source: J Ayub Med Coll Abbottabad. 2001 July-September; 13(3): 24-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11873394&dopt=Abstract
•
Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2 diabetes mellitus. Author(s): Lal J, Vasudev K, Kela AK, Jain SK. Source: J Assoc Physicians India. 2003 January; 51: 37-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12693452&dopt=Abstract
•
Effect of propofol with and without EDTA on haemodynamics and calcium and magnesium homeostasis during and after cardiac surgery. Author(s): Wahr J, Vender J, Gilbert HC, Spiess B, Horrow JC, Maddi R. Source: Intensive Care Medicine. 2000; 26 Suppl 4: S443-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11310907&dopt=Abstract
•
Effects of alpha- and beta-adrenergic stimulation on free magnesium concentrations in platelets from healthy and obese individuals. Author(s): Malara A, Corsonello A, Buemi M, De Domenico D, Ientile R, Corica F. Source: Magnes Res. 2001 December; 14(4): 263-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11794634&dopt=Abstract
Studies
81
•
Effects of calcium carbonate, magnesium oxide and sodium citrate bicarbonate health supplements on the urinary risk factors for kidney stone formation. Author(s): Allie S, Rodgers A. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 January; 41(1): 39-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12636048&dopt=Abstract
•
Effects of dietary fibers on magnesium absorption in animals and humans. Author(s): Coudray C, Demigne C, Rayssiguier Y. Source: The Journal of Nutrition. 2003 January; 133(1): 1-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12514257&dopt=Abstract
•
Effects of interleukin 2 therapy on lymphocyte magnesium levels. Author(s): McKee MD, Cecco SA, Niemela JE, Cormier J, Kim CJ, Steinberg SM, Rehak NN, Elin RJ, Rosenberg SA. Source: The Journal of Laboratory and Clinical Medicine. 2002 January; 139(1): 5-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11873239&dopt=Abstract
•
Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Author(s): Caron MF, Kluger J, Tsikouris JP, Ritvo A, Kalus JS, White CM. Source: Pharmacotherapy. 2003 March; 23(3): 296-300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12627926&dopt=Abstract
•
Effects of magnesium sulphate on amplitude-integrated continuous EEG in asphyxiated term neonates. Author(s): Groenendaal F, Rademaker CM, Toet MC, de Vries LS. Source: Acta Paediatrica (Oslo, Norway : 1992). 2002; 91(10): 1073-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12434893&dopt=Abstract
•
Effects of magnesium sulphate on cerebral haemodynamics in healthy volunteers: a transcranial Doppler study. Author(s): Sherman R, Armory P, Moody P, Hope T, Mahajan RP. Source: British Journal of Anaesthesia. 2003 August; 91(2): 273-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878627&dopt=Abstract
•
Effects of metamizol and magnesium sulfate on enzyme activity of glucose 6phosphate dehydrogenase from human erythrocyte in vitro and rat erythrocyte in vivo. Author(s): Ciftci M, Ozmen I, Buyukokuroglu ME, Pence S, Kufrevioglu OI. Source: Clinical Biochemistry. 2001 June; 34(4): 297-302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11440730&dopt=Abstract
82
Magnesium
•
Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Author(s): Shechter M, Bairey Merz CN, Stuehlinger HG, Slany J, Pachinger O, Rabinowitz B. Source: The American Journal of Cardiology. 2003 March 1; 91(5): 517-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12615252&dopt=Abstract
•
Efficacy of intravenous magnesium in neuropathic pain. Author(s): Jaitly V. Source: British Journal of Anaesthesia. 2003 August; 91(2): 302; Author Reply 302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878643&dopt=Abstract
•
Efficacy of intravenous magnesium in neuropathic pain. Author(s): Brill S, Sedgwick PM, Hamann W, Di Vadi PP. Source: British Journal of Anaesthesia. 2002 November; 89(5): 711-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12393768&dopt=Abstract
•
Efficacy of long duration resuscitation and magnesium sulphate treatment in amitriptyline poisoning. Author(s): Citak A, Soysal DD, Ucsel R, Karabocuoglu M, Uzel N. Source: European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine. 2002 March; 9(1): 63-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11989501&dopt=Abstract
•
Esomeprazole magnesium (Nexium). Author(s): Baker DE. Source: Reviews in Gastroenterological Disorders. 2001; 1(1): 32-41. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12120118&dopt=Abstract
•
Evaluation of AVL988/4 analyzer for measurement of ionized magnesium and ionized calcium. Author(s): Cao Z, Tongate C, Elin RJ. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2001; 61(5): 38994. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11569486&dopt=Abstract
•
Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. Author(s): Telci L, Esen F, Akcora D, Erden T, Canbolat AT, Akpir K. Source: British Journal of Anaesthesia. 2002 October; 89(4): 594-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12393361&dopt=Abstract
Studies
83
•
Evolving concepts in epithelial magnesium transport. Author(s): Yu AS. Source: Current Opinion in Nephrology and Hypertension. 2001 September; 10(5): 64953. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11496060&dopt=Abstract
•
Exchangeable magnesium pool masses in healthy women: effects of magnesium supplementation. Author(s): Feillet-Coudray C, Coudray C, Tressol JC, Pepin D, Mazur A, Abrams SA, Rayssiguier Y. Source: The American Journal of Clinical Nutrition. 2002 January; 75(1): 72-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11756062&dopt=Abstract
•
Fetoplacental vascular tone is modified by magnesium sulfate in the preeclamptic ex vivo human placental cotyledon. Author(s): Kovac CM, Howard BC, Pierce BT, Hoeldtke NJ, Calhoun BC, Napolitano PG. Source: American Journal of Obstetrics and Gynecology. 2003 September; 189(3): 839-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14526326&dopt=Abstract
•
Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. Author(s): Elmore AR; Cosmetic Ingredient Review Expert Panel. Source: International Journal of Toxicology. 2003; 22 Suppl 1: 37-102. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12851164&dopt=Abstract
•
Five-week intake of short-chain fructo-oligosaccharides increases intestinal absorption and status of magnesium in postmenopausal women. Author(s): Tahiri M, Tressol JC, Arnaud J, Bornet F, Bouteloup-Demange C, FeilletCoudray C, Ducros V, Pepin D, Brouns F, Rayssiguier AM, Coudray C. Source: Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research. 2001 November; 16(11): 2152-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11697813&dopt=Abstract
•
Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients. Author(s): Noormohamed FH, Youle MS, Tang B, Martin-Munley S, Gazzard BG, Lant AF. Source: Antivir Ther. 1996 August; 1(3): 172-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11322251&dopt=Abstract
84
Magnesium
•
Genetic forms of renal potassium and magnesium wasting. Author(s): Warnock DG. Source: The American Journal of Medicine. 2002 February 15; 112(3): 235-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11893352&dopt=Abstract
•
Genetic heterogeneity in familial renal magnesium wasting. Author(s): Kantorovich V, Adams JS, Gaines JE, Guo X, Pandian MR, Cohn DH, Rude RK. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 February; 87(2): 612-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11836293&dopt=Abstract
•
Glucose-induced alterations of intracellular ionized magnesium in human lymphocytes. Author(s): Delva P, Degan M, Pastori C, Faccini G, Lechi A. Source: Life Sciences. 2002 September 20; 71(18): 2119-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12204770&dopt=Abstract
•
Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Author(s): Ryves WJ, Dajani R, Pearl L, Harwood AJ. Source: Biochemical and Biophysical Research Communications. 2002 January 25; 290(3): 967-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11798168&dopt=Abstract
•
Hematology tests of blood anticoagulated with magnesium sulphate. Author(s): Kondo H, Kobayashi E, Itani T, Tatsumi N, Tsuda I. Source: Southeast Asian J Trop Med Public Health. 2002; 33 Suppl 2: 6-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12755260&dopt=Abstract
•
Hemodialysis for toxic hypermagnesemia caused by intravenous magnesium in a woman with eclampsia and renal insufficiency. A case report. Author(s): Hirose M, Kobayashi M, Sudo S, Nakanishi K, Noda Y. Source: J Reprod Med. 2002 December; 47(12): 1050-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12516329&dopt=Abstract
•
High magnesium concentration in vitro decreases human leukocyte activation. Author(s): Bussiere FI, Mazur A, Fauquert JL, Labbe A, Rayssiguier Y, Tridon A. Source: Magnes Res. 2002 March; 15(1-2): 43-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030423&dopt=Abstract
Studies
85
•
High prevelance of chronic magnesium deficiency in T cell lymphoblastic leukemia and chronic zinc deficiency in children with acute lymphoblastic leukemia and malignant lymphoma. Author(s): Sahin G, Ertem U, Duru F, Birgen D, Yuksek N. Source: Leukemia & Lymphoma. 2000 November; 39(5-6): 555-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11342338&dopt=Abstract
•
High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Author(s): Cohen JS. Source: The Annals of Pharmacotherapy. 2002 February; 36(2): 255-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847944&dopt=Abstract
•
Homogeneity and stability studies on sodium, calcium, magnesium, and manganese in human saliva. Author(s): Czegeny ZS, Chicharro JL, Fernandez P, Gutierrez A, Camara C. Source: Biological Trace Element Research. 2001 February; 79(2): 131-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11330519&dopt=Abstract
•
Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia. Author(s): Altura RA, Wang WC, Wynn L, Altura BM, Altura BT. Source: The Journal of Pediatrics. 2002 May; 140(5): 565-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12032523&dopt=Abstract
•
Hypomagnesaemia due to malabsorption is not always responsive to oral magnesium oxide supplementation alone. Author(s): Arasaradnam RP, Bolton RP. Source: Gut. 2002 June; 50(6): 897. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010899&dopt=Abstract
•
Hypothalamic digoxin, cerebral chemical dominance, and calcium/magnesium metabolism. Author(s): Kurup RK, Kurup PA. Source: The International Journal of Neuroscience. 2003 July; 113(7): 999-1004. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12881191&dopt=Abstract
•
Impact of supplementary high calcium milk with additional magnesium on parathyroid hormone and biochemical markers of bone turnover in postmenopausal women. Author(s): Green JH, Booth C, Bunning R. Source: Asia Pacific Journal of Clinical Nutrition. 2002; 11(4): 268-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12495258&dopt=Abstract
86
Magnesium
•
Increases of calcium and magnesium and decreases of phosphorus and iron with aging in human uterine tubes. Author(s): Yoshida S, Takano Y, Moriwake Y, Tohno Y, Masuda M, Tohno S, Minami T, Yamasaki M, Morikawa H, Yuri K. Source: Biological Trace Element Research. 2001 April; 80(1): 13-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11393306&dopt=Abstract
•
Infantile renal dysfunction associated with intrauterine exposure to ritodrine and magnesium sulfate. Author(s): Ohta N, Tsukahara H, Yamashita N, Kobata R, Hiraoka M, Shukunami K, Hosokawa K, Kotsuji F, Mayumi M. Source: Nephron. 2002 June; 91(2): 352-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12053081&dopt=Abstract
•
Influence of blood sampling techniques on ionized magnesium level. Author(s): Matthiesen G, Olofsson K, Rudnicki M. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2002; 62(8): 565-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12564614&dopt=Abstract
•
Influence of heart surgery on magnesium concentrations in pediatric patients. Author(s): Hoshino K, Ogawa K, Hishitani T, Kitazawa R. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2003 February; 45(1): 39-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12654067&dopt=Abstract
•
Influence of magnesium sulphate and isradipine on human placental cotyledon fetal vessels in vitro. Author(s): Skoczynski M, Semczuk M. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001 December 10; 100(1): 25-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11728652&dopt=Abstract
•
Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Author(s): Pezzati M, Giani T, Gambi B, Dani C, Bertini G, Biagiotti R, Rubaltelli FF. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2001 September; 80(9): 818-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11531632&dopt=Abstract
•
Insulin-mimetic action of vanadate: role of intracellular magnesium. Author(s): Barbagallo M, Dominguez LJ, Resnick LM. Source: Hypertension. 2001 September; 38(3 Pt 2): 701-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11566960&dopt=Abstract
Studies
87
•
Intracellular magnesium of platelets in children with diabetes and obesity. Author(s): Takaya J, Higashino H, Kotera F, Kobayashi Y. Source: Metabolism: Clinical and Experimental. 2003 April; 52(4): 468-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12701060&dopt=Abstract
•
Intraperitoneal route of magnesium sulphate supplementation in a patient with severe renal magnesium wasting. Author(s): Bastani B, Pandurangan G. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2001 October; 16(10): 2086-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11572903&dopt=Abstract
•
Intrathecal magnesium prolongs fentanyl analgesia. Author(s): Arakawa M. Source: Anesthesia and Analgesia. 2003 May; 96(5): 1533; Author Reply 1533. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12707174&dopt=Abstract
•
Intrathecal magnesium prolongs fentanyl analgesia: a prospective, randomized, controlled trial. Author(s): Buvanendran A, McCarthy RJ, Kroin JS, Leong W, Perry P, Tuman KJ. Source: Anesthesia and Analgesia. 2002 September; 95(3): 661-6, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12198056&dopt=Abstract
•
Intravenous magnesium does not influence the activity of the coagulation cascade. Author(s): Ravn HB, Lassen JF, Bergenhem N, Kristensen AT. Source: Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis. 2001 June; 12(4): 223-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11460004&dopt=Abstract
•
Intravenous magnesium is ineffective in adult asthma, a randomized trial. Author(s): Porter RS, Nester, Braitman LE, Geary U, Dalsey WC. Source: European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine. 2001 March; 8(1): 9-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11314826&dopt=Abstract
•
Intravenous magnesium sulfate administration reduces propofol infusion requirements during maintenance of propofol-N2O anesthesia: part I: comparing propofol requirements according to hemodynamic responses: part II: comparing bispectral index in control and magnesium groups. Author(s): Choi JC, Yoon KB, Um DJ, Kim C, Kim JS, Lee SG. Source: Anesthesiology. 2002 November; 97(5): 1137-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12411798&dopt=Abstract
88
Magnesium
•
Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension. Author(s): Brewer RP, Parra A, Borel CO, Hopkins MB, Reynolds JD. Source: Clinical Neuropharmacology. 2001 November-December; 24(6): 341-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11801809&dopt=Abstract
•
Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study. Author(s): Schenk P, Vonbank K, Schnack B, Haber P, Lehr S, Smetana R. Source: Clinical Pharmacology and Therapeutics. 2001 May; 69(5): 365-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11372005&dopt=Abstract
•
Intravenous magnesium sulfate prophylaxis for atrial fibrillation after coronary artery bypass surgery. Author(s): Kaplan M, Kut MS, Icer UA, Demirtas MM. Source: The Journal of Thoracic and Cardiovascular Surgery. 2003 February; 125(2): 34452. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12579104&dopt=Abstract
•
Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Author(s): Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Source: International Journal of Cardiology. 2001 July; 79(2-3): 287-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11461753&dopt=Abstract
•
Intravenous magnesium sulphate effect on maternal serum and amniotic fluid cytokines levels in preterm labour patients. Author(s): Mezad D, Hallak M, Huleihel M, Gortzak-Uzan L, Smolin A, Mazor M. Source: Magnes Res. 2002 December; 15(3-4): 247-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635880&dopt=Abstract
•
Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Author(s): Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Source: Cephalalgia : an International Journal of Headache. 2002 June; 22(5): 345-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12110110&dopt=Abstract
•
Ion chromatographic determination of calcium and magnesium cations in human saliva and urine with a piezoelectric detector. Author(s): Yu BS, Yuan QG, Nie LH, Yao SZ. Source: Journal of Pharmaceutical and Biomedical Analysis. 2001 July; 25(5-6): 1027-32. Erratum In: J Pharm Biomed Anal 2002 July 31; 29(5): 969. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11377089&dopt=Abstract
Studies
89
•
Ionised and total serum magnesium in renal transplant patients. Author(s): Mazzaferro S, Barberi S, Scarda A, Pasquali M, Rubino F, D'Erasmo E. Source: Journal of Nephrology. 2002 May-June; 15(3): 275-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12113599&dopt=Abstract
•
IV magnesium in the treatment of acute severe asthma? Author(s): Rodrigo GJ, Rodrigo C. Source: Chest. 2003 April; 123(4): 1314-5; Author Reply 1315-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684332&dopt=Abstract
•
IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Author(s): Silverman RA, Osborn H, Runge J, Gallagher EJ, Chiang W, Feldman J, Gaeta T, Freeman K, Levin B, Mancherje N, Scharf S; Acute Asthma/Magnesium Study Group. Source: Chest. 2002 August; 122(2): 489-97. Erratum In: Chest 2002 November; 122(5): 1870. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12171821&dopt=Abstract
•
Large-dose intravenous methotrexate-induced cutaneous toxicity: can oral magnesium oxide reduce pain? Author(s): Suresh S, Lozono S, Hall SC. Source: Anesthesia and Analgesia. 2003 May; 96(5): 1413-4, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12707144&dopt=Abstract
•
Lead, copper, zinc, and magnesium content in hair of children and young people with some neurological diseases. Author(s): Lech T. Source: Biological Trace Element Research. 2002 February; 85(2): 111-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11899019&dopt=Abstract
•
Loading dose versus standard regime of magnesium sulfate in the management of eclampsia: a randomized trial. Author(s): Begum MR, Begum A, Quadir E. Source: The Journal of Obstetrics and Gynaecology Research. 2002 June; 28(3): 154-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12214831&dopt=Abstract
•
Long-term calcineurin inhibition and magnesium balance after renal transplantation. Author(s): Mazzola BL, Vannini SD, Truttmann AC, von Vigier RO, Wermuth B, Ferrari P, Bianchetti MG. Source: Transplant International : Official Journal of the European Society for Organ Transplantation. 2003 February; 16(2): 76-81. Epub 2003 January 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12595968&dopt=Abstract
90
Magnesium
•
Long-term outcome of intravenous magnesium therapy in thrombolysis-ineligible acute myocardial infarction patients. Author(s): Shechter M, Hod H, Rabinowitz B, Boyko V, Chouraqui P. Source: Cardiology. 2003; 99(4): 205-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12845247&dopt=Abstract
•
Low dietary magnesium increases supraventricular ectopy. Author(s): Klevay LM, Milne DB. Source: The American Journal of Clinical Nutrition. 2002 March; 75(3): 550-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11864862&dopt=Abstract
•
Low plasma magnesium in type 2 diabetes. Author(s): Walti MK, Zimmermann MB, Spinas GA, Hurrell RF. Source: Swiss Medical Weekly : Official Journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology. 2003 May 17; 133(19-20): 289-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12844272&dopt=Abstract
•
Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery. Author(s): Booth JV, Phillips-Bute B, McCants CB, Podgoreanu MV, Smith PK, Mathew JP, Newman MF. Source: American Heart Journal. 2003 June; 145(6): 1108-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12796771&dopt=Abstract
•
Low serum magnesium levels and foot ulcers in subjects with type 2 diabetes. Author(s): Rodriguez-Moran M, Guerrero-Romero F. Source: Archives of Medical Research. 2001 July-August; 32(4): 300-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11440788&dopt=Abstract
•
Low serum magnesium levels and metabolic syndrome. Author(s): Guerrero-Romero F, Rodriguez-Moran M. Source: Acta Diabetologica. 2002 December; 39(4): 209-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12486495&dopt=Abstract
•
Low-volume oral colonoscopy bowel preparation: sodium phosphate and magnesium citrate. Author(s): Berkelhammer C, Ekambaram A, Silva RG, Silva RG. Source: Gastrointestinal Endoscopy. 2002 July; 56(1): 89-94. Erratum In: Gastrointest Endosc 2002 October; 56(4): 612. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12085041&dopt=Abstract
Studies
91
•
Magnesium absorption from mineral water. Author(s): Sabatier M, Arnaud MJ, Turnlund JR. Source: European Journal of Clinical Nutrition. 2003 June; 57(6): 801-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12792665&dopt=Abstract
•
Magnesium and affective disorders. Author(s): Murck H. Source: Nutritional Neuroscience. 2002 December; 5(6): 375-89. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12509067&dopt=Abstract
•
Magnesium and calcium in drinking water and the risk of death from esophageal cancer. Author(s): Yang CY, Chiu HF, Tsai SS, Wu TN, Chang CC. Source: Magnes Res. 2002 December; 15(3-4): 215-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635875&dopt=Abstract
•
Magnesium deficiency in African-Americans: does it contribute to increased cardiovascular risk factors? Author(s): Fox CH, Mahoney MC, Ramsoomair D, Carter CA. Source: Journal of the National Medical Association. 2003 April; 95(4): 257-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12749615&dopt=Abstract
•
Magnesium deficit and sudden infant death syndrome (SIDS): SIDS due to magnesium deficiency and SIDS due to various forms of magnesium depletion: possible importance of the chronopathological form. Author(s): Durlach J, Pages N, Bac P, Bara M, Guiet-Bara A. Source: Magnes Res. 2002 December; 15(3-4): 269-78. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635883&dopt=Abstract
•
Magnesium in acute myocardial infarction? Author(s): Wiedermann CJ. Source: Wiener Klinische Wochenschrift. 2002 October 31; 114(19-20): 817-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12503471&dopt=Abstract
•
Magnesium in drinking water and liver cancer morbidity--a possible relation? Author(s): Tukiendorf A. Source: Cent Eur J Public Health. 2002 December; 10(4): 157-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12528390&dopt=Abstract
92
Magnesium
•
Magnesium in drinking water and the risk of death from liver cancer. Author(s): Yang CY, Chiu HF, Tsai SS, Chang CC, Chuang HY. Source: Magnes Res. 2002 December; 15(3-4): 223-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635876&dopt=Abstract
•
Magnesium in drinking water and the risk of delivering a child of very low birth weight. Author(s): Yang CY, Chiu HF, Tsai SS, Chang CC, Sung FC. Source: Magnes Res. 2002 December; 15(3-4): 207-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635874&dopt=Abstract
•
Magnesium in stroke treatment. Author(s): Muir KW. Source: Postgraduate Medical Journal. 2002 November; 78(925): 641-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12496316&dopt=Abstract
•
Magnesium infusion to treat Irukandji syndrome. Author(s): Corkeron MA. Source: The Medical Journal of Australia. 2003 April 21; 178(8): 411. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12697017&dopt=Abstract
•
Magnesium may help patients with recessive hereditary inclusion body myopathy, a pathological review. Author(s): Darvish D. Source: Medical Hypotheses. 2003 January; 60(1): 94-101. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12450772&dopt=Abstract
•
Magnesium potentiates neuromuscular blockade with cisatracurium during cardiac surgery. Author(s): Pinard AM, Donati F, Martineau R, Denault AY, Taillefer J, Carrier M. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2003 February; 50(2): 172-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12560310&dopt=Abstract
•
Magnesium status of patients with renal stones and its effect on urinary citrate excretion. Author(s): Reungjui S, Prasongwatana V, Premgamone A, Tosukhowong P, Jirakulsomchok S, Sriboonlue P. Source: Bju International. 2002 November; 90(7): 635-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12410738&dopt=Abstract
Studies
93
•
Magnesium sulfate administered via continuous intravenous infusion in pediatric patients with refractory wheezing. Author(s): Glover ML, Machado C, Totapally BR. Source: Journal of Critical Care. 2002 December; 17(4): 255-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501154&dopt=Abstract
•
Magnesium sulfate and neonatal outcomes of preterm neonates. Author(s): Elimian A, Verma R, Ogburn P, Wiencek V, Spitzer A, Quirk JG. Source: J Matern Fetal Neonatal Med. 2002 August;12(2):118-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12420842&dopt=Abstract
•
Magnesium sulfate for mild preeclampsia. Author(s): Scott JR. Source: Obstetrics and Gynecology. 2003 February; 101(2): 213. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576239&dopt=Abstract
•
Magnesium sulfate for preeclampsia. Author(s): Greene MF. Source: The New England Journal of Medicine. 2003 January 23; 348(4): 275-6. Erratum In: N Engl J Med. 2003 Jan 23; 348(4): 1730. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540639&dopt=Abstract
•
Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Author(s): Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Source: Obstetrics and Gynecology. 2003 February; 101(2): 217-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576241&dopt=Abstract
•
Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Author(s): Duley L, Gulmezoglu AM, Henderson-Smart DJ. Source: Cochrane Database Syst Rev. 2003; (2): Cd000025. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12804383&dopt=Abstract
•
Magnesium sulphate as a first line therapy in the management of tetanus. Author(s): Thwaites CL, Farrar JJ. Source: Anaesthesia. 2003 March; 58(3): 286. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12603464&dopt=Abstract
•
Magnesium sulphate for preventing preterm birth in threatened preterm labour. Author(s): Crowther CA, Hiller JE, Doyle LW. Source: Cochrane Database Syst Rev. 2002; (4): Cd001060. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519550&dopt=Abstract
94
Magnesium
•
Magnesium therapy after aneurysmal subarachnoid haemorrhage a dose-finding study for long term treatment. Author(s): van den Bergh WM, Albrecht KW, Berkelbach van der Sprenkel JW, Rinkel GJ. Source: Acta Neurochirurgica. 2003 March; 145(3): 195-9; Discussion 199. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12632115&dopt=Abstract
•
Magnesium. Author(s): Wallace C. Source: Emergency Medicine (Fremantle, W.A.). 2003 February; 15(1): 92-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12656794&dopt=Abstract
•
Magnesium: its proven and potential clinical significance. Author(s): Byrd RP Jr, Roy TM. Source: Southern Medical Journal. 2003 January; 96(1): 104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12602735&dopt=Abstract
•
Magnesium-aluminum hydroxide suspension for the treatment of dermal capsaicin exposures. Author(s): Lee DC, Ryan JR. Source: Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine. 2003 June; 10(6): 688-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12782534&dopt=Abstract
•
Magnesium-creatine supplementation effects on body water. Author(s): Brilla LR, Giroux MS, Taylor A, Knutzen KM. Source: Metabolism: Clinical and Experimental. 2003 September; 52(9): 1136-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14506619&dopt=Abstract
•
Measurement of magnesium absorption and retention in type 2 diabetic patients with the use of stable isotopes. Author(s): Walti MK, Zimmermann MB, Walczyk T, Spinas GA, Hurrell RF. Source: The American Journal of Clinical Nutrition. 2003 September; 78(3): 448-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12936928&dopt=Abstract
•
Mechanisms responsible for vasodilation upon magnesium infusion in vivo: clinical evidence. Author(s): Teragawa H, Matsuura H, Chayama K, Oshima T. Source: Magnes Res. 2002 December; 15(3-4): 241-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635879&dopt=Abstract
Studies
95
•
Modifications of magnesium and copper concentrations in serum and arterial wall of patients with vascular diseases related to ageing, atherosclerosis and aortic aneurysm. Author(s): Iskra M, Majewski W, Piorunska-Stolzmann M. Source: Magnes Res. 2002 December; 15(3-4): 279-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635884&dopt=Abstract
•
Nebulised magnesium in asthma: the right solution for an old remedy? Author(s): Bucca C, Rolla G. Source: Lancet. 2003 June 21; 361(9375): 2095-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12826427&dopt=Abstract
•
Nephrolithiasis in a neonate with transient renal wasting of calcium and magnesium. Author(s): Stoll ML, Listman JA. Source: Pediatric Nephrology (Berlin, Germany). 2002 May; 17(5): 386-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12042901&dopt=Abstract
•
Neuronal protection with magnesium. Author(s): Gathwala G. Source: Indian J Pediatr. 2001 May; 68(5): 417-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11407156&dopt=Abstract
•
New insights from cDNA array techniques in magnesium biology research. Author(s): Zimowska W, Mazur A, Rayssiguier Y. Source: Magnes Res. 2001 March; 14(1-2): 69-70. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11300624&dopt=Abstract
•
Nickel and cobalt activate complement factor C3 faster than magnesium. Author(s): Acevedo F, Vesterberg O. Source: Toxicology. 2003 March 14; 185(1-2): 9-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12505440&dopt=Abstract
•
Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Author(s): Patrick L. Source: Alternative Medicine Review : a Journal of Clinical Therapeutic. 2002 August; 7(4): 276-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12197781&dopt=Abstract
96
Magnesium
•
Nucleation of biomimetic Ca-P coatings on ti6A14V from a SBF x 5 solution: influence of magnesium. Author(s): Barrere F, van BC, de GK, Layrolle P. Source: Biomaterials. 2002 May; 23(10): 2211-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11962662&dopt=Abstract
•
Oral magnesium ion shortens prolonged QTc interval. Author(s): Bachman DM. Source: The Journal of Clinical Psychiatry. 2003 June; 64(6): 733-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823094&dopt=Abstract
•
Oral magnesium load test in patients with migraine. Author(s): Trauninger A, Pfund Z, Koszegi T, Czopf J. Source: Headache. 2002 February; 42(2): 114-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12005285&dopt=Abstract
•
Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Author(s): Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Source: Headache. 2003 June; 43(6): 601-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12786918&dopt=Abstract
•
Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Author(s): Rodriguez-Moran M, Guerrero-Romero F. Source: Diabetes Care. 2003 April; 26(4): 1147-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12663588&dopt=Abstract
•
Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. Author(s): Blanchard A, Jeunemaitre X, Coudol P, Dechaux M, Froissart M, May A, Demontis R, Fournier A, Paillard M, Houillier P. Source: Kidney International. 2001 June; 59(6): 2206-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11380823&dopt=Abstract
•
Patient education; foods high in magnesium. Author(s): Reams SM. Source: Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation. 2002 January; 12(1): 60-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11823996&dopt=Abstract
Studies
97
•
pH effects on measurements of ionized calcium and ionized magnesium in blood. Author(s): Wang S, McDonnell EH, Sedor FA, Toffaletti JG. Source: Archives of Pathology & Laboratory Medicine. 2002 August; 126(8): 947-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12171493&dopt=Abstract
•
Pharmacokinetic-pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women. Author(s): Lu J, Pfister M, Ferrari P, Chen G, Sheiner L. Source: Clinical Pharmacokinetics. 2002; 41(13): 1105-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403646&dopt=Abstract
•
Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia. Author(s): Taber EB, Tan L, Chao CR, Beall MH, Ross MG. Source: American Journal of Obstetrics and Gynecology. 2002 May; 186(5): 1017-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12015530&dopt=Abstract
•
Pharmacological spinal cord protection with magnesium during replacement of the thoracic and thoracoabdominal aorta. Author(s): Lang-Lazdunski L, Bachet J. Source: The Annals of Thoracic Surgery. 2001 December; 72(6): 2180-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11789833&dopt=Abstract
•
Phloroglucinol: novel synthesis and role of the magnesium cation on its binding with human serum albumin (HSA) using a biochromatographic approach based on Langmuir isotherms. Author(s): Ismaili L, Refouvelet B, Xicluna A, Robert JF, Guillaume YC. Source: Journal of Pharmaceutical and Biomedical Analysis. 2003 July 14; 32(3): 549-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14565560&dopt=Abstract
•
Physiologic assessment of magnesium status in humans: a combination of load retention and renal excretion. Author(s): Cohen L. Source: Isr Med Assoc J. 2000 December; 2(12): 938-9. Review. No Abstract Available. Erratum In: Isr Med Assoc J 2001 April; 3(4): 302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11344780&dopt=Abstract
•
Physiologic concentrations of magnesium and placental apoptosis: prevention by antioxidants. Author(s): Black S, Yu H, Lee J, Sachchithananthan M, Medcalf RL. Source: Obstetrics and Gynecology. 2001 August; 98(2): 319-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11506852&dopt=Abstract
98
Magnesium
•
Piperacillin-induced magnesium and potassium loss in intensive care unit patients. Author(s): Polderman KH, Girbes AR. Source: Intensive Care Medicine. 2002 April; 28(4): 520-2. Epub 2002 March 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11967611&dopt=Abstract
•
Population pharmacokinetics of magnesium in preeclampsia. Author(s): Chuan FS, Charles BG, Boyle RK, Rasiah RL. Source: American Journal of Obstetrics and Gynecology. 2001 September; 185(3): 593-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11568783&dopt=Abstract
•
Preventing and treating eclamptic seizures. Will magnesium sulphate for preeclampsia really help? Author(s): Moran NF. Source: Bmj (Clinical Research Ed.). 2003 January 4; 326(7379): 50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12511469&dopt=Abstract
•
Pro-fibrogenic effects of magnesium deficiency in the cardiovascular system. Author(s): Shivakumar K. Source: Magnes Res. 2002 December; 15(3-4): 307-15. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635886&dopt=Abstract
•
Prolongation of rapacuronium neuromuscular blockade by clindamycin and magnesium. Author(s): Sloan PA, Rasul M. Source: Anesthesia and Analgesia. 2002 January; 94(1): 123-4, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11772813&dopt=Abstract
•
Protective role of magnesium in cardiovascular diseases: a review. Author(s): Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Source: Molecular and Cellular Biochemistry. 2002 September; 238(1-2): 163-79. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12349904&dopt=Abstract
•
Prothrombin time ratio is reduced by magnesium contamination in evacuated blood collection tubes. Author(s): van den Besselaar AM, van Dam W, Sturk A, Bertina RM. Source: Thrombosis and Haemostasis. 2001 April; 85(4): 647-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11341499&dopt=Abstract
Studies
99
•
Quantitative changes of calcium, phosphorus, and magnesium in common iliac arteries with aging. Author(s): Tohno S, Tohno Y, Moriwake Y, Azuma C, Ohnishi Y, Minami T. Source: Biological Trace Element Research. 2001 Winter; 84(1-3): 57-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11817696&dopt=Abstract
•
Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Author(s): Roffe C, Sills S, Crome P, Jones P. Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2002 May; 8(5): Cr326-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12011773&dopt=Abstract
•
Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Author(s): Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ. Source: Annals of Emergency Medicine. 2001 December; 38(6): 621-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719739&dopt=Abstract
•
Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. Author(s): Longstreth WT Jr, Fahrenbruch CE, Olsufka M, Walsh TR, Copass MK, Cobb LA. Source: Neurology. 2002 August 27; 59(4): 506-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196641&dopt=Abstract
•
Randomized controlled trial of magnesium sulfate infusion for severe birth asphyxia. Author(s): Ichiba H, Tamai H, Negishi H, Ueda T, Kim TJ, Sumida Y, Takahashi Y, Fujinaga H, Minami H; Kansai Magnesium Study Group. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2002 October; 44(5): 505-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12225549&dopt=Abstract
•
Rapid preparation of a patient with pheochromocytoma with labetolol and magnesium sulfate. Author(s): Poopalalingam R, Chin EY. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2001 October; 48(9): 876-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11606344&dopt=Abstract
100 Magnesium
•
Recent advances in molecular genetics of hereditary magnesium-losing disorders. Author(s): Konrad M, Weber S. Source: Journal of the American Society of Nephrology : Jasn. 2003 January; 14(1): 24960. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12506158&dopt=Abstract
•
Recurarization in the recovery room following the use of magnesium sulphate. Author(s): Fawcett WJ, Stone JP. Source: British Journal of Anaesthesia. 2003 September; 91(3): 435-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12925489&dopt=Abstract
•
Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Author(s): Guerrero-Romero F, Rodriguez-Moran M. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 2002 April; 26(4): 469-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12075573&dopt=Abstract
•
Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate. Author(s): Cho MS, Lee KS, Lee YK, Ma SK, Ko JH, Kim SW, Kim NH, Choi KC. Source: Korean J Intern Med. 2002 June; 17(2): 114-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12164088&dopt=Abstract
•
Relationships between serum magnesium levels and clinical background factors in patients with mood disorders. Author(s): Imada Y, Yoshioka S, Ueda T, Katayama S, Kuno Y, Kawahara R. Source: Psychiatry and Clinical Neurosciences. 2002 October; 56(5): 509-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12193239&dopt=Abstract
•
Repeat postpartum magnesium sulfate administration for seizure prophylaxis: is there a patient profile predictive of need for additional therapy? Author(s): Isler CM, Barrilleaux PS, Rinehart BK, Magann EF, Martin JN Jr. Source: J Matern Fetal Neonatal Med. 2002 February;11(2):75-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12375546&dopt=Abstract
•
Rethinking the role of urinary magnesium in calcium urolithiasis. Author(s): Schwartz BF, Bruce J, Leslie S, Stoller ML. Source: Journal of Endourology / Endourological Society. 2001 April; 15(3): 233-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11339386&dopt=Abstract
Studies
101
•
Role of intra-muscular magnesium therapy in management of persistent apnea and prevention of adverse life threatening events. Author(s): Gupta M, Mangoli S, Sharma P, Sharma RB, Jora R, Meena K. Source: Indian Pediatrics. 2001 June; 38(6): 646-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11418730&dopt=Abstract
•
Role of the magnesium cation on antihypertensive molecule-human serum albumin binding: affinity chromatography approach. Author(s): Guillaum YC, Nicod L, Truong-Thanh T, Guinchard C, Robert JF, Thomassin M. Source: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2002 February 25; 768(1): 129-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11939546&dopt=Abstract
•
Safety of magnesium-lidocaine combination for severe head injury: the Turin lidomag pilot study. Author(s): Canavero S, Bonicalzi V, Narcisi P. Source: Surgical Neurology. 2003 August; 60(2): 165-9; Discussion 169. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12900133&dopt=Abstract
•
Serum and tissue glycoconjugates, digoxin and magnesium levels in chronic calcific pancreatitis. Author(s): Kumar RA, Kurup PA. Source: Indian J Gastroenterol. 2001 November-December; 20(6): 230-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11817776&dopt=Abstract
•
Serum and urinary magnesium during treatment of patients with chronic congestive heart failure. Author(s): Oladapo OO, Falase AO. Source: Afr J Med Med Sci. 2000 September-December; 29(3-4): 301-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11714011&dopt=Abstract
•
Serum creatine phosphokinase elevation in patients treated with intravenous magnesium sulfate. Author(s): Kuno N, Ishikawa K. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 March; 76(3): 257-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11880128&dopt=Abstract
•
Serum ionized magnesium in post-traumatic headaches. Author(s): Marcus JC, Altura BT, Altura BM. Source: The Journal of Pediatrics. 2001 September; 139(3): 459-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11562631&dopt=Abstract
102 Magnesium
•
Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Author(s): Mauskop A, Altura BT, Altura BM. Source: Headache. 2002 April; 42(4): 242-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010379&dopt=Abstract
•
Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation. Author(s): Cohen N, Almoznino-Sarafian D, Zaidenstein R, Alon I, Gorelik O, Shteinshnaider M, Chachashvily S, Averbukh Z, Golik A, Chen-Levy Z, Modai D. Source: Heart (British Cardiac Society). 2003 April; 89(4): 411-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12639869&dopt=Abstract
•
Serum magnesium and calcium in patients with dorsalgias. Author(s): Steidl L, Ditmar R, Dostal A. Source: Magnes Res. 2001 September; 14(3): 225-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11599556&dopt=Abstract
•
Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients. Author(s): Navarro JF, Mora C, Macia M, Garcia J. Source: Perit Dial Int. 1999 September-October; 19(5): 455-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11379859&dopt=Abstract
•
Serum magnesium in Thai coronary artery disease patients. Author(s): Wannasilp N, Poungvarin N, Pokum S, Leowattana W, Mahanonda N. Source: J Med Assoc Thai. 2001 December; 84 Suppl 3: S645-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12002905&dopt=Abstract
•
Serum magnesium levels and cognitive impairment in hospitalized hypertensive patients. Author(s): Corsonello A, Pedone C, Pahor M, Malara A, Carosella L, Mazzei B, Onder G, Corsonello F, Carbonin P, Corica F; Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA). Source: Magnes Res. 2001 December; 14(4): 273-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11794635&dopt=Abstract
•
Serum magnesium must also be known in profound hypokalaemia. Author(s): Loughrey CM. Source: Bmj (Clinical Research Ed.). 2002 April 27; 324(7344): 1039-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11976255&dopt=Abstract
Studies
103
•
Serum magnesium status during lipid-lowering drug treatment in non-insulindependent diabetic patients. Author(s): Haenni A, Ohrvall M, Lithell H. Source: Metabolism: Clinical and Experimental. 2001 October; 50(10): 1147-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11586485&dopt=Abstract
•
Serum magnesium, copper, and zinc alterations following spinal fusion. Author(s): Tatari H, Islekel H, Altekin E, Gocen S, Ozcan C, Ergor A. Source: Biological Trace Element Research. 2001 April; 80(1): 33-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11393308&dopt=Abstract
•
Simultaneous accumulation of calcium, phosphorus, and magnesium in various human arteries. Author(s): Tohno Y, Tohno S, Moriwake Y, Azuma C, Ohnishi Y, Minami T. Source: Biological Trace Element Research. 2001 Summer; 82(1-3): 21-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11697768&dopt=Abstract
•
Simultaneous accumulation of magnesium with calcium and phosphorus in aorta and iliac arteries of Thai. Author(s): Tohno Y, Tohno S, Mahakkanukrauh P, Vaidhayakarn P, Somsarp V, Minami T, Moriwake Y, Azuma C. Source: Biological Trace Element Research. 2001 Winter; 84(1-3): 19-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11817689&dopt=Abstract
•
Skeletal muscle magnesium content in identical twins, discordant for type 2 diabetes. Author(s): Djurhuus MS, Vaag A, Altura BM, Altura BT, Klitgaard NA. Source: Diabetes & Metabolism. 2002 June; 28(3): 201-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149600&dopt=Abstract
•
Skeletal muscle magnesium content is correlated with plasma glucose concentration in patients with essential hypertension treated with lisinopril or bendrofluazide. Author(s): Haenni A, Reneland R, Andersson PE, Lind L, Lithell H. Source: American Journal of Hypertension : Journal of the American Society of Hypertension. 2002 August; 15(8): 735-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12160198&dopt=Abstract
•
Storage of platelets in additive solutions: a pilot in vitro study of the effects of potassium and magnesium. Author(s): Gulliksson H, AuBuchon JP, Vesterinen M, Sandgren P, Larsson S, Pickard CA, Herschel I, Roger J, Tracy JE, Langweiler M; Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Source: Vox Sanguinis. 2002 April; 82(3): 131-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11952987&dopt=Abstract
104 Magnesium
•
Storage of platelets in additive solutions: effects of magnesium and/or potassium. Author(s): de Wildt-Eggen J, Schrijver JG, Bins M, Gulliksson H. Source: Transfusion. 2002 January; 42(1): 76-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11896316&dopt=Abstract
•
Studies of magnesium in congenital long QT syndrome. Author(s): Hoshino K, Ogawa K, Hishitani T, Kitazawa R. Source: Pediatric Cardiology. 2002 January-February; 23(1): 41-8. Epub 2002 February 19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11922507&dopt=Abstract
•
Sufficient dosing of intravenous magnesium for severe asthma. Author(s): Li J. Source: Annals of Emergency Medicine. 2001 May; 37(5): 552-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11326199&dopt=Abstract
•
Summary measure of dietary musculoskeletal nutrient (calcium, vitamin D, magnesium, and phosphorus) intakes is associated with lower-extremity physical performance in homebound elderly men and women. Author(s): Sharkey JR, Giuliani C, Haines PS, Branch LG, Busby-Whitehead J, Zohoori N. Source: The American Journal of Clinical Nutrition. 2003 April; 77(4): 847-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12663282&dopt=Abstract
•
Surreptitious abuse of magnesium laxatives as a cause of chronic diarrhoea. Author(s): Duncan A, Forrest JA. Source: European Journal of Gastroenterology & Hepatology. 2001 May; 13(5): 599-601. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11396544&dopt=Abstract
•
Tension headaches and muscle tension: is there a role for magnesium? Author(s): Altura BM, Altura BT. Source: Medical Hypotheses. 2001 December; 57(6): 705-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11918431&dopt=Abstract
•
The 2002 Moyer Award. Metabolic effects of vitamin D on serum calcium, magnesium, and phosphorus in pediatric burn patients. Author(s): Wray CJ, Mayes T, Khoury J, Warden GD, Gottschlich M. Source: The Journal of Burn Care & Rehabilitation. 2002 November-December; 23(6): 416-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12432318&dopt=Abstract
Studies
105
•
The apparent impact of gestational magnesium (Mg) deficiency on the sudden infant death syndrome (SIDS). Author(s): Caddell JL. Source: Magnes Res. 2001 December; 14(4): 291-303. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11794637&dopt=Abstract
•
The central role of magnesium deficiency in Tourette's syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette's syndrome and several reported comorbid conditions. Author(s): Grimaldi BL. Source: Medical Hypotheses. 2002 January; 58(1): 47-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11863398&dopt=Abstract
•
The effect of intrapartum magnesium sulfate therapy on fetal cardiac troponin I levels at delivery. Author(s): Blackwell SC, Redman ME, Whitty JE, Refuerzo JS, Berry SM, Sorokin Y, Russell E, Cotton DB. Source: J Matern Fetal Neonatal Med. 2002 November;12(5):327-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12607765&dopt=Abstract
•
The effect of magnesium on coagulation in parturients with preeclampsia. Author(s): Harnett MJ, Datta S, Bhavani-Shankar K. Source: Anesthesia and Analgesia. 2001 May; 92(5): 1257-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11323357&dopt=Abstract
•
The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Author(s): Jee SH, Miller ER 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. Source: American Journal of Hypertension : Journal of the American Society of Hypertension. 2002 August; 15(8): 691-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12160191&dopt=Abstract
•
The effects of intrapartum magnesium sulfate therapy on fetal serum interleukin1beta, interleukin-6, and tumor necrosis factor-alpha at delivery: a randomized, placebo-controlled trial. Author(s): Blackwell SC, Hallak M, Hassan SS, Berry SM, Russell E, Sorokin Y. Source: American Journal of Obstetrics and Gynecology. 2001 June; 184(7): 1320-3; Discussion 1323-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11408847&dopt=Abstract
106 Magnesium
•
The effects of magnesium prime solution on magnesium levels and potassium loss in open heart surgery. Author(s): Jian W, Su L, Yiwu L. Source: Anesthesia and Analgesia. 2003 June; 96(6): 1617-20, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12760983&dopt=Abstract
•
The first micturition times of the newborns whose mothers were treated with magnesium sulfate. Author(s): Sahin H, Akay AF, Bircan MK, Gocmen A, Bircan Z. Source: International Urology and Nephrology. 2001; 32(4): 651-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11989558&dopt=Abstract
•
The human mitochondrial Mrs2 protein functionally substitutes for its yeast homologue, a candidate magnesium transporter. Author(s): Zsurka G, Gregan J, Schweyen RJ. Source: Genomics. 2001 March 1; 72(2): 158-68. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11401429&dopt=Abstract
•
The importance of determination of magnesium concentration in the serum of patients with cancer metastases to the liver. Author(s): Kopanski Z, Piekoszewski W, Schlegel-Zawadzka M, Wojewoda T, Szuszko R. Source: Przegl Lek. 2002; 59(4-5): 267-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12183985&dopt=Abstract
•
The importance of effect mechanism in the design and interpretation of clinical trials: the role of magnesium in acute myocardial infarction. Author(s): Woods KL, Abrams K. Source: Progress in Cardiovascular Diseases. 2002 January-February; 44(4): 267-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12007082&dopt=Abstract
•
The influence of dietary palmitic acid triacylglyceride position on the fatty acid, calcium and magnesium contents of at term newborn faeces. Author(s): Lopez-Lopez A, Castellote-Bargallo AI, Campoy-Folgoso C, Rivero-Urgel M, Tormo-Carnice R, Infante-Pina D, Lopez-Sabater MC. Source: Early Human Development. 2001 November; 65 Suppl: S83-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11755039&dopt=Abstract
•
The ionized fraction of serum total magnesium in hemodialysis patients: is it really lower than in healthy subjects? Author(s): Dewitte K, Dhondt A, Lameire N, Stockl D, Thienpont LM. Source: Clinical Nephrology. 2002 September; 58(3): 205-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12356189&dopt=Abstract
Studies
107
•
The Israel Society for Research on Magnesium in Biology and Medicine: proceedings of the first meeting. Author(s): Stendig-Lindberg G; Israel Society for Research on Magnesium in Biology and Medicine. Source: Isr Med Assoc J. 2001 October; 3(10): 783-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11692561&dopt=Abstract
•
The level of magnesium in the serum of children hospitalized for severe respiratory infections. Author(s): Florianczyk B, Karska M, Bednarek A. Source: Ann Univ Mariae Curie Sklodowska [med]. 2001; 56: 243-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11977318&dopt=Abstract
•
The multifaceted and widespread pathology of magnesium deficiency. Author(s): Johnson S. Source: Medical Hypotheses. 2001 February; 56(2): 163-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11425281&dopt=Abstract
•
The prevention of pain from injection of rocuronium by magnesium sulphate, lignocaine, sodium bicarbonate and alfentanil. Author(s): Turan A, Memis D, Karamanlioglu B, Sut N, Pamukcu Z. Source: Anaesthesia and Intensive Care. 2003 June; 31(3): 277-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12879672&dopt=Abstract
•
The relationship between residual renal function, protein catabolic rate, and phosphate and magnesium levels in peritoneal dialysis patients. Author(s): Page DE, Knoll GA, Cheung V. Source: Adv Perit Dial. 2002; 18: 189-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12402616&dopt=Abstract
•
The role of magnesium in the emergency department. Author(s): Kaye P, O'Sullivan I. Source: Emergency Medicine Journal : Emj. 2002 July; 19(4): 288-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12101132&dopt=Abstract
•
The role of magnesium sulphate in the treatment of persistent pulmonary hypertension of the newborn. Author(s): Saidy KM, Itto BA. Source: Saudi Med J. 2003 July; 24(7): 801-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12883626&dopt=Abstract
108 Magnesium
•
The role of magnesium. Author(s): Cohen L. Source: Isr Med Assoc J. 2002 March; 4(3): 232-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11908277&dopt=Abstract
•
The significance of routine serum magnesium determination in the ED. Author(s): Stalnikowicz R. Source: The American Journal of Emergency Medicine. 2003 September; 21(5): 444-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14523888&dopt=Abstract
•
The simultaneous measurement of ionized and total calcium and ionized and total magnesium in intensive care unit patients. Author(s): Koch SM, Warters RD, Mehlhorn U. Source: Journal of Critical Care. 2002 September; 17(3): 203-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297997&dopt=Abstract
•
The use of magnesium sulfate to prevent pain on injection of propofol. Author(s): Memis D, Turan A, Karamanlioglu B, Sut N, Pamukcu Z. Source: Anesthesia and Analgesia. 2002 September; 95(3): 606-8, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12198045&dopt=Abstract
•
The use of magnesium to prevent laryngospasm after tonsillectomy and adenoidectomy: a preliminary study. Author(s): Gulhas N, Durmus M, Demirbilek S, Togal T, Ozturk E, Ersoy MO. Source: Paediatric Anaesthesia. 2003 January; 13(1): 43-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12535038&dopt=Abstract
•
The value of P dispersion on predicting atrial fibrillation after coronary artery bypass surgery: effect of magnesium on P dispersion. Author(s): Dagdelen S, Toraman F, Karabulut H, Alhan C. Source: Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2002 July; 7(3): 211-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12167181&dopt=Abstract
•
Tocolytic magnesium sulfate toxicity and unexpected neonatal death. Author(s): Herschel M, Mittendorf R. Source: Journal of Perinatology : Official Journal of the California Perinatal Association. 2001 June; 21(4): 261-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533846&dopt=Abstract
Studies
109
•
Two polyol, low digestible carbohydrates improve the apparent absorption of magnesium but not of calcium in healthy young men. Author(s): Coudray C, Bellanger J, Vermorel M, Sinaud S, Wils D, Feillet-Coudray C, Brandolini M, Bouteloup-Demange C, Rayssiguier Y. Source: The Journal of Nutrition. 2003 January; 133(1): 90-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12514273&dopt=Abstract
•
Umbilical cord serum ionized magnesium level and total pediatric mortality. Author(s): Mittendorf R, Covert R, Elin R, Pryde PG, Khoshnood B, Lee K. Source: Obstetrics and Gynecology. 2001 July; 98(1): 75-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11430960&dopt=Abstract
•
Unexpected toxicity induced by magnesium orotate treatment in congenital hypomagnesemia. Author(s): Guillard O, Piriou A, Fauconneau B, Mauco G, Mettey R. Source: Journal of Internal Medicine. 2002 July; 252(1): 88-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12074744&dopt=Abstract
•
Use of cisapride with magnesium oxide in chronic pediatric constipation. Author(s): Ni YH, Lin CC, Chang SH, Yeung CY; Taiwan Pediatric Constipation Study Group. Source: Acta Paediatr Taiwan. 2001 November-December; 42(6): 345-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11811223&dopt=Abstract
•
Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Author(s): Hughes R, Goldkorn A, Masoli M, Weatherall M, Burgess C, Beasley R. Source: Lancet. 2003 June 21; 361(9375): 2114-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12826434&dopt=Abstract
•
Use of magnesium to treat tetanus. Author(s): Williams S. Source: British Journal of Anaesthesia. 2002 January; 88(1): 152-3; Author Reply 153. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11881879&dopt=Abstract
•
Usefulness of magnesium sulfate in stabilizing cardiac repolarization in heart failure secondary to ischemic cardiomyopathy. Author(s): Ince C, Schulman SP, Quigley JF, Berger RD, Kolasa M, Ferguson R, Silver B, Haigney MC. Source: The American Journal of Cardiology. 2001 August 1; 88(3): 224-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11472698&dopt=Abstract
110 Magnesium
•
Whole blood ionized magnesium in neonatal acidosis and preterm infants: a prospective consecutive study. Author(s): Olofsson K, Matthiesen G, Rudnicki M. Source: Acta Paediatrica (Oslo, Norway : 1992). 2001 December; 90(12): 1398-401. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11853336&dopt=Abstract
111
CHAPTER 2. NUTRITION AND MAGNESIUM Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and magnesium.
Finding Nutrition Studies on Magnesium The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “magnesium” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
112 Magnesium
The following is a typical result when searching for recently indexed consumer information on magnesium: •
Dietary reference intakes (DRIs) for calcium, phosphorus, magnesium, vitamin D, and fluoride. Source: Nutrition-today (USA). (October 1997). volume 32(5) page 182-188.
•
EN's nutrition advice for women of 'a certain age'. Source: Ternus, M. Environmental-nutrition (USA). (August 1996). volume 19(8) page 1, 6.
•
Magnesium depletion and diuretics. Source: Nutrition-and-the-M.D (USA). (December 1989). volume 15(12) page 4-5.
•
The effect of diet on blood Vitamin K status and urinary mineral excretion assessed by a food questionnaire. Author(s): Department of Hygiene, Hyogo College of Medicine (Japan) Source: Sakamoto, N. Nishiike, T. Iguchi, H. Sakamoto, K. Nutrition-and-Health (United Kingdom). (1999). volume 13(1) page 1-10.
Additional consumer oriented references include: •
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. Author(s): Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
[email protected] Source: Belfort, M A Anthony, J Saade, G R Allen, J C Jr N-Engl-J-Med. 2003 January 23; 348(4): 304-11 1533-4406
•
Combined vitamin B6-magnesium treatment in autism spectrum disorder. Author(s): UCF Center for Autism & Related Disabilities, 12001 Science Dr, Suite 145, Orlando, Florida 32826, USA.
[email protected] Source: Nye, C Brice, A Cochrane-Database-Syst-Revolume 2002; (4): CD003497 1469493X
•
Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Author(s): Department of Chemisty, Yonsei University, Seoul, Korea.
[email protected] Source: Jung, M Lee, H C Ahn, C W Park, W Choi, S Kim, H Cho, D Lee, G T Li, H R Chem-Pharm-Bull-(Tokyo). 2002 August; 50(8): 1135-6 0009-2363
•
Initial reperfusion with magnesium after cardioplegic arrest attenuates myocardial reperfusion injury. Author(s): Institute for Surgical Research, Ludwig-Maximilians-Universitat Munchen, Germany. Source: Fuchs, F Messmer, K Kuppe, H Habazettl, H Thorac-Cardiovasc-Surg. 2002 August; 50(4): 208-15 0171-6425
•
Intestinal and renal handling of oxalate in magnesium-deficient rats. Evaluation of intestinal in vivo 14C-oxalate perfusion. Author(s): Department of Urology, Klinikum Benjamin Franklin, Freie Universitat Berlin, Germany.
[email protected] Source: Straub, B Muller, M Schrader, M Goessl, C Heicappell, R Miller, K BJU-Int. 2002 August; 90(3): 312-6 1464-4096
Nutrition
113
•
Magnesium and manganese ions accelerate tissue factor-induced coagulation independently of factor IX. Author(s): Haemostasis and Thrombosis Research Center, Leiden University Medical Center, The Netherlands.
[email protected] Source: van den Besselaar, A M Blood-Coagul-Fibrinolysis. 2002 January; 13(1): 19-23 0957-5235
•
Magnesium and trace elements in the elderly: intake, status and recommendations. Author(s): Instituto de Nutricion y Bromatologia, Ciudad Universitaria, Madrid, Spain.
[email protected] Source: Vaquero, M P J-Nutr-Health-Aging. 2002; 6(2): 147-53 1279-7707
•
Magnesium in critical illness: metabolism, assessment, and treatment. Author(s): Division of Pulmonary, Critical Care, and Occupational Medicine, Departments of Internal Medicine and Pharmacological and Physiological Science, School of Medicine, Saint Louis University, 3635 Vista Ave., Saint Louis, MO 63110-0250, USA. Source: Noronha, J L Matuschak, G M Intensive-Care-Med. 2002 June; 28(6): 667-79 03424642
•
Magnesium ions alleviate the negative effect of manganese on Glomus claroideum BEG23. Author(s): Institute of Botany, Academy of Sciences of the Czech Republic, 252 43 Pruhonice, Czech Republic.
[email protected] Source: Malcova, R Gryndler, M Vosatka, M Mycorrhiza. 2002 June; 12(3): 125-9 09406360
•
Magnesium status of patients with renal stones and its effect on urinary citrate excretion. Author(s): Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Source: Reungjui, S Prasongwatana, V Premgamone, A Tosukhowong, P Jirakulsomchok, S Sriboonlue, P BJU-Int. 2002 November; 90(7): 635-9 1464-4096
•
Magnesium sulphate for preventing preterm birth in threatened preterm labour. Author(s): Department of Obstetrics and Gynaecology, University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide, South Australia, Australia, 5006.
[email protected] Source: Crowther, C A Hiller, J E Doyle, L W Cochrane-Database-Syst-Revolume 2002; (4): CD001060 1469-493X
•
Magnesium-DNA interactions and the possible relation of magnesium to carcinogenesis. Irradiation and free radicals. Author(s): National Technical University of Athens, Chemical Engineering Department, Radiation Chemistry and Biospectroscopy, Zografou Campus, Zografou 15780, Athens, Greece.
[email protected] Source: Anastassopoulou, J Theophanides, T Crit-Rev-Oncol-Hematol. 2002 April; 42(1): 79-91 1040-8428
•
Nickel and cobalt activate complement factor C3 faster than magnesium. Author(s): Institute for Environmental Medicin, Karolinska Institute, Solna, Sweden.
[email protected] Source: Acevedo, F Vesterberg, O Toxicology. 2003 March 14; 185(1-2): 9-16 0300-483X
114 Magnesium
•
Novel mode of transcription regulation of divergently overlapping promoters by PhoP, the regulator of two-component system sensing external magnesium availability. Author(s): National Institute of Genetics, Department of Molecular Genetics, Mishima, Shizuoka 411-8540, Japan. Source: Yamamoto, K Ogasawara, H Fujita, N Utsumi, R Ishihama, A Mol-Microbiol. 2002 July; 45(2): 423-38 0950-382X
•
Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Author(s): Department of Geriatric Medicine, Keele University, Staffordshire, UK.
[email protected] Source: Roffe, C Sills, S Crome, P Jones, P Med-Sci-Monit. 2002 May; 8(5): CR326-30 1234-1010
•
Renal reabsorption of magnesium and calcium by cattle with renal tubular dysplasia. Author(s): Division of Veterinary Medicine, Faculty of Agriculture, Gifu University, Japan. Source: Ohba, Y Kitoh, K Nakamura, H Okuda, H Kunieda, T Sasaki, Y Kitagawa, H Vet-Rec. 2002 September 28; 151(13): 384-7 0042-4900
•
Structural changes of tRNA and 5S rRNA induced with magnesium and visualized with synchrotron mediated hydroxyl radical cleavage. Author(s): Institute of Bioorganic Chemistry, Poznan, Poland. Source: Barciszewska, M Z Rapp, G Betzel, C Erdmann, V A Barciszewski, J Mol-BiolRepage 2001; 28(2): 103-10 0301-4851
•
The role of magnesium in the emergency department. Author(s): Emergency Department, Bristol Royal Infirmary, Bristol,
[email protected] Source: Kaye, P O'Sullivan, I Emerg-Med-J. 2002 July; 19(4): 288-91 1472-0205
•
UK.
The role of magnesium ions and 2'-hydroxyl groups in the VS ribozyme-substrate interaction. Author(s): Centre for Chemical Biology, Department of Chemistry, Krebs Institute, University of Sheffield, Dainton Building, Brook Hill, S3 7HF, Sheffield, UK. Source: Tzokov, S B Murray, I A Grasby, J A J-Mol-Biol. 2002 November 22; 324(2): 21526 0022-2836
The following information is typical of that found when using the “Full IBIDS Database” to search for “magnesium” (or a synonym): •
Effect of nutrition in rabbit does. 2: Study of enzyme and mineral plasma profile. Author(s): Padua Univ. (Italy). Dipartimento di Scienze Zootecniche Source: Rizzi, C. Chiericato, G.M. Zani, C. Proceedings-of-the-ASPA-Congress-RecentProgress-in-Animal-Production-Science (Italy). (2001). volume 2 page 469-471.
•
Levels of selected macro- and microelements in goat milk from farms in the Czech Republic. Author(s): Ceska Zemedelska Univ., Prague (Czech Republic). Agronomicka Fakulta Source: Hejtmankova, A. Kucerova, J. Miholova, D. Kolihova, D. Orsak, M. CzechJournal-of-Animal-Science-UZPI (Czech Republic). (June 2002). volume 47(6) page 253260.
Nutrition
115
Additional physician-oriented references include: •
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. Author(s): Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
[email protected] Source: Belfort, M A Anthony, J Saade, G R Allen, J C Jr N-Engl-J-Med. 2003 January 23; 348(4): 304-11 1533-4406
•
Combined vitamin B6-magnesium treatment in autism spectrum disorder. Author(s): UCF Center for Autism & Related Disabilities, 12001 Science Dr, Suite 145, Orlando, Florida 32826, USA.
[email protected] Source: Nye, C Brice, A Cochrane-Database-Syst-Revolume 2002; (4): CD003497 1469493X
•
Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Author(s): Department of Chemisty, Yonsei University, Seoul, Korea.
[email protected] Source: Jung, M Lee, H C Ahn, C W Park, W Choi, S Kim, H Cho, D Lee, G T Li, H R Chem-Pharm-Bull-(Tokyo). 2002 August; 50(8): 1135-6 0009-2363
•
Initial reperfusion with magnesium after cardioplegic arrest attenuates myocardial reperfusion injury. Author(s): Institute for Surgical Research, Ludwig-Maximilians-Universitat Munchen, Germany. Source: Fuchs, F Messmer, K Kuppe, H Habazettl, H Thorac-Cardiovasc-Surg. 2002 August; 50(4): 208-15 0171-6425
•
Intestinal and renal handling of oxalate in magnesium-deficient rats. Evaluation of intestinal in vivo 14C-oxalate perfusion. Author(s): Department of Urology, Klinikum Benjamin Franklin, Freie Universitat Berlin, Germany.
[email protected] Source: Straub, B Muller, M Schrader, M Goessl, C Heicappell, R Miller, K BJU-Int. 2002 August; 90(3): 312-6 1464-4096
•
Magnesium and manganese ions accelerate tissue factor-induced coagulation independently of factor IX. Author(s): Haemostasis and Thrombosis Research Center, Leiden University Medical Center, The Netherlands.
[email protected] Source: van den Besselaar, A M Blood-Coagul-Fibrinolysis. 2002 January; 13(1): 19-23 0957-5235
•
Magnesium and trace elements in the elderly: intake, status and recommendations. Author(s): Instituto de Nutricion y Bromatologia, Ciudad Universitaria, Madrid, Spain.
[email protected] Source: Vaquero, M P J-Nutr-Health-Aging. 2002; 6(2): 147-53 1279-7707
•
Magnesium in critical illness: metabolism, assessment, and treatment. Author(s): Division of Pulmonary, Critical Care, and Occupational Medicine, Departments of Internal Medicine and Pharmacological and Physiological Science, School of Medicine, Saint Louis University, 3635 Vista Ave., Saint Louis, MO 63110-0250, USA. Source: Noronha, J L Matuschak, G M Intensive-Care-Med. 2002 June; 28(6): 667-79 03424642
116 Magnesium
•
Magnesium ions alleviate the negative effect of manganese on Glomus claroideum BEG23. Author(s): Institute of Botany, Academy of Sciences of the Czech Republic, 252 43 Pruhonice, Czech Republic.
[email protected] Source: Malcova, R Gryndler, M Vosatka, M Mycorrhiza. 2002 June; 12(3): 125-9 09406360
•
Magnesium status of patients with renal stones and its effect on urinary citrate excretion. Author(s): Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Source: Reungjui, S Prasongwatana, V Premgamone, A Tosukhowong, P Jirakulsomchok, S Sriboonlue, P BJU-Int. 2002 November; 90(7): 635-9 1464-4096
•
Magnesium sulphate for preventing preterm birth in threatened preterm labour. Author(s): Department of Obstetrics and Gynaecology, University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide, South Australia, Australia, 5006.
[email protected] Source: Crowther, C A Hiller, J E Doyle, L W Cochrane-Database-Syst-Revolume 2002; (4): CD001060 1469-493X
•
Magnesium-DNA interactions and the possible relation of magnesium to carcinogenesis. Irradiation and free radicals. Author(s): National Technical University of Athens, Chemical Engineering Department, Radiation Chemistry and Biospectroscopy, Zografou Campus, Zografou 15780, Athens, Greece.
[email protected] Source: Anastassopoulou, J Theophanides, T Crit-Rev-Oncol-Hematol. 2002 April; 42(1): 79-91 1040-8428
•
Nickel and cobalt activate complement factor C3 faster than magnesium. Author(s): Institute for Environmental Medicin, Karolinska Institute, Solna, Sweden.
[email protected] Source: Acevedo, F Vesterberg, O Toxicology. 2003 March 14; 185(1-2): 9-16 0300-483X
•
Novel mode of transcription regulation of divergently overlapping promoters by PhoP, the regulator of two-component system sensing external magnesium availability. Author(s): National Institute of Genetics, Department of Molecular Genetics, Mishima, Shizuoka 411-8540, Japan. Source: Yamamoto, K Ogasawara, H Fujita, N Utsumi, R Ishihama, A Mol-Microbiol. 2002 July; 45(2): 423-38 0950-382X
•
Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Author(s): Department of Geriatric Medicine, Keele University, Staffordshire, UK.
[email protected] Source: Roffe, C Sills, S Crome, P Jones, P Med-Sci-Monit. 2002 May; 8(5): CR326-30 1234-1010
•
Renal reabsorption of magnesium and calcium by cattle with renal tubular dysplasia. Author(s): Division of Veterinary Medicine, Faculty of Agriculture, Gifu University, Japan. Source: Ohba, Y Kitoh, K Nakamura, H Okuda, H Kunieda, T Sasaki, Y Kitagawa, H Vet-Rec. 2002 September 28; 151(13): 384-7 0042-4900
Nutrition
117
•
Structural changes of tRNA and 5S rRNA induced with magnesium and visualized with synchrotron mediated hydroxyl radical cleavage. Author(s): Institute of Bioorganic Chemistry, Poznan, Poland. Source: Barciszewska, M Z Rapp, G Betzel, C Erdmann, V A Barciszewski, J Mol-BiolRepage 2001; 28(2): 103-10 0301-4851
•
The role of magnesium in the emergency department. Author(s): Emergency Department, Bristol Royal Infirmary, Bristol,
[email protected] Source: Kaye, P O'Sullivan, I Emerg-Med-J. 2002 July; 19(4): 288-91 1472-0205
UK.
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
118 Magnesium
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to magnesium; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Folic Acid Source: Healthnotes, Inc.; www.healthnotes.com Multiple Vitamin-mineral Supplements Source: Healthnotes, Inc.; www.healthnotes.com Niacin Source: Integrative Medicine Communications; www.drkoop.com Pyridoxine Source: Integrative Medicine Communications; www.drkoop.com Vitamin B3 (niacin) Source: Integrative Medicine Communications; www.drkoop.com Vitamin B6 Source: Healthnotes, Inc.; www.healthnotes.com Vitamin B6 Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin B6 (pyridoxine) Source: Integrative Medicine Communications; www.drkoop.com Vitamin D Alternative names: Calciferol, Calcitrol, Cholecalciferol, Erocalciferol Source: Integrative Medicine Communications; www.drkoop.com Vitamin D Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,905,00.html
•
Minerals ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors) Source: Prima Communications, Inc.www.personalhealthzone.com
Nutrition
Atorvastatin Source: Healthnotes, Inc.; www.healthnotes.com Boron Source: Healthnotes, Inc.; www.healthnotes.com Boron Source: Prima Communications, Inc.www.personalhealthzone.com Calcium Source: Healthnotes, Inc.; www.healthnotes.com Calcium Source: Integrative Medicine Communications; www.drkoop.com Calcium Source: Prima Communications, Inc.www.personalhealthzone.com Calcium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,884,00.html Calcium Rich Rolaids Source: Healthnotes, Inc.; www.healthnotes.com Calcium/magnesium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,937,00.html Calcium: Which Form Is Best? Source: Healthnotes, Inc.; www.healthnotes.com Cisplatin Source: Healthnotes, Inc.; www.healthnotes.com Folate Source: Prima Communications, Inc.www.personalhealthzone.com Iron Source: Healthnotes, Inc.; www.healthnotes.com Iron Alternative names: Ferrous Sulfate Source: Integrative Medicine Communications; www.drkoop.com Magnesium Source: Healthnotes, Inc.; www.healthnotes.com Magnesium Source: Integrative Medicine Communications; www.drkoop.com
119
120 Magnesium
Magnesium Source: Prima Communications, Inc.www.personalhealthzone.com Magnesium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,890,00.html Magnesium Hydroxide Source: Healthnotes, Inc.; www.healthnotes.com Manganese Source: Prima Communications, Inc.www.personalhealthzone.com Potassium Source: Healthnotes, Inc.; www.healthnotes.com Potassium Source: Integrative Medicine Communications; www.drkoop.com Potassium Source: Prima Communications, Inc.www.personalhealthzone.com Potassium-Sparing Diuretics Source: Integrative Medicine Communications; www.drkoop.com Potassium-Sparing Diuretics Source: Prima Communications, Inc.www.personalhealthzone.com Pravastatin Source: Healthnotes, Inc.; www.healthnotes.com Spironolactone Source: Healthnotes, Inc.; www.healthnotes.com Zinc Source: Healthnotes, Inc.; www.healthnotes.com Zinc Source: Integrative Medicine Communications; www.drkoop.com Zinc Source: Prima Communications, Inc.www.personalhealthzone.com Zinc Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10071,00.html
Nutrition
•
Food and Diet Abalone Source: Healthnotes, Inc.; www.healthnotes.com Acorn Squash Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,190,00.html Almonds Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,113,00.html Amaranth Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,69,00.html Avocados Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,46,00.html Black Beans Source: Healthnotes, Inc.; www.healthnotes.com Bluefish Source: Healthnotes, Inc.; www.healthnotes.com Brazil Nuts Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,115,00.html Buckwheat Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,71,00.html Butternut Squash Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,189,00.html Cardoon Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,239,00.html
121
122 Magnesium
Carp Source: Healthnotes, Inc.; www.healthnotes.com Chocolate Source: Healthnotes, Inc.; www.healthnotes.com Chocolate Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,179,00.html Cod Source: Healthnotes, Inc.; www.healthnotes.com Crabs Source: Healthnotes, Inc.; www.healthnotes.com Ferrous Sulfate Source: Integrative Medicine Communications; www.drkoop.com Flour Source: Healthnotes, Inc.; www.healthnotes.com Great Northern Beans Source: Healthnotes, Inc.; www.healthnotes.com Hazelnuts Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,307,00.html High Cholesterol Source: Healthnotes, Inc.; www.healthnotes.com Honey Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,283,00.html Jacob's Cattle Beans Source: Healthnotes, Inc.; www.healthnotes.com Kamut Source: Healthnotes, Inc.; www.healthnotes.com Lima Beans Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,151,00.html Natural Sweeteners Source: Healthnotes, Inc.; www.healthnotes.com
Nutrition
Nuts Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,84,00.html Okra Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,26,00.html Oranges Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,59,00.html Peanuts Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,110,00.html Pike Source: Healthnotes, Inc.; www.healthnotes.com Pumpkin Seeds Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,176,00.html Quinoa Source: Healthnotes, Inc.; www.healthnotes.com Quinoa Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,74,00.html Refined Sweeteners Source: Healthnotes, Inc.; www.healthnotes.com Ricotta Source: Healthnotes, Inc.; www.healthnotes.com Rockfish Source: Healthnotes, Inc.; www.healthnotes.com Salmon Source: Healthnotes, Inc.; www.healthnotes.com Scallops Source: Healthnotes, Inc.; www.healthnotes.com
123
124 Magnesium
Sea Bass Source: Healthnotes, Inc.; www.healthnotes.com Seaweed Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,217,00.html Shark Source: Healthnotes, Inc.; www.healthnotes.com Soybeans Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,105,00.html Spinach Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,35,00.html Sunflower Seeds Source: Healthnotes, Inc.; www.healthnotes.com Sunflower Seeds Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,158,00.html Swedish Brown Beans Source: Healthnotes, Inc.; www.healthnotes.com Tilefish Source: Healthnotes, Inc.; www.healthnotes.com Tofu Source: Healthnotes, Inc.; www.healthnotes.com Tofu Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,136,00.html Triticale Source: Healthnotes, Inc.; www.healthnotes.com Tuna Source: Healthnotes, Inc.; www.healthnotes.com Turkey Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com
Nutrition
Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,92,00.html Walnuts Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,100,00.html Water Source: Healthnotes, Inc.; www.healthnotes.com Wheat Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,78,00.html Wheat Free Pasta Source: Healthnotes, Inc.; www.healthnotes.com Whitefish Source: Healthnotes, Inc.; www.healthnotes.com Winter Squash Source: Healthnotes, Inc.; www.healthnotes.com Yellow Eye Beans Source: Healthnotes, Inc.; www.healthnotes.com
125
127
CHAPTER 3. ALTERNATIVE MEDICINE AND MAGNESIUM Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to magnesium. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to magnesium and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “magnesium” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to magnesium: •
A case of hypomagnesaemia due to malabsorption, unresponsive to oral administration of magnesium glycerophosphate, but responsive to oral magnesium oxide supplementation. Author(s): Ross JR, Dargan PI, Jones AL, Kostrzewski A. Source: Gut. 2001 June; 48(6): 857-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11358909&dopt=Abstract
•
A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. Author(s): De Souza MC, Walker AF, Robinson PA, Bolland K. Source: Journal of Women's Health & Gender-Based Medicine. 2000 March; 9(2): 131-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10746516&dopt=Abstract
128 Magnesium
•
Activation of transcription factors AP-1 and NF-kappaB in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation. Author(s): Asai T, Nakatani T, Tamada S, Kuwabara N, Yamanaka S, Tashiro K, Nakao T, Komiya T, Okamura M, Kim S, Iwao H, Miura K. Source: Transplantation. 2003 April 15; 75(7): 1040-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12698095&dopt=Abstract
•
Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption. Author(s): Green JH, Booth C, Bunning R. Source: European Journal of Clinical Nutrition. 2003 January; 57(1): 61-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548298&dopt=Abstract
•
Beneficial effect of pollen and/or propolis on the metabolism of iron, calcium, phosphorus, and magnesium in rats with nutritional ferropenic anemia. Author(s): Haro A, Lopez-Aliaga I, Lisbona F, Barrionuevo M, Alferez MJ, Campos MS. Source: Journal of Agricultural and Food Chemistry. 2000 November; 48(11): 5715-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11087544&dopt=Abstract
•
Calcium- and magnesium-dependent aggregation of legume seed storage proteins. Author(s): Ferreira RB, Franco E, Teixeira AR. Source: Journal of Agricultural and Food Chemistry. 1999 August; 47(8): 3009-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10552601&dopt=Abstract
•
Calcium-magnesium interactions in pancreatic acinar cells. Author(s): Mooren FC, Turi S, Gunzel D, Schlue WR, Domschke W, Singh J, Lerch MM. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2001 March; 15(3): 659-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11259384&dopt=Abstract
•
Combined vitamin B6-magnesium treatment in autism spectrum disorder. Author(s): Nye C, Brice A. Source: Cochrane Database Syst Rev. 2002; (4): Cd003497. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519599&dopt=Abstract
•
Comparing nutrient intake from food to the estimated average requirements shows middle- to upper-income pregnant women lack iron and possibly magnesium. Author(s): Turner RE, Langkamp-Henken B, Littell RC, Lukowski MJ, Suarez MF. Source: Journal of the American Dietetic Association. 2003 April; 103(4): 461-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12669009&dopt=Abstract
•
Complexation and ionophoric properties of taxol and colchicine: complex formation and transport of sodium, potassium, magnesium and calcium ions across a liquid
Alternative Medicine 129
membrane. Author(s): Blaghen M, Lahlou N, Dzairi FZ, Moutaouakkil A, Talbi M. Source: Natural Toxins. 1999; 7(5): 179-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10945480&dopt=Abstract •
Diet enrichment with calcium and magnesium enhances the cholesterol-lowering effect of plant sterols in obese Zucker rats. Author(s): Vaskonen T, Mervaala E, Seppanen-Laakso T, Karppanen H. Source: Nutr Metab Cardiovasc Dis. 2001 June; 11(3): 158-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11590991&dopt=Abstract
•
Dietary magnesium depletion affects metabolic responses during submaximal exercise in postmenopausal women. Author(s): Lukaski HC, Nielsen FH. Source: The Journal of Nutrition. 2002 May; 132(5): 930-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11983816&dopt=Abstract
•
Dietary magnesium supplementation affects bone metabolism and dynamic strength of bone in ovariectomized rats. Author(s): Toba Y, Kajita Y, Masuyama R, Takada Y, Suzuki K, Aoe S. Source: The Journal of Nutrition. 2000 February; 130(2): 216-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10720172&dopt=Abstract
•
Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. Author(s): Pere AK, Lindgren L, Tuomainen P, Krogerus L, Rauhala P, Laakso J, Karppanen H, Vapaatalo H, Ahonen J, Mervaala EM. Source: Kidney International. 2000 December; 58(6): 2462-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11115079&dopt=Abstract
•
EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Author(s): Waters RS, Bryden NA, Patterson KY, Veillon C, Anderson RA. Source: Biological Trace Element Research. 2001 December; 83(3): 207-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11794513&dopt=Abstract
•
Effect of acupuncture on serum magnesium level in treatment of migraine. Author(s): Chen B. Source: J Tradit Chin Med. 2000 June; 20(2): 126-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11039001&dopt=Abstract
•
Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by 31P-NMRS and ion selective electrodes.
130 Magnesium
Author(s): Wary C, Brillault-Salvat C, Bloch G, Leroy-Willig A, Roumenov D, Grognet JM, Leclerc JH, Carlier PG. Source: British Journal of Clinical Pharmacology. 1999 November; 48(5): 655-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10594466&dopt=Abstract •
Effect of extracellular magnesium on topoisomerase II activity and expression in human leukemia HL-60 cells. Author(s): Covacci V, Bruzzese N, Sgambato A, Ganapathi R, Cittadini A, Wolf FI. Source: Journal of Cellular Biochemistry. 2000 May; 78(2): 325-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10842326&dopt=Abstract
•
Effect of glucose/insulin infusion and magnesium supplementation on serum and muscle sodium and potassium and muscle [3H]ouabain binding capacity in Type 1 diabetes mellitus. Author(s): Djurhuus MS, Klitgaard NA, Pedersen KK. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2003; 63(2): 93102. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12751690&dopt=Abstract
•
Effect of magnesium lithospermate B on calcium and nitric oxide in endothelial cells upon hypoxia/reoxygenation. Author(s): Luo WB, Dong L, Wang YP. Source: Acta Pharmacologica Sinica. 2002 October; 23(10): 930-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12370098&dopt=Abstract
•
Effect of magnesium on fibrin formation from lower molecular weight (LMW) fibrinogen. Author(s): Lipinski B, Lipinska I. Source: Magnes Res. 2000 December; 13(4): 233-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11153893&dopt=Abstract
•
Effect of magnesium supplementation containing mineral bishofit (MgCl2 x 6H2O) solution and pyridoxine hydrochloride on erythrocyte magnesium depletion and behaviour of rats after three-month alcoholization. Author(s): Iezhitsa IN, Onishchenko NV, Churbakova NV, Parshev VV, Petrov VI, Spasov AA. Source: Magnes Res. 2002 December; 15(3-4): 179-89. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635870&dopt=Abstract
•
Effect of magnesium supplementation on oxidative stress in alloxanic diabetic rats. Author(s): Hans CP, Chaudhary DP, Bansal DD.
Alternative Medicine 131
Source: Magnes Res. 2003 March; 16(1): 13-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12735478&dopt=Abstract •
Effect of magnesium supplementation on the fractional intestinal absorption of 45CaCl2 in women with a low erythrocyte magnesium concentration. Author(s): Basso LE, Ubbink JB, Delport R, Spies J, Vermaak WJ. Source: Metabolism: Clinical and Experimental. 2000 August; 49(8): 1092-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10954032&dopt=Abstract
•
Effect of magnesium tanshinoate B on the production of nitric oxide in endothelial cells. Author(s): O K, Cheung F, Sung FL, Zhu DY, Siow YL. Source: Molecular and Cellular Biochemistry. 2000 April; 207(1-2): 35-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10888224&dopt=Abstract
•
Effect of oral magnesium supplementation on blood pressure in deoxycorticosterone acetate-induced hypertension in rats. Author(s): Whitworth JA. Source: Journal of Hypertension. 2000 December; 18(12): 1877. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11132614&dopt=Abstract
•
Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. Author(s): Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R. Source: Journal of Hypertension. 2000 July; 18(7): 919-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10930190&dopt=Abstract
•
Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate-induced hypertension in rats. Author(s): Kisters K, Hausberg M, Kosch M. Source: Journal of Hypertension. 2001 January; 19(1): 161-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11204298&dopt=Abstract
•
Effect of oral magnesium supplementation on experimental pre-eclampsia induced by prolonged blockade of nitric oxide synthesis in pregnant rats. Author(s): Pandhi P, Saha L, Malhotra S. Source: Indian J Exp Biol. 2002 March; 40(3): 349-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635709&dopt=Abstract
•
Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2 diabetes mellitus. Author(s): Lal J, Vasudev K, Kela AK, Jain SK.
132 Magnesium
Source: J Assoc Physicians India. 2003 January; 51: 37-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12693452&dopt=Abstract •
Effect of propofol with and without EDTA on haemodynamics and calcium and magnesium homeostasis during and after cardiac surgery. Author(s): Wahr J, Vender J, Gilbert HC, Spiess B, Horrow JC, Maddi R. Source: Intensive Care Medicine. 2000; 26 Suppl 4: S443-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11310907&dopt=Abstract
•
Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Author(s): Jung M, Lee HC, Ahn CW, Park W, Choi S, Kim H, Cho D, Lee GT, Li HR. Source: Chemical & Pharmaceutical Bulletin. 2002 August; 50(8): 1135-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12192155&dopt=Abstract
•
Effects of acute maternal hyperglycaemia and hyperosmolality on maternofetal transfer of calcium and magnesium across the in situ perfused rat placenta. Author(s): Husain SM, Mughal MZ, Sibley CP. Source: Magnes Res. 2000 December; 13(4): 239-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11153894&dopt=Abstract
•
Effects of calcium carbonate, magnesium oxide and sodium citrate bicarbonate health supplements on the urinary risk factors for kidney stone formation. Author(s): Allie S, Rodgers A. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 January; 41(1): 39-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12636048&dopt=Abstract
•
Effects of magnesium on the production of extracellular matrix metalloproteinases in cultured rat vascular smooth muscle cells. Author(s): Yue H, Lee JD, Shimizu H, Uzui H, Mitsuke Y, Ueda T. Source: Atherosclerosis. 2003 February; 166(2): 271-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12535739&dopt=Abstract
•
Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Author(s): Shechter M, Bairey Merz CN, Stuehlinger HG, Slany J, Pachinger O, Rabinowitz B. Source: The American Journal of Cardiology. 2003 March 1; 91(5): 517-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12615252&dopt=Abstract
Alternative Medicine 133
•
Effects of oral zinc and magnesium supplementation on serum thyroid hormone and lipid levels in experimentally induced diabetic rats. Author(s): Baydas B, Karagoz S, Meral I. Source: Biological Trace Element Research. 2002 September; 88(3): 247-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12350134&dopt=Abstract
•
Effects of order of magnesium exposure on the postantibiotic effect and bactericidal activity of ciprofloxacin. Author(s): Li RC, Lo KN, Lam JS, Lau PY. Source: Journal of Chemotherapy (Florence, Italy). 1999 August; 11(4): 243-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10465124&dopt=Abstract
•
Erythrocyte magnesium concentration as an index of magnesium status: a perspective from a magnesium supplementation study. Author(s): Basso LE, Ubbink JB, Delport R. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2000 January 20; 291(1): 1-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10612712&dopt=Abstract
•
Exchangeable magnesium pool masses in healthy women: effects of magnesium supplementation. Author(s): Feillet-Coudray C, Coudray C, Tressol JC, Pepin D, Mazur A, Abrams SA, Rayssiguier Y. Source: The American Journal of Clinical Nutrition. 2002 January; 75(1): 72-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11756062&dopt=Abstract
•
Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B. Author(s): Wu XJ, Wang YP, Wang W, Sun WK, Xu YM, Xuan LJ. Source: Acta Pharmacologica Sinica. 2000 September; 21(9): 855-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11501171&dopt=Abstract
•
Hair calcium and magnesium levels in patients with fibromyalgia: a case center study. Author(s): Ng SY. Source: Journal of Manipulative and Physiological Therapeutics. 1999 NovemberDecember; 22(9): 586-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10626702&dopt=Abstract
•
Hematology tests of blood anticoagulated with magnesium sulphate. Author(s): Kondo H, Kobayashi E, Itani T, Tatsumi N, Tsuda I.
134 Magnesium
Source: Southeast Asian J Trop Med Public Health. 2002; 33 Suppl 2: 6-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12755260&dopt=Abstract •
High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Author(s): Cohen JS. Source: The Annals of Pharmacotherapy. 2002 February; 36(2): 255-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847944&dopt=Abstract
•
Hypomagnesaemia due to malabsorption is not always responsive to oral magnesium oxide supplementation alone. Author(s): Arasaradnam RP, Bolton RP. Source: Gut. 2002 June; 50(6): 897. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010899&dopt=Abstract
•
Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. Author(s): Ceremuzynski L, Gebalska J, Wolk R, Makowska E. Source: Journal of Internal Medicine. 2000 January; 247(1): 78-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10672134&dopt=Abstract
•
In vitro evidence for effects of magnesium supplementation on quinolone-treated horse and dog chondrocytes. Author(s): Egerbacher M, Wolfesberger B, Gabler C. Source: Veterinary Pathology. 2001 March; 38(2): 143-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11280370&dopt=Abstract
•
Intraperitoneal route of magnesium sulphate supplementation in a patient with severe renal magnesium wasting. Author(s): Bastani B, Pandurangan G. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2001 October; 16(10): 2086-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11572903&dopt=Abstract
•
Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Author(s): Alter HJ, Koepsell TD, Hilty WM. Source: Annals of Emergency Medicine. 2000 September; 36(3): 191-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10969219&dopt=Abstract
•
Intravenously and topically applied magnesium in the prevention of arterial thrombosis. Author(s): Toft G, Ravn HB, Hjortdal VE.
Alternative Medicine 135
Source: Thrombosis Research. 2000 July 1; 99(1): 61-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10904104&dopt=Abstract •
Ionized magnesium supplementation in critically ill patients: comparing ionized and total magnesium. Author(s): Barrera R, Fleischer M, Miletic J, Groeger J. Source: Journal of Critical Care. 2000 March; 15(1): 36-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10757197&dopt=Abstract
•
Large-dose intravenous methotrexate-induced cutaneous toxicity: can oral magnesium oxide reduce pain? Author(s): Suresh S, Lozono S, Hall SC. Source: Anesthesia and Analgesia. 2003 May; 96(5): 1413-4, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12707144&dopt=Abstract
•
Long-term excessive magnesium supplementation is deleterious whereas suboptimal supply is beneficial for bones in rats. Author(s): Riond JL, Hartmann P, Steiner P, Ursprung R, Wanner M, Forrer R, Spichiger UE, Thomsen JS, Mosekilde L. Source: Magnes Res. 2000 December; 13(4): 249-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11153895&dopt=Abstract
•
Magnesium and exercise. Author(s): Bohl CH, Volpe SL. Source: Critical Reviews in Food Science and Nutrition. 2002; 42(6): 533-63. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12487419&dopt=Abstract
•
Magnesium and potassium supplementation in the prevention of diabetic vascular disease. Author(s): Whang R, Sims G. Source: Medical Hypotheses. 2000 September; 55(3): 263-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10985921&dopt=Abstract
•
Magnesium deposition and depletion in magnesium supplemented rats during and after hypokinesia and vivarium control. Author(s): Zorbas YG, Kakurin VJ, Afonin VB, Denogradov SD, Yarullin VL. Source: Biological Trace Element Research. 2002 June; 86(3): 203-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12019518&dopt=Abstract
•
Magnesium in human milk. Author(s): Dorea JG.
136 Magnesium
Source: Journal of the American College of Nutrition. 2000 April; 19(2): 210-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10763902&dopt=Abstract •
Magnesium lithospermate B inhibits hypoxia-induced calcium influx and nitric oxide release in endothelial cells. Author(s): Luo WB, Wang YP. Source: Acta Pharmacologica Sinica. 2001 December; 22(12): 1135-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11749815&dopt=Abstract
•
Magnesium reduces insulin-stimulated glucose uptake and serum lipid concentrations in type 1 diabetes. Author(s): Djurhuus MS, Klitgaard NA, Pedersen KK, Blaabjerg O, Altura BM, Altura BT, Henriksen JE. Source: Metabolism: Clinical and Experimental. 2001 December; 50(12): 1409-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11735085&dopt=Abstract
•
Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. Author(s): Manuel y Keenoy B, Moorkens G, Vertommen J, Noe M, Neve J, De Leeuw I. Source: Journal of the American College of Nutrition. 2000 June; 19(3): 374-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10872900&dopt=Abstract
•
Magnesium status of patients with renal stones and its effect on urinary citrate excretion. Author(s): Reungjui S, Prasongwatana V, Premgamone A, Tosukhowong P, Jirakulsomchok S, Sriboonlue P. Source: Bju International. 2002 November; 90(7): 635-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12410738&dopt=Abstract
•
Magnesium supplementation and bone turnover. Author(s): Martini LA. Source: Nutrition Reviews. 1999 July; 57(7): 227-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10453178&dopt=Abstract
•
Magnesium supplementation and deoxycorticosterone acetate--salt hypertension: effect on arterial mechanical properties and on activity of endothelin-1. Author(s): Berthon N, Laurant P, Hayoz D, Fellmann D, Brunner HR, Berthelot A. Source: Canadian Journal of Physiology and Pharmacology. 2002 June; 80(6): 553-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12117304&dopt=Abstract
•
Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. Author(s): Touyz RM, Milne FJ.
Alternative Medicine 137
Source: American Journal of Hypertension : Journal of the American Society of Hypertension. 1999 August; 12(8 Pt 1): 757-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10480467&dopt=Abstract •
Magnesium supplementation does not delay disease onset or increase survival in a mouse model of familial ALS. Author(s): Pamphlett R, Todd E, Vink R, McQuilty R, Cheema SS. Source: Journal of the Neurological Sciences. 2003 December 15; 216(1): 95-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14607308&dopt=Abstract
•
Magnesium supplementation in Gitelman syndrome. Author(s): Bettinelli A, Basilico E, Metta MG, Borella P, Jaeger P, Bianchetti MG. Source: Pediatric Nephrology (Berlin, Germany). 1999 May; 13(4): 311-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10454780&dopt=Abstract
•
Magnesium supplementation in pregnancy. Author(s): Makrides M, Crowther CA. Source: Cochrane Database Syst Rev. 2001; (4): Cd000937. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11687087&dopt=Abstract
•
Magnesium supplementation in pregnancy. Author(s): Makrides M, Crowther CA. Source: Cochrane Database Syst Rev. 2000; (2): Cd000937. Review. Update In: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10796220&dopt=Abstract
•
Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects. Author(s): Dorman BH, Sade RM, Burnette JS, Wiles HB, Pinosky ML, Reeves ST, Bond BR, Spinale FG. Source: American Heart Journal. 2000 March; 139(3): 522-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10689268&dopt=Abstract
•
Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Author(s): Asai T, Nakatani T, Yamanaka S, Tamada S, Kishimoto T, Tashiro K, Nakao T, Okamura M, Kim S, Iwao H, Miura K. Source: Transplantation. 2002 September 27; 74(6): 784-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12364856&dopt=Abstract
•
Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. Author(s): O K, Lynn EG, Vazhappilly R, Au-Yeung KK, Zhu DY, Siow YL.
138 Magnesium
Source: Life Sciences. 2001 January 12; 68(8): 903-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11213360&dopt=Abstract •
Magnesium. An update on physiological, clinical and analytical aspects. Author(s): Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2000 April; 294(1-2): 1-26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10727669&dopt=Abstract
•
Magnesium-creatine supplementation effects on body water. Author(s): Brilla LR, Giroux MS, Taylor A, Knutzen KM. Source: Metabolism: Clinical and Experimental. 2003 September; 52(9): 1136-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14506619&dopt=Abstract
•
Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Author(s): Zavaczki Z, Szollosi J, Kiss SA, Koloszar S, Fejes I, Kovacs L, Pal A. Source: Magnes Res. 2003 June; 16(2): 131-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12892384&dopt=Abstract
•
Media calcification, low erythrocyte magnesium, altered plasma magnesium, and calcium homeostasis following grafting of the thoracic aorta to the infrarenal aorta in the rat--differential preventive effects of long-term oral magnesium supplementation alone and in combination with alkali. Author(s): Schwille PO, Schmiedl A, Schwille R, Brunner P, Kissler H, Cesnjevar R, Gepp H. Source: Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2003 March; 57(2): 88-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12842494&dopt=Abstract
•
Metabolic and clinical effects of oral magnesium supplementation in furosemidetreated patients with severe congestive heart failure. Author(s): Cohen N, Alon I, Almoznino-Sarafian D, Zaidenstein R, Weissgarten J, Gorelik O, Berman S, Modai D, Golik A. Source: Clin Cardiol. 2000 June; 23(6): 433-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10875034&dopt=Abstract
•
Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Author(s): Patrick L.
Alternative Medicine 139
Source: Alternative Medicine Review : a Journal of Clinical Therapeutic. 2002 August; 7(4): 276-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12197781&dopt=Abstract •
Non-enzymatic RNA hydrolysis promoted by the combined catalytic activity of buffers and magnesium ions. Author(s): AbouHaidar MG, Ivanov IG. Source: Z Naturforsch [c]. 1999 July-August; 54(7-8): 542-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10488562&dopt=Abstract
•
Nutrients and HIV: part two--vitamins A and E, zinc, B-vitamins, and magnesium. Author(s): Patrick L. Source: Alternative Medicine Review : a Journal of Clinical Therapeutic. 2000 February; 5(1): 39-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10696118&dopt=Abstract
•
Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Author(s): Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Source: Headache. 2003 June; 43(6): 601-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12786918&dopt=Abstract
•
Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Author(s): Rodriguez-Moran M, Guerrero-Romero F. Source: Diabetes Care. 2003 April; 26(4): 1147-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12663588&dopt=Abstract
•
Oral magnesium supplementation induces favorable antiatherogenic changes in ApoE-deficient mice. Author(s): Ravn HB, Korsholm TL, Falk E. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2001 May; 21(5): 858-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11348887&dopt=Abstract
•
Plasma calcium, inorganic phosphate and magnesium during hypocalcaemia induced by a standardized EDTA infusion in cows. Author(s): Mellau LS, Jorgensen RJ, Enemark JM. Source: Acta Vet Scand. 2001; 42(2): 251-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11503370&dopt=Abstract
•
Postoperative atrial tachyarrhythmias in patients undergoing coronary artery bypass graft surgery without cardiopulmonary bypass: a role for intraoperative magnesium
140 Magnesium
supplementation. Author(s): Maslow AD, Regan MM, Heindle S, Panzica P, Cohn WE, Johnson RG. Source: Journal of Cardiothoracic and Vascular Anesthesia. 2000 October; 14(5): 524-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11052432&dopt=Abstract •
Preventive effect of magnesium supplement on noise-induced hearing loss in the guinea pig. Author(s): Scheibe F, Haupt H, Ising H. Source: European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (Eufos) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2000; 257(1): 10-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10664038&dopt=Abstract
•
Preventive magnesium supplement protects the inner ear against noise-induced impairment of blood flow and oxygenation in the guinea pig. Author(s): Haupt H, Scheibe F. Source: Magnes Res. 2002 March; 15(1-2): 17-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030419&dopt=Abstract
•
Preventive magnesium supplement reduces ischemia-induced hearing loss and blood viscosity in the guinea pig. Author(s): Scheibe F, Haupt H, Vlastos GA. Source: European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (Eufos) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2000; 257(7): 355-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11052244&dopt=Abstract
•
Removal of magnesium by Mg-dechelatase is a major step in the chlorophylldegrading pathway in Ginkgo biloba in the process of autumnal tints. Author(s): Tang L, Okazawa A, Fukusaki E, Kobayashi A. Source: Z Naturforsch [c]. 2000 November-December; 55(11-12): 923-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11204197&dopt=Abstract
•
Role of magnesium in genomic stability. Author(s): Hartwig A. Source: Mutation Research. 2001 April 18; 475(1-2): 113-21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11295157&dopt=Abstract
•
Should we use oral magnesium supplementation to improve sleep in the elderly?. Article reviewed: K. Held, I.A. Antonijevic, H. Kunzel, M. Uhr, T.C. Wetter, I.C. Golly, A. Steiger, H. Murck, Oral MG(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans, Pharmacopsychiatry, 35 (2002), 135-143. Author(s): Allen RP.
Alternative Medicine 141
Source: Sleep Medicine. 2003 May; 4(3): 263-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14592337&dopt=Abstract •
Studies of magnesium in congenital long QT syndrome. Author(s): Hoshino K, Ogawa K, Hishitani T, Kitazawa R. Source: Pediatric Cardiology. 2002 January-February; 23(1): 41-8. Epub 2002 February 19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11922507&dopt=Abstract
•
The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases. Author(s): Bryan PM, Potter LR. Source: The Journal of Biological Chemistry. 2002 May 3; 277(18): 16041-7. Epub 2002 January 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11821394&dopt=Abstract
•
The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Author(s): Jee SH, Miller ER 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. Source: American Journal of Hypertension : Journal of the American Society of Hypertension. 2002 August; 15(8): 691-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12160191&dopt=Abstract
•
The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Author(s): Frick M, Darpo B, Ostergren J, Rosenqvist M. Source: European Heart Journal. 2000 July; 21(14): 1177-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10924301&dopt=Abstract
•
The effect of zeolite A supplementation in the dry period on periparturient calcium, phosphorus, and magnesium homeostasis. Author(s): Thilsing-Hansen T, Jorgensen RJ, Enemark JM, Larsen T. Source: Journal of Dairy Science. 2002 July; 85(7): 1855-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12201536&dopt=Abstract
•
The effects of magnesium sulphate and EDTA in the hypercholesterolaemic rabbit. Author(s): Evans DA, Tariq M, Sujata B, McCann G, Sobki S. Source: Diabetes, Obesity & Metabolism. 2001 December; 3(6): 417-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11903413&dopt=Abstract
•
The effects of magnesium supplementation on exercise performance. Author(s): Finstad EW, Newhouse IJ, Lukaski HC, Mcauliffe JE, Stewart CR.
142 Magnesium
Source: Medicine and Science in Sports and Exercise. 2001 March; 33(3): 493-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11252079&dopt=Abstract •
The effects of magnesium supplementation on exercise performance. Author(s): Newhouse IJ, Finstad EW. Source: Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine. 2000 July; 10(3): 195-200. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10959930&dopt=Abstract
•
The influence of magnesium supplementation on magnesium and calcium concentrations in hair of children with magnesium shortage. Author(s): Kozielec T, Salacka A, Radomska K, Strecker D, Durska G. Source: Magnes Res. 2001 March; 14(1-2): 33-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11300620&dopt=Abstract
•
Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Author(s): Hughes R, Goldkorn A, Masoli M, Weatherall M, Burgess C, Beasley R. Source: Lancet. 2003 June 21; 361(9375): 2114-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12826434&dopt=Abstract
•
Zinc, magnesium and copper profiles in three experimental models of epilepsy. Author(s): Doretto MC, Simoes S, Paiva AM, Osorio-Neto E. Source: Brain Research. 2002 November 22; 956(1): 166-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12426059&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
Alternative Medicine 143
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to magnesium; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Alcohol Withdrawal Source: Healthnotes, Inc.; www.healthnotes.com Alcoholism Source: Integrative Medicine Communications; www.drkoop.com Alopecia Source: Integrative Medicine Communications; www.drkoop.com Amenorrhea Source: Integrative Medicine Communications; www.drkoop.com Angina Source: Healthnotes, Inc.; www.healthnotes.com Angina Source: Integrative Medicine Communications; www.drkoop.com Anorexia Nervosa Source: Integrative Medicine Communications; www.drkoop.com Anxiety Source: Healthnotes, Inc.; www.healthnotes.com Anxiety Source: Integrative Medicine Communications; www.drkoop.com Arteriosclerosis Source: Integrative Medicine Communications; www.drkoop.com Asthma Source: Healthnotes, Inc.; www.healthnotes.com Asthma Source: Integrative Medicine Communications; www.drkoop.com Asthma Source: Prima Communications, Inc.www.personalhealthzone.com
144 Magnesium
Atherosclerosis Source: Integrative Medicine Communications; www.drkoop.com Atherosclerosis and Heart Disease Prevention Source: Prima Communications, Inc.www.personalhealthzone.com Attention Deficit Disorder Source: Prima Communications, Inc.www.personalhealthzone.com Attention Deficit Hyperactivity Disorder Source: Integrative Medicine Communications; www.drkoop.com Autism Source: Healthnotes, Inc.; www.healthnotes.com Bone Cancer Source: Integrative Medicine Communications; www.drkoop.com Bone Loss Source: Integrative Medicine Communications; www.drkoop.com Candidiasis Source: Integrative Medicine Communications; www.drkoop.com Cardiac Arrhythmia Source: Healthnotes, Inc.; www.healthnotes.com Celiac Disease Source: Healthnotes, Inc.; www.healthnotes.com Chickenpox and Shingles Source: Integrative Medicine Communications; www.drkoop.com Chronic Fatigue Syndrome Source: Healthnotes, Inc.; www.healthnotes.com Chronic Fatigue Syndrome Source: Integrative Medicine Communications; www.drkoop.com Chronic Obstructive Pulmonary Disease Source: Healthnotes, Inc.; www.healthnotes.com Chronic Obstructive Pulmonary Disease Source: Integrative Medicine Communications; www.drkoop.com Cluster Headache Source: Healthnotes, Inc.; www.healthnotes.com Congestive Heart Failure Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 145
Congestive Heart Failure Source: Integrative Medicine Communications; www.drkoop.com Congestive Heart Failure Source: Prima Communications, Inc.www.personalhealthzone.com Constipation Source: Integrative Medicine Communications; www.drkoop.com Coronary Artery Disease Source: Integrative Medicine Communications; www.drkoop.com Crohn's Disease Source: Integrative Medicine Communications; www.drkoop.com Cutaneous Drug Reactions Source: Integrative Medicine Communications; www.drkoop.com Dementia Source: Integrative Medicine Communications; www.drkoop.com Depression Source: Integrative Medicine Communications; www.drkoop.com Diabetes Source: Healthnotes, Inc.; www.healthnotes.com Diabetes Source: Prima Communications, Inc.www.personalhealthzone.com Diabetes Mellitus Source: Integrative Medicine Communications; www.drkoop.com Diarrhea Source: Healthnotes, Inc.; www.healthnotes.com Dysmenorrhea Source: Healthnotes, Inc.; www.healthnotes.com Dysmenorrhea Source: Integrative Medicine Communications; www.drkoop.com Dysmenorrhea Alternative names: Painful Menstruation Source: Prima Communications, Inc.www.personalhealthzone.com Edema Source: Integrative Medicine Communications; www.drkoop.com Emphysema Source: Integrative Medicine Communications; www.drkoop.com
146 Magnesium
Endocarditis Source: Integrative Medicine Communications; www.drkoop.com Endometriosis Source: Integrative Medicine Communications; www.drkoop.com Epilepsy Source: Integrative Medicine Communications; www.drkoop.com Eye Disorders Source: Integrative Medicine Communications; www.drkoop.com Fatigue Source: Integrative Medicine Communications; www.drkoop.com Fibromyalgia Source: Healthnotes, Inc.; www.healthnotes.com Fibromyalgia Source: Integrative Medicine Communications; www.drkoop.com Food Poisoning Source: Integrative Medicine Communications; www.drkoop.com Gastroesophageal Reflux Disease Source: Healthnotes, Inc.; www.healthnotes.com Gestational Hypertension Source: Healthnotes, Inc.; www.healthnotes.com Glaucoma Source: Healthnotes, Inc.; www.healthnotes.com Glaucoma Source: Integrative Medicine Communications; www.drkoop.com Hair Disorders Source: Integrative Medicine Communications; www.drkoop.com Hair Loss Source: Integrative Medicine Communications; www.drkoop.com Hearing Loss Source: Integrative Medicine Communications; www.drkoop.com Heart Attack Source: Healthnotes, Inc.; www.healthnotes.com Heart Attack Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 147
Heat Exhaustion Source: Integrative Medicine Communications; www.drkoop.com Herpes Zoster and Varicella Viruses Source: Integrative Medicine Communications; www.drkoop.com High Blood Pressure Source: Integrative Medicine Communications; www.drkoop.com High Cholesterol Source: Prima Communications, Inc.www.personalhealthzone.com Hyperkalemia Source: Integrative Medicine Communications; www.drkoop.com Hypertension Source: Healthnotes, Inc.; www.healthnotes.com Hypertension Source: Integrative Medicine Communications; www.drkoop.com Hypertension Alternative names: High Blood Pressure Source: Prima Communications, Inc.www.personalhealthzone.com Hyperthyroidism Source: Integrative Medicine Communications; www.drkoop.com Hypochondriasis Source: Integrative Medicine Communications; www.drkoop.com Hypoglycemia Source: Healthnotes, Inc.; www.healthnotes.com Hypoglycemia Source: Integrative Medicine Communications; www.drkoop.com Hypoparathyroidism Source: Integrative Medicine Communications; www.drkoop.com Hypothyroidism Source: Integrative Medicine Communications; www.drkoop.com Inflammatory Bowel Disease Source: Integrative Medicine Communications; www.drkoop.com Insomnia Source: Healthnotes, Inc.; www.healthnotes.com Insomnia Source: Integrative Medicine Communications; www.drkoop.com
148 Magnesium
Insulin Resistance Syndrome Source: Healthnotes, Inc.; www.healthnotes.com Intermittent Claudication Source: Healthnotes, Inc.; www.healthnotes.com Irritability Source: Integrative Medicine Communications; www.drkoop.com Irritable Bowel Syndrome Source: Integrative Medicine Communications; www.drkoop.com Kidney Stones Source: Healthnotes, Inc.; www.healthnotes.com Kidney Stones Source: Integrative Medicine Communications; www.drkoop.com Low Back Pain Source: Integrative Medicine Communications; www.drkoop.com Low Blood Sugar Source: Integrative Medicine Communications; www.drkoop.com Lyme Disease Source: Integrative Medicine Communications; www.drkoop.com Malabsorption Source: Healthnotes, Inc.; www.healthnotes.com Male Infertility Source: Healthnotes, Inc.; www.healthnotes.com Menopause Source: Integrative Medicine Communications; www.drkoop.com Menstrual Disorders Source: Integrative Medicine Communications; www.drkoop.com Menstrual Pain Source: Integrative Medicine Communications; www.drkoop.com Migraine Headache Source: Integrative Medicine Communications; www.drkoop.com Migraine Headaches Source: Healthnotes, Inc.; www.healthnotes.com Migraine Headaches Source: Prima Communications, Inc.www.personalhealthzone.com
Alternative Medicine 149
Miscarriage Source: Integrative Medicine Communications; www.drkoop.com Mitral Valve Prolapse Source: Healthnotes, Inc.; www.healthnotes.com Multiple Sclerosis Source: Healthnotes, Inc.; www.healthnotes.com Multiple Sclerosis Source: Integrative Medicine Communications; www.drkoop.com Muscular Dystrophy Source: Integrative Medicine Communications; www.drkoop.com Myocardial Infarction Source: Integrative Medicine Communications; www.drkoop.com Osteoporosis Source: Healthnotes, Inc.; www.healthnotes.com Osteoporosis Source: Integrative Medicine Communications; www.drkoop.com Osteoporosis Source: Prima Communications, Inc.www.personalhealthzone.com Pancreatitis Source: Integrative Medicine Communications; www.drkoop.com Periodontal Disease Alternative names: Gum Disease Source: Prima Communications, Inc.www.personalhealthzone.com Peripheral Vascular Disease Source: Healthnotes, Inc.; www.healthnotes.com PMS Source: Integrative Medicine Communications; www.drkoop.com PMS Alternative names: Premenstrual Stress Syndrome Source: Prima Communications, Inc.www.personalhealthzone.com Preeclampsia Source: Healthnotes, Inc.; www.healthnotes.com Preeclampsia Source: Integrative Medicine Communications; www.drkoop.com Pregnancy Source: Integrative Medicine Communications; www.drkoop.com
150 Magnesium
Premenstrual Syndrome Source: Healthnotes, Inc.; www.healthnotes.com Premenstrual Syndrome Source: Integrative Medicine Communications; www.drkoop.com Proctitis Source: Integrative Medicine Communications; www.drkoop.com Prostate Cancer Source: Healthnotes, Inc.; www.healthnotes.com Prostatitis Source: Healthnotes, Inc.; www.healthnotes.com Psychological Conditions and Disorders Source: Integrative Medicine Communications; www.drkoop.com Pulmonary Edema Source: Integrative Medicine Communications; www.drkoop.com Pulmonary Hypertension Source: Integrative Medicine Communications; www.drkoop.com Raynaud's Disease Source: Healthnotes, Inc.; www.healthnotes.com Raynaud's Phenomenon Source: Integrative Medicine Communications; www.drkoop.com Rectal Inflammation Source: Integrative Medicine Communications; www.drkoop.com Retinopathy Source: Healthnotes, Inc.; www.healthnotes.com Rheumatoid Arthritis Source: Prima Communications, Inc.www.personalhealthzone.com Scleroderma Source: Integrative Medicine Communications; www.drkoop.com Seizure Disorders Source: Integrative Medicine Communications; www.drkoop.com Senile Dementia Source: Integrative Medicine Communications; www.drkoop.com Sexual Dysfunction Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 151
Shingles and Chickenpox Source: Integrative Medicine Communications; www.drkoop.com Sickle Cell Anemia Source: Healthnotes, Inc.; www.healthnotes.com Sleep Disorders Source: Integrative Medicine Communications; www.drkoop.com Spastic Colon Source: Integrative Medicine Communications; www.drkoop.com Spontaneous Abortion Source: Integrative Medicine Communications; www.drkoop.com Stress Source: Integrative Medicine Communications; www.drkoop.com Stroke Source: Healthnotes, Inc.; www.healthnotes.com Stroke Source: Integrative Medicine Communications; www.drkoop.com Tendinitis Source: Integrative Medicine Communications; www.drkoop.com Tension Headache Source: Integrative Medicine Communications; www.drkoop.com Thyroid Inflammation Source: Integrative Medicine Communications; www.drkoop.com Thyroiditis Source: Integrative Medicine Communications; www.drkoop.com TIAs Source: Integrative Medicine Communications; www.drkoop.com Transient Ischemic Attacks Source: Integrative Medicine Communications; www.drkoop.com Ulcerative Colitis Source: Integrative Medicine Communications; www.drkoop.com Ulcers Source: Prima Communications, Inc.www.personalhealthzone.com Urinary Incontinence Source: Integrative Medicine Communications; www.drkoop.com
152 Magnesium
Varicella and Herpes Zoster Viruses Source: Integrative Medicine Communications; www.drkoop.com Water Retention Source: Integrative Medicine Communications; www.drkoop.com Yeast Infection Source: Healthnotes, Inc.; www.healthnotes.com Yeast Infection Source: Integrative Medicine Communications; www.drkoop.com •
Alternative Therapy Schuessler Biochemic System of Medicine Alternative names: biochemic medicine biochemic system of medicine biochemic system of medicines tissue salts therapy Source: The Canoe version of A Dictionary of Alternative-Medicine Methods, by Priorities for Health editor Jack Raso, M.S., R.D. Hyperlink: http://www.canoe.ca/AltmedDictionary/s.html
•
Chinese Medicine Huashi Alternative names: Talc; Talcum Source: Chinese Materia Medica
•
Herbs and Supplements Advanced Formula Di-gel Tablets Source: Healthnotes, Inc.; www.healthnotes.com Albuterol Source: Healthnotes, Inc.; www.healthnotes.com Alendronate Source: Healthnotes, Inc.; www.healthnotes.com Aloe Alternative names: Aloe vera L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Aluminum Hydroxide Source: Healthnotes, Inc.; www.healthnotes.com Amiloride Source: Healthnotes, Inc.; www.healthnotes.com Aminoglycosides Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 153
Amphotericin B Source: Healthnotes, Inc.; www.healthnotes.com Antacids Source: Prima Communications, Inc.www.personalhealthzone.com Antacids/Acid Blockers Source: Healthnotes, Inc.; www.healthnotes.com Antituberculosis Agents Source: Integrative Medicine Communications; www.drkoop.com Arnica Alternative names: Arnica montana L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Athletic Performance Source: Healthnotes, Inc.; www.healthnotes.com Azithromycin Source: Healthnotes, Inc.; www.healthnotes.com Barbiturates Source: Integrative Medicine Communications; www.drkoop.com Betula Alternative names: Birch; Betula sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Bisphosphonate Derivatives Source: Integrative Medicine Communications; www.drkoop.com Bone-Building Formula Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,838,00.html Calciferol Source: Integrative Medicine Communications; www.drkoop.com Calcitrol Source: Integrative Medicine Communications; www.drkoop.com Cardiac Glycosides Source: Integrative Medicine Communications; www.drkoop.com Chemotherapy Source: Healthnotes, Inc.; www.healthnotes.com Cholecalciferol Source: Integrative Medicine Communications; www.drkoop.com
154 Magnesium
Cimetidine Source: Healthnotes, Inc.; www.healthnotes.com Ciprofloxacin Source: Healthnotes, Inc.; www.healthnotes.com Crataegus Alternative names: Hawthorn; Crataegus oxyacantha L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Cycloserine Source: Healthnotes, Inc.; www.healthnotes.com Cyclosporine Source: Healthnotes, Inc.; www.healthnotes.com Dandelion Alternative names: Taraxacum officinale Source: Healthnotes, Inc.; www.healthnotes.com Dandelion Source: Prima Communications, Inc.www.personalhealthzone.com Digoxin Source: Healthnotes, Inc.; www.healthnotes.com Digoxin Alternative names: Crystodigin, Lanoxicaps, Lanoxin Source: Prima Communications, Inc.www.personalhealthzone.com Docusate Source: Healthnotes, Inc.; www.healthnotes.com Doxycycline Source: Healthnotes, Inc.; www.healthnotes.com Dryopteris Alternative names: Male Fern; Dryopteris sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org EDTA Source: Integrative Medicine Communications; www.drkoop.com Epinephrine Source: Healthnotes, Inc.; www.healthnotes.com Eriodictyon Yerbasanta Alternative names: Yerba Santa; Eriodictyon californicum Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Erocalciferol Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 155
Erythromycin Source: Healthnotes, Inc.; www.healthnotes.com Estrogen Source: Prima Communications, Inc.www.personalhealthzone.com Estrogens (combined) Source: Healthnotes, Inc.; www.healthnotes.com Ethylenediaminetetraacetic Acid (EDTA) Source: Integrative Medicine Communications; www.drkoop.com Famotidine Source: Healthnotes, Inc.; www.healthnotes.com Felodipine Source: Healthnotes, Inc.; www.healthnotes.com Fentanyl Source: Healthnotes, Inc.; www.healthnotes.com Fiber Source: Healthnotes, Inc.; www.healthnotes.com Fluoroquinolones Source: Prima Communications, Inc.www.personalhealthzone.com Fructo-Oligosaccharides (FOS) and Other Oligosaccharides Source: Healthnotes, Inc.; www.healthnotes.com Gentamicin Source: Healthnotes, Inc.; www.healthnotes.com GLA (Gamma-Linolenic Acid) Source: Prima Communications, Inc.www.personalhealthzone.com Glimepiride Source: Healthnotes, Inc.; www.healthnotes.com Glipizide Source: Healthnotes, Inc.; www.healthnotes.com H2 Blockers Source: Prima Communications, Inc.www.personalhealthzone.com Histamine H2 Antagonists Source: Integrative Medicine Communications; www.drkoop.com Hydantoin Derivatives Source: Integrative Medicine Communications; www.drkoop.com
156 Magnesium
Hydroxychloroquine Source: Healthnotes, Inc.; www.healthnotes.com Isoniazid Source: Healthnotes, Inc.; www.healthnotes.com Kelp Source: Healthnotes, Inc.; www.healthnotes.com Levofloxacin Source: Healthnotes, Inc.; www.healthnotes.com Loop Diuretics Source: Healthnotes, Inc.; www.healthnotes.com Loop Diuretics Source: Integrative Medicine Communications; www.drkoop.com Loop Diuretics Source: Prima Communications, Inc.www.personalhealthzone.com Maalox Source: Healthnotes, Inc.; www.healthnotes.com Malic Acid Source: Healthnotes, Inc.; www.healthnotes.com Medroxyprogesterone Source: Healthnotes, Inc.; www.healthnotes.com Menopause Herbal Combination Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10096,00.html Metformin Source: Healthnotes, Inc.; www.healthnotes.com Minocycline Source: Healthnotes, Inc.; www.healthnotes.com Miscellaneous Preparations Source: Integrative Medicine Communications; www.drkoop.com Misoprostol Source: Healthnotes, Inc.; www.healthnotes.com Mixed Amphetamines Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 157
Musa Banana Alternative names: Plantain, Banana; Musa sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Mylanta Source: Healthnotes, Inc.; www.healthnotes.com Neomycin Source: Healthnotes, Inc.; www.healthnotes.com Nitrofurantoin Source: Healthnotes, Inc.; www.healthnotes.com Nitrofurantoin Alternative names: Furadantin, Macrobid, Macrodantin Source: Prima Communications, Inc.www.personalhealthzone.com Nizatidine Source: Healthnotes, Inc.; www.healthnotes.com Ofloxacin Source: Healthnotes, Inc.; www.healthnotes.com Oral Contraceptives Source: Healthnotes, Inc.; www.healthnotes.com Oral Contraceptives Source: Prima Communications, Inc.www.personalhealthzone.com Oral Corticosteroids Source: Healthnotes, Inc.; www.healthnotes.com Oral Hypoglycemics Source: Prima Communications, Inc.www.personalhealthzone.com Oregano/Wild Marjoram Alternative names: Origanum vulgare Source: Healthnotes, Inc.; www.healthnotes.com Passiflora Alternative names: Passion Flower; Passiflora alata L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Phosphorus Source: Integrative Medicine Communications; www.drkoop.com Piper Alternative names: Kava; Piper methysticum Forst.f Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
158 Magnesium
Plantago Psyllium Alternative names: Psyllium, Ispaghula; Plantago psyllium/ovata Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org PMS Herbal Combination Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,947,00.html Quinidine Source: Healthnotes, Inc.; www.healthnotes.com Ranitidine Source: Healthnotes, Inc.; www.healthnotes.com Red Clover Alternative names: Trifolium pratense , beebread, cow clover, cow grass, meadow clover, purple clover Source: Integrative Medicine Communications; www.drkoop.com Risedronate Source: Healthnotes, Inc.; www.healthnotes.com Sotalol Source: Healthnotes, Inc.; www.healthnotes.com Sulfamethoxazole Source: Healthnotes, Inc.; www.healthnotes.com Tempo Tablets Source: Healthnotes, Inc.; www.healthnotes.com Tetracycline Source: Healthnotes, Inc.; www.healthnotes.com Tetracyclines Source: Healthnotes, Inc.; www.healthnotes.com Tetracyclines Source: Prima Communications, Inc.www.personalhealthzone.com Theophylline/aminophylline Source: Healthnotes, Inc.; www.healthnotes.com Thiazide Diuretics Source: Healthnotes, Inc.; www.healthnotes.com Thiazide Diuretics Source: Integrative Medicine Communications; www.drkoop.com Thiazide Diuretics Source: Prima Communications, Inc.www.personalhealthzone.com
Alternative Medicine 159
Tobramycin Source: Healthnotes, Inc.; www.healthnotes.com Trace Minerals Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10061,00.html Triamterene Source: Healthnotes, Inc.; www.healthnotes.com Trimethoprim Source: Healthnotes, Inc.; www.healthnotes.com Vasodilators Source: Integrative Medicine Communications; www.drkoop.com Warfarin Source: Healthnotes, Inc.; www.healthnotes.com Women's Herbal Combination Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10100,00.html Zizyphus Alternative names: Jujube; Ziziphus sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
161
CHAPTER 4. DISSERTATIONS ON MAGNESIUM Overview In this chapter, we will give you a bibliography on recent dissertations relating to magnesium. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “magnesium” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on magnesium, we have not necessarily excluded nonmedical dissertations in this bibliography.
Dissertations on Magnesium ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to magnesium. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
A Comparison of Tld Dosimeters: Lithium Fluoride:magnesium, Titanium and Lithium Fluoride:magnesium, Copper, Phosphate, for Measurement of Radiation Therapy Doses by Glennie, Gilbert Douglas; PhD from University of Virginia, 2003, 272 pages http://wwwlib.umi.com/dissertations/fullcit/3083065
•
A Kinetic Study of Beta Silicon Nitride Grown in Yttrium-Magnesium-AluminumSilicon-Oxygen-Nitrogen Liquids by Wang, Lingling; PhD from University of Michigan, 2002, 212 pages http://wwwlib.umi.com/dissertations/fullcit/3058073
•
A Study of the Kinetic Mechanism and Affinity Chromatographic Purification of Sadenosyl-l-methionine Magnesium Protoporphyrin Methyltransferase from Plant, Algal and Bacterial Sources by Hinchigeri, Shivayogeppa B; PhD from Simon Fraser University (Canada), 1983 http://wwwlib.umi.com/dissertations/fullcit/NK58795
162 Magnesium
•
Ab Initio Studies on the Size Dependence Effects of Solvation Structure and Intracluster Reaction on Aluminum Ion(water), Magnesium Ion(water) and Protonated Methanol Cluster Ions by Siu, Chi-kit; PhD from Chinese University of Hong Kong (People's Republic of China), 2002, 213 pages http://wwwlib.umi.com/dissertations/fullcit/3077695
•
Amidinate Complexes of Magnesium and First Row Transition Metals: Source Compounds for Semiconductor Films by Sadique, Azwana Rizan; PhD from Wayne State University, 2003, 144 pages http://wwwlib.umi.com/dissertations/fullcit/3086469
•
An Investigation of the Discontinuous Coarsening Reaction Taking Place in the Leadcadmium, Zinc-cadmium and the Copper-magnesium-copper Lamellar Eutectic Materials by Kaya, Mustafa; PhD from Queen's University at Kingston (Canada), 1988 http://wwwlib.umi.com/dissertations/fullcit/NL42299
•
An Investigation of Water Hardness, Calcium and Magnesium in Relation to Mortality in Ontario by Allen, Hugh A. J; PhD from University of Waterloo (Canada), 1972 http://wwwlib.umi.com/dissertations/fullcit/NK12898
•
Cadmium-induced Toxicity, Bioaccumulation, Structural Changes and Ionic Influences and Their Amelioration by Calcium and Magnesium in Embryos and Alevins of Atlantic Salmon and Brook Trout (salmonidae) by Rombough, Peter John; PhD from Dalhousie University (Canada), 1980 http://wwwlib.umi.com/dissertations/fullcit/NK48239
•
Calcium(2+) and Magnesium(2+) Binding Characteristics of Chlamydomonas Centrin Domains by Ocana Rivera, Wanda; MS from University of Puerto Rico, Mayaguez (Puerto Rico), 2003, 79 pages http://wwwlib.umi.com/dissertations/fullcit/1413172
•
Cavity Characteristics in a Magnesium Alloy by Matsumura, Terumi; MS from University of Southern California, 2002, 53 pages http://wwwlib.umi.com/dissertations/fullcit/1411798
•
Chemisorption and Thermal Decomposition of Alcohols on Magnesium Oxide and Tungsten Oxide a Study by Solid-state Nuclear Magnetic Resonance Spectroscopy by Liang, Septimus H. C; PhD from Simon Fraser University (Canada), 1985 http://wwwlib.umi.com/dissertations/fullcit/NL30856
•
Computer Simulation Study of the Positive Fluoride Center in Magnesium Oxide by Pandey, Ravindra; PhD from The University of Manitoba (Canada), 1988 http://wwwlib.umi.com/dissertations/fullcit/NL44156
•
Computer Simulations of the Structure, Stability and Phase Transitions of Diatomic Molecules Physisorbed on Ionic Surfaces: the Carbon Monoxide/magnesium Oxide(001), Nitrogen/magnesium Oxide(001) and Nitrogen/sodium Chloride(001) Systems by Sallabi, Abdulwahab K.; PhD from Concordia University (Canada), 2002, 194 pages http://wwwlib.umi.com/dissertations/fullcit/NQ68200
•
Deformation Behaviour in Single and Polycrystalline Magnesium Oxide by Sinha, Madhav Narain; PhD from The University of Manitoba (Canada), 1974 http://wwwlib.umi.com/dissertations/fullcit/NK20442
Dissertations 163
•
Desulphurization Kinetics of Molten Iron by Magnesium Vapour by Irons, Gordon A; PhD from McGill University (Canada), 1978 http://wwwlib.umi.com/dissertations/fullcit/NK39699
•
Development of Aluminum-silicon-magnesium Alloys for Semi-solid Processing and Silicon Spheroidization Treatment (sst) for Aluminum-silicon Cast Alloys by Ogris, Erhard; Drsctech from Eidgenoessische Technische Hochschule Zuerich (Switzerland), 2002, 138 pages http://wwwlib.umi.com/dissertations/fullcit/f749569
•
Doping Experiments on Low-dimensional Oxides and a Search for Unusual Magnetic Properties of Magnesium Aluminum Boride by Hill, Julienne Marie; PhD from Iowa State University, 2002, 134 pages http://wwwlib.umi.com/dissertations/fullcit/3073453
•
Dynamic Compression of Minerals in the Magnesium Oxide-iron Oxide-silicon Dioxide System by Akins, Joseph A.; PhD from California Institute of Technology, 2003, 94 pages http://wwwlib.umi.com/dissertations/fullcit/3093471
•
Effect of Iron-intermetallics and Porosity on Tensile and Impact Properties of Aluminum-silicon-copper and Aluminum-silicon-magnesium Cast Alloys by Ma, Zheyuan; PhD from Universite Du Quebec a Chicoutimi (Canada), 2002, 281 pages http://wwwlib.umi.com/dissertations/fullcit/NQ76012
•
Effects of Strontium on the Oxidation of Molten Aluminum Alloys Containing Silicon and Magnesium by Yuen, Pui Kei; Meng from McGill University (Canada), 2002, 91 pages http://wwwlib.umi.com/dissertations/fullcit/MQ79107
•
Effet Du Magnesium, Des Traitements Thermiques Et De La Porosite Sur Les Proprietes Mecaniques De Traction Et De Fatigue De L'alliage Sous Pression A380.1 (french Text) by Morin, Sebastien; MSCA from Universite Du Quebec a Chicoutimi (Canada), 2002, 222 pages http://wwwlib.umi.com/dissertations/fullcit/MQ73375
•
Elaboration Et Caracterisation Des Platres Mousses Utilises Pour Le Moulage Des Alliages De Magnesium (french Text) by Belanger, Jean-Francois; MSC from Universite Laval (Canada), 2002, 104 pages http://wwwlib.umi.com/dissertations/fullcit/MQ76307
•
Electrical and Magnetic Properties of Several Ruthenates and Superconductivity in Magnesium Boride and MGCNI(3) by He, Tao; PhD from Princeton University, 2002, 133 pages http://wwwlib.umi.com/dissertations/fullcit/3039699
•
Electrochemical Determination of Thermodynamic Properties of Magnesium Cell Electrolyte the System Mgcl#1bb2#1bs-nacl-cacl#1bb2#1bs by Karakaya, Ishak; PhD from McGill University (Canada), 1985 http://wwwlib.umi.com/dissertations/fullcit/NL20892
•
Electrofission of Magnesium-24 by Chung, Archie Hsiao-Chuan; PhD from University of Toronto (Canada), 1973 http://wwwlib.umi.com/dissertations/fullcit/NK25464
164 Magnesium
•
Electron Nuclear Double Resonance of Chromium(3+) and Manganese(2+) in a Magnesium Oxide Lattice by Dyer, Gleen Lionel; AdvDeg from McGill University (Canada), 1967 http://wwwlib.umi.com/dissertations/fullcit/NK01308
•
Electrooptic Modulator Based on Thin Film Barium Titanium Oxide on Magnesium Oxide by Kim, Seong-Soo; PhD from Northwestern University, 2003, 83 pages http://wwwlib.umi.com/dissertations/fullcit/3087932
•
Gas-phase Ethylene/1-hexene Copolymerization over Magnesium Chloridesupported Ziegler-natta Catalysts by Liu, Wei; PhD from University of Alberta (Canada), 2002, 132 pages http://wwwlib.umi.com/dissertations/fullcit/NQ68599
•
Growth of Lead Magnesium Niobate-lead Titanate Single Crystals by Seeded Polycrystal Conversion by Scotch, Adam Matthew; PhD from Lehigh University, 2003, 124 pages http://wwwlib.umi.com/dissertations/fullcit/3073992
•
Hydrogen Storage in Encapsulated Magnesium Nickel Alloys Prepared by Intergranular Diffusion by Addepalli, Pratima V.; MSE from The University of Alabama in Huntsville, 2002, 130 pages http://wwwlib.umi.com/dissertations/fullcit/1410520
•
I. Chiral Mixed Phosphorus/sulfur Ligands: Structure and Application to Rhodiumcatalyzed Ketone Hydrosilylation. Ii. Development of a Magnesium-catalyzed Direct Aldol Reaction of Chiral N-acyloxazolidinones by Tedrow, Jason Scot; PhD from Harvard University, 2002, 388 pages http://wwwlib.umi.com/dissertations/fullcit/3038490
•
Magnesium(ii) Ion Interaction with Biological Ligands by Sanchez, Elizabeth Ruth; PhD from Arizona State University, 2003, 149 pages http://wwwlib.umi.com/dissertations/fullcit/3084676
•
Manganese Toxicity in Marigold As Affected by Calcium and Magnesium by Eaton, Touria El-jaoual; PhD from University of Massachusetts Amherst, 2002, 311 pages http://wwwlib.umi.com/dissertations/fullcit/3056221
•
Mechanism of Magnesium Oxide Chlorination by Hydrogen Chloride in a Molten Salt by Lamy, Martin; Meng from McGill University (Canada), 2002, 81 pages http://wwwlib.umi.com/dissertations/fullcit/MQ79080
•
Metal-organic Chemical Vapor Deposition of Cerium Oxide, Gallium-indium-oxide, and Magnesium Oxide Thin Films: Precursor Design, Film Growth, and Film Characterization by Edleman, Nikki Lynn; PhD from Northwestern University, 2002, 147 pages http://wwwlib.umi.com/dissertations/fullcit/3050514
•
Metalorganic Chemical Vapor Growth and Characterizations of Epitaxial Magnesium Zinc Oxide Films on R-aluminum Oxide Substrates by Muthukumar, Sriram; PhD from Rutgers the State University of New Jersey - New Brunswick, 2003, 145 pages http://wwwlib.umi.com/dissertations/fullcit/3092975
•
Metamorphic Reactions in the System Potassium Oxide-magnesium Oxide-aluminum Oxide-silicon Dioxide-water at Water Pressures to 10 Kilobars by Bird, Gordon Winslow; PhD from University of Toronto (Canada), 1971 http://wwwlib.umi.com/dissertations/fullcit/NK11541
Dissertations 165
•
Methods Variability for Magnesium Determination in a Biological Standard and Other Biological Materials by Meyerhof, Thomas Paul; PhD from McMaster University (Canada), 1974 http://wwwlib.umi.com/dissertations/fullcit/NK22644
•
Micropuncture Study of Magnesium Transport in the Proximal and Distal Tubule of the Dog Kidney with Evidence for Magnesium Secretion by Evanson, Raphael Ledwood; AdvDeg from Mcgill University (Canada), 1970 http://wwwlib.umi.com/dissertations/fullcit/NK09712
•
Microstructural Evolution and Strengthening Mechanisms in Aluminum-scandium and Aluminum-magnesium-scandium Alloys by Marquis, Emmanuelle Anne; PhD from Northwestern University, 2002, 223 pages http://wwwlib.umi.com/dissertations/fullcit/3071679
•
Mould Coatings for Magnesium Permanent Mould Casting by Lockie, Alison Fiona; MSC(Eng) from Queen's University at Kingston (Canada), 2002, 110 pages http://wwwlib.umi.com/dissertations/fullcit/MQ69312
•
Multiphoton and Above-threshold Ionization of Magnesium Using High-intensity Titanium-sapphire Laser Pulses by Gillen, Glen David; PhD from The Ohio State University, 2002, 152 pages http://wwwlib.umi.com/dissertations/fullcit/3059251
•
Pathogenesis of Hypocalcemia in Magnesium Depletion by Suh, Se Mo; PhD from University of Toronto (Canada), 1972 http://wwwlib.umi.com/dissertations/fullcit/NK13076
•
Photophysics and Photochemistry of Matrix-isolated Atomic Magnesium in Inert and Reactive Low-temperature Solids by Mccaffrey, John G; PhD from University of Toronto (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL39213
•
Positron Annihilation in Single Crystals of Copper, Zinc and Magnesium by Senicki, Eugene; PhD from The University of Manitoba (Canada), 1972 http://wwwlib.umi.com/dissertations/fullcit/NK10991
•
Potential Applications of Magnesium Hydroxide for Municipal Wastewater Treatment: Sludge Digestion Enhancement and Nutrient Removal by Wu, Qingzhong; PhD from University of Cincinnati, 2002, 144 pages http://wwwlib.umi.com/dissertations/fullcit/3053593
•
Process Development for the Recovery of High Purity Magnesia and Magnesium Salt Solutions from Northern Ontario Magnesites by Nanayakkara-Tantirige, Kanthi Nimalka; PhD from University of Toronto (Canada), 1990 http://wwwlib.umi.com/dissertations/fullcit/NL56941
•
Raman and Infrared Studies of Silver(+), Strontium(2+), Magnesium(2+), and Beryllium(2+) by Chang, Tien-chung Godfrey; PhD from University of Waterloo (Canada), 1972 http://wwwlib.umi.com/dissertations/fullcit/NK10909
•
Raman Study of Relaxor Ferroelectrics Potassium Tantalum Niobium Oxide, Lead Magnesium Niobate and Lead Zinc Niobate by Svitelskiy, Oleksiy Vasyl; PhD from Lehigh University, 2003, 187 pages http://wwwlib.umi.com/dissertations/fullcit/3073963
166 Magnesium
•
Reaction Products of Orthophosphates in Soils Containing Varying Amounts of Calcium and Magnesium by Racz, Geza; AdvDeg from The University of Manitoba (Canada), 1966 http://wwwlib.umi.com/dissertations/fullcit/NK00713
•
Single Crystal Electrical Resistivities in Cadmium and Cadmium-magnesium Alloys by Stackhouse, Brian Jeffrey; PhD from University of Alberta (Canada), 1977 http://wwwlib.umi.com/dissertations/fullcit/NK34487
•
Solid Solution Strengthening of Magnesium by Akhtar, A; AdvDeg from The University of British Columbia (Canada), 1968 http://wwwlib.umi.com/dissertations/fullcit/NK03027
•
Solubilities of Iron, Aluminum, Magnesium and Nickel in Sulfuric Acid Media between 230 Degrees and 270 Degrees C by Zhu, Xuetang; MASC from University of Toronto (Canada), 2003, 86 pages http://wwwlib.umi.com/dissertations/fullcit/MQ78506
•
Structure and Mechanism of Iron and Magnesium Chelatases: at the Hemechlorophyll Branch-point by Fodje, Michel Nkwenti; PhD from Lunds Universitet (Sweden), 2003, 130 pages http://wwwlib.umi.com/dissertations/fullcit/f50497
•
Studies of the Binding Function for a Soil Organic Acid with Copper and Magnesium by Lee, Stephen L. F; PhD from Carleton University (Canada), 1982 http://wwwlib.umi.com/dissertations/fullcit/NK55615
•
Studies on the Myosin Nucleoside Triphosphatase and the Actin-myosin Interaction under the Influence of Calcium and Magnesium at Low Concentrations of Potassium Chloride by Sugden, Edward Arthur; AdvDeg from University of Alberta (Canada), 1971 http://wwwlib.umi.com/dissertations/fullcit/NK08127
•
Study of (a) the Ge(p,d) and (p,t) Reactions; (b) the Magnesium-26(p,t)magnesium-24 Reaction by Fournier, Rodolphe; PhD from University of Ottawa (Canada), 1972 http://wwwlib.umi.com/dissertations/fullcit/NK11090
•
Study of the Interactions of Magnesium(+) and Nickel(+) with Polar Molecules Using Laser Vaporization-ionization High-pressure Mass Spectrometry by Herring, Angelina Maria; MS from Virginia Commonwealth University, 2003, 121 pages http://wwwlib.umi.com/dissertations/fullcit/1412783
•
Synaptosomal Doubly Charged Positive Calcium Ion + Doubly Charged Positive Magnesium Ion-atpase from the Brain of the Bertha Armyworm Mamestra Configurata Preparation, Properties and the Effect of Insecticides by Luo, Ma; PhD from The University of Manitoba (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL37389
•
Synchrotron X-ray Scattering Studies of Local Fluctuations in Lead Magnesium Niobate Relaxor Ferroelectrics by Tkachuk, Andrei; PhD from University of Illinois at Urbana-Champaign, 2002, 159 pages http://wwwlib.umi.com/dissertations/fullcit/3070458
•
Synthesis and Characterisation of Basic Magnesium Carbonate by Botha, Adele; DPhil from University of Pretoria (South Africa), 2002 http://wwwlib.umi.com/dissertations/fullcit/f513201
Dissertations 167
•
Synthesis, Structure and Magnetic Properties of Low Dimensional Spin Systems in the 3d Transition Metal Oxides and Superconductivity in Magnesium Borate by Rogado, Nyrissa S.; PhD from Princeton University, 2003, 142 pages http://wwwlib.umi.com/dissertations/fullcit/3089880
•
Textures, Microstructures, Anisotropy and Formability of Aluminum-manganesemagnesium and Aluminum-magnesium Alloys by Liu, Jiantao; PhD from University of Kentucky, 2003, 275 pages http://wwwlib.umi.com/dissertations/fullcit/3092317
•
The Distribution of Magnesium and Iron between Olivine and Spinel at 1300 Degrees C by Jamieson, Heather Edith; PhD from Queen's University at Kingston (Canada), 1982 http://wwwlib.umi.com/dissertations/fullcit/NK55949
•
The Effect of Alloying and Cold Rolling on the Texture and Mechanical Properties of Magnesium and Magnesium-lithium Alloys by Wootton, George Claude; AdvDeg from The University of British Columbia (Canada), 1967 http://wwwlib.umi.com/dissertations/fullcit/NK01827
•
The Effects of Potassium and Magnesium Salts of Aspartic Acid on Strength, Endurance, and Body Composition of Male College-Age Advanced Weightlifters by Bowers, Charles Jefferson, EDD from The University of Mississippi, 1981, 151 pages http://wwwlib.umi.com/dissertations/fullcit/8128090
•
The Effects of Vitamin D Metabolites on the Renal Handling of Calcium, Magnesium and Phosphate in the Hamster by Burnatowska, Maria A; PhD from Mcgill University (Canada), 1979 http://wwwlib.umi.com/dissertations/fullcit/NK50402
•
The Fusion Welding of Magnesium Alloys by Laser Beams and Flux-assisted Gas Tungsten Electric Arcs by Marya, Manuel Paul; PhD from Colorado School of Mines, 2002 http://wwwlib.umi.com/dissertations/fullcit/f769681
•
The Growth of Bones in the Rat As Influenced by Magnesium Deficiency and Hormonal Variations by Bogoroch, Rita; PhD from University of Ottawa (Canada), 1972 http://wwwlib.umi.com/dissertations/fullcit/NK14170
•
The High-temperature Phase Chemistry and Thermochemistry of the Lead Magnesium Niobium Titanium Oxide System by Mangham, Robert Ingvar; PhD from Arizona State University, 2003, 236 pages http://wwwlib.umi.com/dissertations/fullcit/3084659
•
The New Technique of Selective Sublimation and Its Application to the Study of the Cadmium - Copper-cadmium(3) and Magnesium - Magnesium(2)-silicide Eutectics by Haour, Georges; PhD from University of Toronto (Canada), 1974 http://wwwlib.umi.com/dissertations/fullcit/NK27869
•
The Removal of Magnesium and Silicon from Aluminum-based Melts by Stubina, Nathan M; PhD from University of Toronto (Canada), 1988 http://wwwlib.umi.com/dissertations/fullcit/NL43422
•
The Roles of Lithium(+), Magnesium(2+), and Sodium Ions in Bipolar Disorder and Essential Hypertension: a Multinuclear Nmr and Fluorescence Study by Williams, Nicole Marie; PhD from Loyola University of Chicago, 2002, 152 pages http://wwwlib.umi.com/dissertations/fullcit/3056455
168 Magnesium
•
The Shock Production and Quantitative Spectroscopy of the Magnesium Hydride Doublet-a Pi - Doublet-x-sigma + Delta(v)=0 Sequence by McGregor, Andrew Thomas; PhD from The University of Western Ontario (Canada), 1975 http://wwwlib.umi.com/dissertations/fullcit/NK24606
•
The Threshold Behavior of Electron-atom Superelastic Scattering in Magnesium by Baynard, Tahllee; PhD from The University of Chicago, 2002, 138 pages http://wwwlib.umi.com/dissertations/fullcit/3070155
•
The Transfer of Alkyl Groups from Boron to Magnesium: Aspects of Theory and Experiment by Threlfall, Clinton Armstrong; PhD from University of California, San Diego and San Diego State University, 2002, 134 pages http://wwwlib.umi.com/dissertations/fullcit/3061749
•
The Uptake of Sulphur, Calcium, and Magnesium and Their Distribution in Phaseolus Vulgaris L. As Affected by Cyclohexanecarboxylic Acid by Peirson, David R; PhD from The University of British Columbia (Canada), 1972 http://wwwlib.umi.com/dissertations/fullcit/NK13251
•
Theory of Elastic Strain Fields, Chemical Substitutions, and Crystal Lattice Defects in 123-structure-cuprates and Magnesium Borate Superconductors by Su, Haibin; PhD from State University of New York at Stony Brook, 2002, 186 pages http://wwwlib.umi.com/dissertations/fullcit/3088069
•
Thermodynamics of Magnesium in Liquid Nickel Solutions by Samuelsson, Eva; PhD from The University of British Columbia (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL44657
•
Two Topics in Biological Nmr: Hydrogen Nmr Studies of Adriamycin and Magnesium-25 Nmr Studies of Magnesium(II) Binding to Low Molecular Weight Ligands by McLennan, Ian J; PhD from University of Guelph (Canada), 1988 http://wwwlib.umi.com/dissertations/fullcit/NL41236
•
Visual, Microscopic, and Colorimetric Examination of Calcium and Magnesium Levels in Parenteral Nutrition Solutions Containing 6 Percent Amino Acids, 25 Percent Dextrose, and 65 Mmol of Phosphorus/l by Lorenz, Kimberly Lynn; MS from Rush University, 2003, 99 pages http://wwwlib.umi.com/dissertations/fullcit/1411748
•
Wide Bandgap Magnesium Zinc Oxide Semiconducting Thin Films and Applications to Solar/visible Blind Ultraviolet Photodetectors by Yang, Wei; PhD from University of Maryland College Park, 2002, 260 pages http://wwwlib.umi.com/dissertations/fullcit/3080284
•
Zinc Oxide and Magnesium Zinc Oxide-based Multilayer Structures for Tunable Surface Acoustic Wave Devices by Emanetoglu, Nuri William; PhD from Rutgers the State University of New Jersey - New Brunswick, 2003, 139 pages http://wwwlib.umi.com/dissertations/fullcit/3092934
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
169
CHAPTER 5. CLINICAL TRIALS AND MAGNESIUM Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning magnesium.
Recent Trials on Magnesium The following is a list of recent trials dedicated to magnesium.8 Further information on a trial is available at the Web site indicated. •
Magnesium and Asthma - Clinical Trials Condition(s): Asthma Study Status: This study is currently recruiting patients. Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) Purpose - Excerpt: Asthma currently affects an estimated 15 million Americans. A number of studies have found an association between low dietary magnesium (Mg) intake and increased asthma incidence and severity of symptoms. However, clinical intervention trials are necessary to directly assess whether there is a true protective or preventative causal relationship between low Mg and asthma. In our study, we will assess the effects of 6 1/2 months of oral Mg supplements or placebo on clinical markers of asthma control, indirect biomarkers of inflammation, bronchial hyperresponsiveness, and indices of oxidative defense and damage in subjects with mild to moderate persistent asthma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00029510
8
These are listed at www.ClinicalTrials.gov.
170 Magnesium
•
Magnesium Effects in Apheresis Condition(s): Healthy Study Status: This study is currently recruiting patients. Sponsor(s): Warren G Magnuson Clinical Center (CC) Purpose - Excerpt: This study will determine whether magnesium replacement during apheresis can decrease side effects that donors commonly experience. Apheresis is a method of collecting large numbers of certain blood cells, such as white cells, stem cells, or platelets. In this procedure, whole blood is collected through a needle in an arm vein, similar to donating blood. The blood is separated into its components by centrifugation (spinning), the required cells are extracted, and the rest of the blood is returned to the body, either through the same needle or through another needle in the other arm. When healthy people donate cells by apheresis, a blood thinner called citrate is added to prevent the blood from clotting in the apheresis machine. Citrate works by reducing calcium in the blood. When the blood is returned to the donor, citrate from the machine is also returned, lowering the donor's calcium levels. As a result, donors often feel tingling around the mouth, hands, and feet. Some of these symptoms can be prevented by giving calcium intravenously (through a vein) during the procedure. Even with the added calcium, however, some donors still have symptoms. Magnesium levels are also lowered by citrate, but it is not known if this causes symptoms. This study will examine whether the decrease in magnesium levels also contributes to the side effects of apheresis and whether magnesium replacement can reduce these symptoms. Healthy apheresis donors 18 years of age or older who are enrolled in NIH protocols may participate in this study. Donors will undergo the apheresis procedures required by the NIH protocol they are enrolled in. Throughout the procedure, they will receive an intravenous infusion of a salt solution that may or may not contain magnesium. Blood samples of 5 milliliters (1 teaspoon) each will be taken from the apheresis machine at the beginning and end of the procedure and at 30- to 60-minute intervals during the procedure. No more than 50 ml (3 tablespoons) will be taken during any single apheresis. The last sample will be drawn 60 minutes after completion of the apheresis. In addition, donors will: - Provide a urine sample at the beginning and end of each apheresis procedure. - Donate an additional urine sample and an additional 5 ml blood sample the morning after apheresis - Describe any symptoms experienced during apheresis to the apheresis nurse Phase(s): Phase III; MEDLINEplus consumer health information Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00040235
•
Magnesium Sulfate For Brain Injury Condition(s): Brain Injuries; Head Injury; Brain Concussion Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: The purpose of the study is to determine whether magnesium sulfate, given within 8 hours of a moderate or severe traumatic brain injury improves survival, decreases the number of people developing seizures, improves the survivors' mental and psychological functioning, including the ability to return to daily life, live independently, and return to work or school.
Clinical Trials 171
Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00004730 •
The Effect of Oral Magnesium Pidolate on How Often Painful Crises Happens in Patients with Hemoglobin SC Disease Condition(s): Hemoglobin SC Disease Study Status: This study is currently recruiting patients. Sponsor(s): Baylor College of Medicine; Texas Children's Hospital; Children's Hospital Boston Purpose - Excerpt: The purpose of this study is to find out whether treatment with magnesium pidolate will increase the amount of water in the red blood cell and result in fewer painful crises in patients with hemoglobin SC disease while not causing diarrhea. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00040456
•
Magnesium Sulfate to Prevent Brain Injury in Premature Infants Condition(s): Brain Injuries; Cerebral Palsy Study Status: This study is no longer recruiting patients. Sponsor(s): National Institute of Child Health and Human Development (NICHD) Purpose - Excerpt: Premature infants are at risk for acute brain injuries and long-term developmental problems such as cerebral palsy (CP). Research suggests that high levels of magnesium at and around the time of birth may decrease the risk of brain injuries. This study will evaluate the effects of giving magnesium to premature infants. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00065949
•
Adverse Events with Magnesium Sulfate Condition(s): Lung Diseases Study Status: This study is completed. Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) Purpose - Excerpt: To investigate in pregnant women the adverse pulmonary effects of magnesium sulfate (MgSO4), a commonly used drug for tocolysis or arrest of labor. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00005448
172 Magnesium
•
Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial Condition(s): Cerebrovascular Accident Study Status: This study is not yet open for patient recruitment. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: The goal of this study is to evaluate the effectiveness and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00059332
•
Magnesium in Coronaries (MAGIC) Condition(s): Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia Study Status: This study is completed. Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) Purpose - Excerpt: To determine whether early intravenous magnesium treatment of patients with suspected acute myocardial infarction reduces mortality. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000610
•
Randomized Study of Nimodipine versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients with Severe Preeclampsia Condition(s): Pre-Eclampsia Study Status: This study is completed. Sponsor(s): FDA Office of Orphan Products Development; University of Utah Purpose - Excerpt: Objectives: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00004399
•
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Condition(s): Cytomegalovirus Infections; HIV Infections; Hypocalcemia Study Status: This study is completed. Sponsor(s): Astra USA
Clinical Trials 173
Purpose - Excerpt: To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium, phosphate, and foscarnet. Phase(s): Phase IV Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002146 •
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease Condition(s): Alagille Syndrome; Cholestasis; Biliary Atresia Study Status: This study is completed. Sponsor(s): National Center for Research Resources (NCRR); Children's Hospital Medical Center - Cincinnati Purpose - Excerpt: Objectives: I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00007033
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “magnesium” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
174 Magnesium
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
175
CHAPTER 6. PATENTS ON MAGNESIUM Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “magnesium” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on magnesium, we have not necessarily excluded nonmedical patents in this bibliography.
Patents on Magnesium By performing a patent search focusing on magnesium, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
176 Magnesium
example of the type of information that you can expect to obtain from a patent search on magnesium: •
Aluminum organic electrolytes and method for electrolytic coating with aluminum or aluminum-magnesium-alloys Inventor(s): Lehmkuhl; Herbert (Mulheim an der Ruhr, DE), Mehler; Klaus-Dieter (Mulheim an der Ruhr, DE), Reinhold; Bertram (Ingolstadt, DE) Assignee(s): Studiengesellschaft Kohle mbH (Mulheim an der Ruhr, DE) Patent Number: 6,652,730 Date filed: May 30, 2001 Abstract: Organoaluminum electrolytes and methods for the coating of electrically conductive materials with aluminum or aluminum-magnesium alloys, essentially and preferably consisting of Na[Et.sub.3 Al--H--AlEt.sub.3 ] for aluminum coating, or of either K[AlEt.sub.4 ] or Na[Et.sub.3 Al--H--AlEt.sub.3 ] and Na[AlEt.sub.4 ] and trialkylaluminum for alloy coating using solutions of these electrolytes in liquid aromatic hydrocarbons or mixtures thereof with aliphatic mono- or polybasic ethers, such as dimethoxyethane, and using soluble anodes of aluminum or of aluminum and magnesium, or of aluminum-magnesium alloy. Excerpt(s): The present invention relates to organoaluminum electrolytes suitable for the electrolytic deposition of aluminum or aluminum-magnesium alloys on electrically conductive materials, and a method for this using soluble aluminum anodes or soluble aluminum and magnesium anodes or an anode made of an aluminum-magnesium alloy. Organoaluminum complex compounds have been used for a long time for the electrolytic deposition of aluminum (dissertation H. Lehmkuhl, TH Aachen 1954, German Patent 1047450; K. Ziegler, H. Lehmkuhl, Z. anorg. allg. Chemie 283 (1956) 414; German Patent 1056377; H. Lehmkuhl, Chem. Ing. Tech. 36 (1964) 616; EP-A-0084816; H. Lehmkuhl, K. Mehler and U. Landau in Adv. in electro-chem. Science and Engineering (Eds. H. Gerischer, C. W. Tobias, Vol. 3, Weinheim 1994). As suitable electrolytes, there have been proposed complex compounds of general type MX2AlR.sub.3, which are employed either as molten salts or in the form of their solutions in liquid aromatic hydrocarbons. MX may be either alkali metal (Na, K, Rb, Cs) or onium halides, preferably fluorides. R represent alkyl residues with preferably one, two or four carbon atoms. The interest in electrolytic coatings of metal workpieces with aluminum has greatly increased due to the excellent corrosion protection by the aluminum layers and their ecological safety. Therefore, the galvanic coating with organoaluminum electrolytes which work at moderately elevated temperatures of between 60 and 150.degree. C. and in closed systems is of great technical importance. Web site: http://www.delphion.com/details?pn=US06652730__
•
Article for use in a semiconductor processing chamber and method of fabricating same Inventor(s): Lingampalli; Ramkishan Rao (Fremont, CA) Assignee(s): Applied Materials, Inc. (Santa Clara, CA) Patent Number: 6,632,325 Date filed: February 7, 2002
Patents 177
Abstract: An article having a protective coating for use in semiconductor applications and method for making the same is provided. In one embodiment, a method of coating an aluminum surface of an article utilized in a semiconductor deposition chamber includes the steps of heating a coating material to a semi-liquidous state, the coating material comprising at least one material from the group consisting of aluminum fluoride and magnesium fluoride and depositing the heated coating material on the aluminum surface. The protective coating has a beta phase grain orientation of less than about 10 percent that has good adhesion to aluminum and resists cracking, flaking and peeling. Some articles that may be advantageously coated include showerheads, blocker plates, support assemblies and vacuum chamber bodies, among others. Excerpt(s): Embodiments of the invention generally relate to an article having a protective coating for use in a semiconductor processing chamber and a method of making the same. Integrated circuits have evolved into complex devices that can include millions of transistors, capacitors and resistors on a single chip. The evolution of chip designs continually requires faster circuitry and greater circuit density that demand increasingly precise fabrication techniques and processes. One fabrication process frequently used is chemical vapor deposition (CVD). Chemical vapor deposition is generally employed to deposit a thin film on a substrate or a semiconductor wafer. Chemical vapor deposition is generally accomplished by introducing a precursor gas into a vacuum chamber. The precursor gas is typically directed through a showerhead situated near the top of the chamber. The precursor gas reacts to form a layer of material on the surface of the substrate that is positioned on a heated substrate support typically fabricated from aluminum. Purge gas is routed through holes in the support to the edge of the substrate to prevent deposition at the substrate's edge that may cause the substrate to adhere to the support. Deposition by-products produced during the reaction are pumped from the chamber through an exhaust system. One material frequently formed on substrates using a chemical vapor deposition process is tungsten. A precursor gas that may be used to form tungsten generally includes tungsten hexafluoride (WF.sub.6) and silane. As the silane and tungsten hexafluoride mix, some "stray" tungsten (i.e., tungsten that does not deposit on the substrate) deposits on the showerhead and other chamber components. The stray tungsten film builds on the showerhead and may become a source of contamination in the chamber. Eventually, the stray tungsten may clog the holes in the showerhead that facilitate passage of the precursor gas therethrough and necessitating the showerhead be removed and cleaned or replaced. Web site: http://www.delphion.com/details?pn=US06632325__ •
Automotive and aerospace materials in a continuous, pressurized mold filling and casting machine Inventor(s): Herron; David J. (1212 N. LaSalle Dr., #1604, Chicago, IL 60610) Assignee(s): none reported Patent Number: 6,637,497 Date filed: May 8, 2002 Abstract: Mold filling and feeding device (400) and process including using refractory filter cloth (202) to seal a mold line (100), in continuous conveyance, to a multi-stage pressurized filling and feeding device. The mold line (100) consists of vertically parted or horizontally parted green sand molds (101), or an extruded bed of media carrying various types of molds, including green sand, nobake, lost foam, investment casting
178 Magnesium
shells, etc. These molds are bottom or side filled while moving for increased production rates. Feeding under pressure, while moving, is a second operation that improves casting integrity. The process includes a new and more efficient method of treating iron with magnesium for compacted graphite or ductile iron. A stitch (242) of filter cloth (202) holds modifying alloy (630) to the molds (101). A vacuum and pressure controlled column (550) provides consistent flow to thin walled castings, and pressurized feeding for heavy castings. Radiant energy losses are contained in the automatic system. The process and several special purpose machine components make a unified system for hardening liquid (600) such as molten metal in casting of aluminum alloy wheels or other metal castings, and also plastic polymer, rubber tires, etc., or food stuff, as in molded chocolate candy. Excerpt(s): This invention relates to the apparatus and processes of molding and casting, particularly to molten metal casting, for such as aluminum alloy wheels, but also to other thermally or chemically hardening liquids such as solidified foodstuff, plastics, rubber or other polymers formed in molds into solid articles for such as the automotive, aerospace industries, and food technology. For centuries, molds have been filled with molten metal to solidify into desired shapes. The processes have been adapted to other natural and synthetic hardening fluids ranging from chocolate to plastics, for example. The fluid or liquid may be poured under gravity from a vessel into an opening in the top of the mold. It may be pumped or flow under pressure into any area of the mold. The mold generally consists of a top and bottom section joined along a somewhat horizontal parting line. A cavity within the assembled mold corresponds to the desired solid shape. The opening for down pouring, or the "sprue", is usually cut or molded through the upper section of the mold, with some difficulties. As most molten metals are highly reactive at the elevated temperatures required, defects often form in proportion to the speed of the filling or the height of the falling stream, both of which increase the turbulence of fluid flow and the reactive exposure; to oxygen, for instance. The mold itself may suffer erosion or liquid penetration of the mold media. The mold may even rupture under the forces applied. Web site: http://www.delphion.com/details?pn=US06637497__ •
Chemical heat pump Inventor(s): Jonsson; Staffan (Karlskoga, SE), Karebring-Olsson; Mona (Hammarland, FI), Olsson; Ray (Hammarland, FI) Assignee(s): Solsam Sunergy AB (Stockholm, SE) Patent Number: 6,634,183 Date filed: December 5, 2001 Abstract: In a chemical heat pump a substance is used which within the temperature range for which the heat pump is intended has a transition between a solid phase and a solution phase. The substance can for a solar driven chemical heat pump comprise magnesium chloride hexahdrate. In an accumulator part of the heat pump a heat exchanger (21) is provided enclosed by a net (23). The solid phase is primary located inside the net in contact with the heat exchanger while the solution phase flow out of the net and is collected in space (24') below the heat exchanger. From this space the solution phase is pumped and sprayed over the heat exchanger from a spray bar (25). Thereby, all the time equilibrium is maintained. The advantage including the constant temperature step and the relatively large energy content of solid substance is thereby combined with the high power of liquid substances. Such a chemical heat pump is
Patents 179
among other things suitable for converting low grade heat energy such as solar energy to cooling and in some cases also for a simultaneous production of heat. Excerpt(s): The present invention relates to a chemical heat pump. The principle of the operation of the chemical heat pump is well-known, see for example U.S. Pat. Nos. 5,440,889, 5,056,591, 4,993,239, 4,754,805 and the published International patent application WO 94/21973. In a chemical heat pump an active substance, the absorbent, is used which performs the very process of the heat pump and which works together with a volatile medium, the absorbate or sorbate, which usually is a dipolar liquid, in most cases water. As the working active substance, according to the known technology, either a solid substance or a liquid substance can be used. A solid substance has the advantages that the vapor pressure remains constant during the whole discharging process for a constant cooling temperature and a relatively large capacity of storing heat. A typical value of the storage capacity for a solid substance having water as the sorbate, counted as cooling energy, is about 0.3 kWh/1 substance. A further advantage associated with a solid substance is that no movable components are required in the system. Heat is transferred to or conducted away from the substance through a lamellar heat exchanger or a plate heat exchanger in a homogenous contact with the substance. The disadvantage associated with a solid substance is the limited power which can be obtained, due to the bad thermal conductivity of solid substances. For systems the charging time of which corresponds to for example six hours of daytime charging using solar energy and the discharging time of which corresponds to a period of twelve hours of cooling for example a building, this provides no major problem. However, a disadvantage is that for continuous cooling at day and night and based on solar energy two installations working in parallel with each other are required. A liquid substance has the advantage of a high power since the substance can be spread over the heat exchanger both in charging and in discharging and thereby be efficiently cooled or heated respectively. The disadvantage of a liquid substance is that the cooling capacity decreases as a function of the dilution of the sorbate. This actually strongly limits the operational interval within which the substance can be used, what in turn reduces the storage capacity, counted as above as cooling energy per liter substance. Most liquid substances or absorbent used in chemical heat pumps comprise solutions of strongly hygroscopical inorganic salts in preferably water together with which water is used as the volatile liquid, the sorbate. Then another limitation is obtained by the fact that the dissolved substance cannot be allowed to crystallize. Crystallization creates problems in spray nozzles and pumps. Thus, the use of a liquid substance is limited to converting heat energy to cooling without any storing of heat and systems therefor are generally known and utilized. In such a process e.g. a lithium bromide solution can be used which when heated is evaporated to pass from a diluted solution to a more concentrated solution. This can be made in a chemical heat pump at a low pressure or at atmospheric pressure using air flows. The amount of working substance is relatively small, since no storing of "charged" concentrated solution is made. The hot concentrated solution is then cooled and is then again made to absorb the sorbate which is evaporated from a heat exchanger, the heat of which is taken from for example the rooms to be cooled. Disadvantages of this known system can be that the hot concentrated solution has to be continuously cooled what practically can result in energy losses and that no cooling can be obtained during the time period when there is no supply of heat. Thus, such a system cannot perform air-conditioning at night. Web site: http://www.delphion.com/details?pn=US06634183__
180 Magnesium
•
Cleaning process and cleaning agent for harmful gas Inventor(s): Nawa; Youji (Kanagawa, JP), Otsuka; Kenji (Kanagawa, JP), Takamatsu; Yukichi (Kanagawa, JP), Tonari; Kazuaki (Kanagawa, JP) Assignee(s): Japan Pionics Co., Ltd. (Tokyo, JP) Patent Number: 6,638,489 Date filed: September 21, 2001 Abstract: There are disclosed a process for cleaning a harmful gas which comprises bringing the harmful gas containing as a harmful component, an organosilicon compound represented by the general formula: CH.sub.2 CH--SiR.sub.3, CH.sub.2 CH-Si(OR).sub.3, CH.sub.2 CHCH.sub.2 --SiR.sub.3 or CH.sub.2 CHCH.sub.2 --Si(OR).sub.3, wherein R indicates a saturated hydrocarbon group or an aromatic compound group, into contact with a cleaning agent comprising activated carbon adhesively incorporated with at least one species selected from the group consisting of bromine, iodine, a metal bromide and a metal iodide in which the metal is exemplified by copper, lithium, sodium, potassium, magnesium, calcium, strontium, manganese, iron, cobalt, nickel, zinc, aluminum and tin; and a cleaning agent comprising the same. The cleaning process and the cleaning agent enable to practically clean a harmful gas which is exhausted from a semiconductor manufacturing process and the like by the use of a dry cleaning process. Excerpt(s): The present invention relates to a process for cleaning a harmful gas containing as a harmful component, an organosilicon compound represented by the general formula: CH.sub.2 CH--SiR.sub.3, CH.sub.2 CH--Si(OR).sub.3, CH.sub.2 CHCH.sub.2 --SiR.sub.3 or CH.sub.2 CHCH.sub.2 --Si(OR).sub.3, wherein R is a saturated hydrocarbon group or an aromatic compound group; and a cleaning agent therefor. More particularly, it is concerned with a process for cleaning, by dry cleaning process, a harmful gas containing the above-mentioned organosilicon compound which gas is exhausted from a semiconductor manufacturing process or the like; and a cleaning agent therefor. There has been developed in recent years, a wiring material of copper films which has low electric resistance and high electro-migration resistance as a new wiring material taking the place of the wiring material of aluminum films or aluminum alloy films. Plating, sputtering, CVD (chemical vapor deposition) and the like method have been put into practical application as a method of forming copper films. With continuous progress towards three dimensional trend of a device and multi-layer trend of a wiring material, the requirement for flatness of a thin film is steadily growing. Thus, there is expected the advancement of film forming technique by CVD method which technique is capable of forming a thin film meeting the requirements of favorable step coverage and a design rule of 0.13.mu.m or less. In regard to copper film formation by means of CVD method, research and investigation have been made on a method in which any of various solid CVD feed materials is sublimed by being kept at an elevated temperature, and supplied in the form of vapor to a semiconductor manufacturing apparatus. However, disadvantages of the method such as an unreasonably small amount of vapor feed and a low rate of film formation led to unsuccess in commercialization thereof. Nevertheless, development has been made in recent years on CVD feed materials in the form of liquid such as hexafluoroacetylacetone-copper vinyltrimethylsilane [(CF.sub.3 CO).sub.2 CHCu.CH.sub.2 CHSi(CH.sub.3).sub.3 ] or hexafluoroacetylacetone-copper allyltrimethylsilane [(CF.sub.3 CO).sub.2 CHCu.CH.sub.2 CHCH.sub.2 Si(CH.sub.3).sub.3 ], whereby the rate of film formation has been improved to such a level as commercializability. it being so, copper film
Patents 181
formation was commenced by the use of the above-mentioned hexafluoroacetylacetonecopper complexes. Web site: http://www.delphion.com/details?pn=US06638489__ •
Composition for aiding in toilet training and method for using same Inventor(s): Fiorella; Erica F. (7114 Davis Rd., Waxhaw, NC 28173) Assignee(s): none reported Patent Number: 6,648,650 Date filed: May 30, 2002 Abstract: A powder for use as a toilet training aid changes from substantially white to a non-white color upon contacting water. The powder-includes at least one powdered water-soluble color additive, and at least one salt for providing a uniform dispersion of color from the color additive when in contact with water. The salt is preferably selected from the group consisting of sodium bicarbonate, sodium chloride, magnesium sulfate, and magnesium chloride. The color additive is preferably a water-soluble powder certified by the United States Food and Drug Administration for use in drugsand cosmetics or for use in food, drugs and cosmetics. After repeated use, the child develops a positive mental association between the act of using the toilet and the amusement derived from watching the change of color, thereby making toilet training easier. Excerpt(s): The invention relates to a composition for assisting in the toilet training of children. The composition is a powder mixture that changes from white to a desired color upon contacting water. The color change of the powder provides a source of amusement to a child to encourage his or her use of the toilet. Toilet training is often a difficult and tedious task for both parent and child. Children are often intimidated or simply disinterested in the prospect of making the transition from diapers to regular toilet use. Forcing an unwilling child to use a toilet can be counterproductive and reinforce the child's fear or dislike for the activity. There is a need for toilet training aids that make the experience of using the toilet more enjoyable for the child, thereby encouraging use of the toilet and making toilet training easier for the parent. An activity in which the source of amusement to the child is directly related to the activity of urinating in the toilet would have the strongest effect in developing a positive incentive in the child's mind for using the toilet. Web site: http://www.delphion.com/details?pn=US06648650__
•
Dry powder for inhalation Inventor(s): Keller; Manfred (Bad Krozingen, DE), Muller-Walz; Rudi (Schopfheim, DE) Assignee(s): Jago Research AG (Muttenz, CH) Patent Number: 6,645,466 Date filed: August 9, 2001 Abstract: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of notinhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the
182 Magnesium
inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions. Excerpt(s): The invention relates to the improvement of the resistance to moisture of dry powder formulations for inhalation, and to the novel dry powder formulations. The active compound must be inhalable. In order to be able to pass into the lungs, it must be present in particles of size about 1 to 10.mu.m. Such microfine particles can be obtained, for example, by micronization, controlled precipitation from suitable solvents or by spray drying if the process conditions are suitably selected, controlled and carried out. Microfine particles, however, have a very unfavorable, i.e. large, ratio of surface to volume or mass and therefore a large surface energy. This is manifested in strong adhesion and cohesion tendencies which in turn lead to poor flow properties and to powder aggregation. Microfine powders of this type are therefore difficult to handle and are strongly influenced by electrostatic charge, processing, atmospheric humidity and the like. In order to guarantee consistent production of the formulation, mechanical filling of the powder inhaler and correct dosage and release by the powder inhaler, the powder must be free-flowing. Good flow properties are as a rule expected with sufficiently large particles which are as spherical as possible and which have a low surface energy and small contact areas. Web site: http://www.delphion.com/details?pn=US06645466__ •
Electrochromic materials, devices and process of making Inventor(s): Richardson; Thomas J. (Oakland, CA) Assignee(s): The Regents of the University of California (Oakland, CA) Patent Number: 6,647,166 Date filed: July 9, 2001 Abstract: Thin films of transition metal compositions formed with magnesium that are metals, alloys, hydrides or mixtures of alloys, metals and/or hydrides exhibit reversible color changes on application of electric current or hydrogen. Thin films of these materials are suitable for optical switching elements, thin film displays, sun roofs, rearview mirrors and architectural glass. Excerpt(s): Devices capable of switching between mirror-like and transparent states find many applications in architectural and transportation energy conservation, lighting and displays, aerospace insulation control, and optical communications systems. Such devices, termed "switchable mirrors", based on rare earth hydrides were discovered by Huiberts et al., Nature 380, 231 (1996), who observed a reversible metal-to-insulator transition when a thin film (150 to 500 nm) of yttrium or lanthanum coated with a thin layer of palladium was exposed to hydrogen gas. The transition accompanies conversion of a metallic dihydride phase to a semiconducting trihydride. Rare earthmagnesium alloy films were subsequently found to be superior to the pure lanthanides in maximum transparency and mirror-state reflectivity, see Van der Sluis et al., Appl. Phys. Lett. 70, 3356 (1997). Phase separation appears to occur when these alloys take up hydrogen, giving transparent MgH.sub.2 and LnH.sub.2-3, both of which may participate in the switching mechanism. Because the rare earths are highly vulnerable to oxidation, a Pd overlayer at least 5 nm thick is required for films exposed to air or to an alkaline electrolyte. Although the Pd catalyzes the uptake and removal of hydrogen, it limits the maximum transparency of the composite film to about 50%. Other fields of art have developed materials that exhibit electrochromism. Among the many transition
Patents 183
metals and alloys that have been investigated for use in low pressure hydrogen storage devices or as electrodes in secondary batteries, a few are known to form semiconducting hydride phases such as Mg.sub.2 NiH.sub.4, Mg.sub.2 CoH.sub.5, and Mg.sub.2 FeH.sub.6, see Reilly et al., Inorg. Chem. 7, 2254, (1968); Zolliker et al., Inorg. Chem., 24, 4177, (1985) and Didisheim et al., Inorg. Chem., 23, 1953, (1984). Web site: http://www.delphion.com/details?pn=US06647166__ •
Fluid resistant silicone compositions for sealing magnesium alloy components Inventor(s): DeCato; Alfred A. (Novara, IT) Assignee(s): Henkel Loctite Corporation (Rocky Hill, CT) Patent Number: 6,645,339 Date filed: April 26, 2002 Abstract: Silicone compositions are disclosed which exhibit excellent adherence to magnesium-based substrates such as magnesium alloys and which exhibit excellent resistance to organic solvents. These compositions include at least one polymerizable silicone component, at least one amino-containing silane adhesion promoter which enhances adhesion of the composition to magnesium-based substrates, and at least one viscosity modifier, which enhances the resistance of the compositions to organic solvents. Methods of making these compositions, articles of manufacture including these compositions, and a method for providing enhanced adhesion to magnesiumbased substrates using these compositions are also disclosed. Excerpt(s): The present invention relates generally to compositions for sealing and adhering magnesium-based substrates. More particularly, the present invention relates to compositions which demonstrate excellent resistance to fluid solvents, particularly automotive fluids, while maintaining excellent adherence to magnesium-based substrates. Room temperature vulcanizable (RTV) silicones posses an interesting combination of properties that make them very desirable for a large number of applications. These properties include a viscosity range that allows for use as flowable liquids or soft pastes, excellent thermal stability characteristics of high-consistency silicone rubber, good adhesion to many surfaces without requiring pressure, and curing without the need for heating, as their name implies. However, RTV silicones have not been used for sealing and bonding magnesium-based substrates, such as magnesium alloy substrates. It is known to add viscosity-modifying filler materials to RTV silicones to improve their resistance to fluid solvents. For example, the addition of certain grades of metal oxides to silicone elastomers is known to result in silicone rubber compositions having a certain degree of oil resistance. European Patent Publication No. 572 148, assigned to General Electric Company, discloses the incorporation of mixed metal oxides into heat cured silicone elastomeric compositions containing MQ resins (M=R.sub.3 SiO.sub.1/2 monofunctional groups; Q=SiO.sub.2 quadri- functional groups). In the '148 publication, such compositions are formed into engine gaskets which are reported to display a certain degree of oil resistance. Web site: http://www.delphion.com/details?pn=US06645339__
184 Magnesium
•
Friction material for brake Inventor(s): Horiya; Takao (Saitama, JP), Kato; Masanori (Saitama, JP), Ogiwara; Osao (Saitama, JP) Assignee(s): Akebono Brake Industry Co., Ltd. (Tokyo, JP), Akebono Research and Development Centre Ltd. (Saitama, JP) Patent Number: 6,635,349 Date filed: October 31, 2001 Abstract: The present invention provides a friction material for brake not containing materials including heavy metals such as Cu or antimony. The friction material contains a fibrous component, a binding component and a friction modifying component, wherein magnesium oxide (MgO) and graphite are contained in a friction material in the amount of 45 to 80 vol %, and volume ratio (MgO/graphite) of magnesium oxide (MgO) to graphite is 1/1 to 4/1. Excerpt(s): The present invention relates to a friction material for brake to be used for brakes of vehicles or industrial machines, and more particularly to such a friction material excellent in frictional performance at high temperatures and mechanical strength without containing Cu based metals or antimony compound. With respect to friction materials, in non-asbestos based friction materials which have gradually become a main stream in substitution for existing asbestos based friction materials, there are employed many kinds of fibrous components, for example, for reinforcing strength, maintaining friction coefficient and improving qualities, and are much used metal fibers such as Cu fiber, steel fiber and the like. Nowadays in general, the non-asbestos based friction materials contain about 0 to 20 vol % Cu fiber or Cu powder. Cu is useful for reinforcing strength, heightening friction coefficient of friction materials, and further maintaining friction coefficient at 400.degree. C. or higher and increasing heat radiating efficiency. Being different from steel fibers, Cu has characteristics less to have aggressiveness, which increases a wear amount of an opposite member such as a rotor, and to generate rusts. Web site: http://www.delphion.com/details?pn=US06635349__
•
Fuel compositions exhibiting improved fuel stability Inventor(s): Orr; William C. (2075 S. University, #240, Denver, CO 80210) Assignee(s): none reported Patent Number: 6,652,608 Date filed: December 8, 1997 Abstract: A fuel composition of the present invention exhibits minimized hydrolysis and increased fuel stability, even after extended storage at 65.degree. F. for 6-9 months. The composition, which is preferably not strongly alkaline (3.0 to 10.5), is more preferably weakly alkaline to mildly acidic (4.5 to 8.5) and most preferably slightly acidic (6.3 to 6.8), includes a lower dialkyl carbonate, a combustion improving amount of at least one high heating combustible compound containing at least one element selected from the group consisting of aluminum, boron, bromine, bismuth, beryllium, calcium, cesium, chromium, cobalt, copper, francium, gallium, germanium, iodine, iron, indium, lithium, magnesium, manganese, molybdenum, nickel, niobium, nitrogen, phosphorus,
Patents 185
potassium, palladium, rubidium, sodium, tin, zinc, praseodymium, rhenium, silicon, vanadium, or mixture, and a hydrocarbon base fuel. Excerpt(s): The present invention relates to enhanced structured fuel compositions for use in jet, turbine, diesel, gasoline, and other combustion systems. More particularly, the present invention relates to fuel compositions using viscous hydrocarbons, which are substantially neutral pH, and which employ a silicon based combustion catalyst. International patent application Nos. PCT/US95/02691, PCT/US95/06758, and PCT/US96/09653, are incorporated in their entirety herein by reference, and disclose fuel compositions and combustion techniques for achieving vapor phase combustion based on an enhanced combustion structure ("ECS"). This enhanced combustion structure includes a combustible metallic and free radical generating oxygenated compound. It has been found that such free radical generating oxygenates include C2C12 aldehydes, aldehydic acids, C2-C12 ethers, C1-C15 alcohols, C2-C12 oxides, C3-C15 ketones, ketonic acids, C3-C15 esters, othroesters, C3-C12 diesters, C5-C12 phenols, C5C20 glycol ethers, C2-C12 glycols, C3-C20 alkyl carbonates, C3-C20 dialkyl carbonates, C3-C20 di-carbonates, C1 to C20 organic and inorganic peroxides, hydroperoxides, carboxylic acids, amines, nitrates, di-nitrates, oxalates, phenols, acetic acids, boric acids, orthoborates, hydroxyacids, orthoacids, anhydrides, acetates, acetyls, formic acids, nitrates, di-nitrates, nitro-ethers, which can meet minimum burning velocity (BV) and latent heats of vaporization (LHV) requirements of aforementioned PCT Applications. Specific compounds can be found in detail in Organic Chemistry 6th Ed, T. W. G. Solomons, John Wiley & Sons, N.Y., (1995), Physical Chemistry, 5th Ed, P. W. Atkins, Oxford University Press, U.K. (1994), Physical Organic Chemistry, 2 Ed, N. S. Issacs, John Wiley & Sons, N.Y. (1995) and Lange's Handbook of Chemistry, 14th Ed, J. A. Dean, McGraw-Hill, N.Y. (1992), and their minimum BV/LHV requirements in aforementioned PCT Applications, which are herein by incorporated by reference. Said enhanced combustion structure oxygenates, when in combination with a combustible non-lead metal or non-metal (as set forth below), exhibit high heats of enthalpy capable, improved combustion, thermal efficiency, fuel economy, and power. Of particularly interest to this invention are the enhanced combustion struture oxygenates of symmetrical dialkyl carbonates, especially dimethyl and diethyl carbonates. Web site: http://www.delphion.com/details?pn=US06652608__ •
Fuel oil compositions Inventor(s): Caprotti; Rinaldo (Oxfordshire, GB) Assignee(s): Exxon Chemical Patents Inc () Patent Number: 6,652,609 Date filed: July 8, 1998 Abstract: This invention relates to fuel oil, especially middle distillate fuel oil, compositions comprising middle distillate fuel oil and at least one fuel-soluble or fuel dispersible calcium and/or magnesium salt. Excerpt(s): This invention relates to fuel oil, especially middle distillate fuel oil, compositions of improved combustion performance, particularly demonstrating reduced particulate matter emission and/or smoke. This invention is especially directed to hydrocarbon middle distillate fuel oil compositions. Certain organometallic compounds are known to be effective combustion improvers for distillate fuels such as home heating oils. For example, U.S. Pat. No. 3,112,789 describes the use of
186 Magnesium
cyclopentadienyl manganese tricarbonyls for this purpose. and its use for reducing the soot, smoke and/or carbonaceous products produced on combustion of the fuel and for reducing the acidity of the carbonaceous products. Web site: http://www.delphion.com/details?pn=US06652609__ •
Galvanic probes as pH and oxidation reduction potential sensors, control devices employing such probes, and related methods Inventor(s): Decker; Paul (Creve Coeur, MO), Martzall; Thomas Lee (St. Charles, MO), Mosley; Michael David (Calverton Park, MO) Assignee(s): Digital Concepts of Missouri (Earth City, MO) Patent Number: 6,653,842 Date filed: July 10, 2001 Abstract: A galvanic probe comprises a sensor electrode and a reference electrode. The sensor electrode has an exposed surface that comprises a noble metal or antimony or bismuth, and, optionally, an oxide or hydroxide thereof. The reference electrode is spaced apart from the sensor electrode and has an exposed surface that comprises zinc or magnesium, and, optionally, an oxide or hydroxide thereof. The probe may be incorporated into a device for controlling the pH and/or ORP of a fluid in a vessel to a desired pH and/or ORP level, incorporated into methods for measuring the pH and/or ORP of a fluid, or used as a galvanic cell. Excerpt(s): The present invention relates to galvanic probes and cells, and more particularly to the use of such probes and cells in the measurement of various characteristics, such as pH and oxidation reduction potential, of fluids such as water. It is often necessary or desirable to measure the pH or oxidation reduction potential (ORP) of a fluid. The ORP measures the relative tendency of materials in the fluid to undergo oxidation or reduction (particularly the ability of the fluid to destroy bacteria in it). Moreover, it is often desirable to monitor pH and/or ORP at frequent intervals--or even continuously. Measurement of pH and ORP levels are of interest in a wide variety of industrial, commercial and domestic processes and situations. For example, many chemical processes are pH-dependent or ORP-dependent. The pH or ORP of effluents from factories is commonly of environmental concern. The pH or ORP of water is critical in many settings. A setting familiar to many laypersons is in various water storage systems, such as air conditioning systems or swimming pools. Therefore, for ease of explanation, much of the following discussion will be with reference to the swimming pool setting, although it should be borne in mind that the discussion is likewise applicable to any other situation in which the pH and/or ORP of a fluid is of interest. In a swimming pool, the quality of the water is closely related to the pH and ORP of the water. In swimming pools, the ORP of the water is a measure of the free chlorine level in the water, which is related to the biological antiseptic quality of the water. Therefore, the pH and chlorine levels of swimming pool water must be monitored to ensure that an adequate quality level is maintained. Conventionally, this is carried out by hand and the owner or other caretaker in charge of maintaining the pool must repeatedly go to the pool with vials and chemicals, scoop out the water into the vials, shake the vials, compare the colors of the resulting solutions to those on charts coordinated with the pool volume to determine the amounts of chemicals to add to restore the